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Chapter 1 Introduction and Aims of the Thesis
Introduction
Chronic Renal Impairment - Scope of the problem
Chronic renal impairment is a global public health concern. Over the past decades the 
prevalence of chronic renal impairment has steadily risen in the entire world.1-4 In the 
NHANES population survey performed between 1999 and 2004 it was estimated that 26 
million adults suffered from impaired renal function, which is approximately 13% of the 
adult US population,5 while in the prior NHANES survey (1988-1994) this was only 10% of 
the adult US population. This indicates an increase of 3% in 10 years time. These high and 
steeply increasing numbers are also seen in other parts of the world, although accurate 
data are limited.6-8
Chronic renal impairment may eventually lead to end stage renal disease (ESRD). Along 
with the prevalence of chronic renal impairment, there has been a dramatic increase 
in the prevalence of ESRD over the last decades (figure 1).2,9 In the US alone, in 2008, 
approximately 480.000 people (~1700 patients per million population) received renal 
replacement therapy for ESRD - consisting of either dialysis or renal transplantation - 
and new renal replacement therapy was started in 353 patients per million population. 
Incidence rates are approximately three times higher in the United States than in Europe, 
where per million population 113 new patients required renal replacement therapy.10 
Whereas there has been a continuous increase in the incidence of ESRD, this increase has 
leveled off over recent years. This observation is suggestive for increased awareness of 































Figure 1| Incidence and prevalence of end-stage renal disease
Incidence and prevalence of end-stage renal disease (ESRD) in the US in 2008 (Adapted from: US 
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ESRD necessitates renal replacement therapy, which poses a severe burden to the 
patients and their environment, and has a profound impact on the costs of healthcare.12-14 
Moreover, chronic renal impairment, but particularly ESRD is associated with increased 
risk of (cardiovascular) mortality. For these reasons prevention or postponement ESRD is 
of utmost importance.
High-Risk populations
One important reason for the increasing prevalence of chronic renal impairment is aging 
of the population, but this is not the only reason for the increase. Especially the increasing 
prevalences of important risk factors for chronic renal impairment in the population such 
as type 2 diabetes and hypertension amount substantially to the total increase in the 
prevalence of renal impairment.15,16 Apart from patients with diabetes and patients with 
hypertension, there are patient groups with an ever higher a priori risk for chronic renal 
impairment, such as solid organ recipients. However, because these groups are much 
smaller in size, they do not contribute as substantially to the total prevalence of chronic 
renal impairment as diabetes and hypertension do. 
Type 2 diabetes and hypertension
It is estimated that ~40% of patients with diabetes develop renal impairment, manifested 
as decline in glomerular function, development of increased urinary albumin excretion or 











Incidence of end-stage renal disease (ESRD) per primary diagnosis in the US in 2008 (Adapted 
from: US renal data system 2010 annual data report).9
Figure 2| Incidence of ESRD per primary diagnosis 
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and implementation of preventive treatment strategies, in the US, the prevalence of 
diabetes increased from 6.0% in NHANES 1988-1994 to 9.4% in NHANES 2005-2008.20 
This is alarming, as diabetes is now already responsible for more than 43% of patients 
developing ESRD. 
Hypertension is another leading risk factor for development of chronic renal insufficiency 
in general, and as a co-morbid factor in patients with diabetes.21 In 2000, hypertension 
affected 29 to 31% of the adult US population, which translates into 58 to 65 million people, 
compared to 43.2 million people in 1991.16 After diabetes, hypertension is the second most 
common risk factor for ESRD, responsible for more 28% of cases (Figure 2). Registry data 
from Europe, Canada, Australia and Japan show a similar increasing role for diabetes and 
hypertension as causes of ESRD.10,11 
Lung Transplantation
A patient population with even higher renal risk than those with diabetes or hypertension, 
is the group of lung transplant recipients. This group does not contribute substantially to 
the total of patients with chronic renal impairment because worldwide “only”~2800 lung 
transplantations are performed annually. However, due to the large surgical procedure 
and the sustained use of nephrotoxic immunosuppressive medication the incidence of 
chronic renal impairment in this group is very high: over 90% of lung transplant recipients 
suffer renal function decline after transplantation and more than 15% of the recipients 
have severe renal impairment 5 years after lung transplantation. Overall, 5-10% of all lung 
transplant recipients may eventually reach ESRD, despite healthy renal function at time 
of transplantation.
Monitoring renal function
The symptoms of worsening kidney function are unspecific and patients therefore are 
frequently unaware of their condition. Nevertheless, it is important to monitor chronic 
renal impairment - especially in those at increased risk – because of the increased cardio-
renal risk. 
Glomerular Filtration Rate (GFR) is accepted as the best overall measure of renal function 
and represents the overall filtering capacity of the kidneys.19 GFR can be measured as the 
plasma clearance of ideal filtration markers, such as radiolabelled 125I-Iothalamate.20 
However, these GFR measurements with ideal filtration markers are complex, demanding 
and expensive. 
Other methods estimate renal function by using serum creatinine as a proxy for renal 
function and are much less demanding and expensive, but also have important limitations 
because certain patient-related factors affect creatinine generation and excretion. Serum 
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creatinine-based GFR equations are superior to using serum creatinine alone as an index 
for renal function because these equations take into account certain patient-specific 
biometric indices that affect creatinine generation and excretion (age, gender, race, 
weight). Nevertheless, the equations also have important shortcomings. They frequently 
underestimate gold-standard measured GFR (mGFR), especially in the high- and high 
normal range, and lack sensitivity in detecting progressive renal function loss.21-23
Another important marker of renal impairment is an increased urinary albumin excretion 
(albuminuria). An increase in albuminuria has been linked to subsequent faster decline 
in renal function.24,25 In addition, albuminuria is an important risk marker for end-
stage renal disease, cardiovascular disease and mortality. Unfortunately, albuminuria is 
highly variable within and between patients and is not an alternative to renal function 
measurements, since not all patients with declining renal function develop albuminuria. 
Nevertheless, albuminuria measurement is very valuable and widely used as a screening 
tool in populations at increased risk for renal impairment. 
The ideal method to monitor renal function and to assess renal risk depends on the 
population under study and the a-priori risk for renal impairment. Measuring renal 
function using gold-standard techniques is only feasible in relatively small, selected 
patient populations with a very high a-priori risk. For the majority of patients the serum 
creatinine-based estimations of renal function and screening of albuminuria are generally 
used to assess renal function and renal risk, despite the obvious shortcomings, because 
the methods are easier to use in clinical practice, less demanding for the patient and less 
expensive. 
Prediction & Prevention
Whereas overall patients with type 2 diabetes and hypertension have increased risk 
for chronic renal impairment, not all patients in these high-risk groups will eventually 
develop renal impairment. Moreover, the rate of renal function decline varies substantially 
between individuals.29 Apart from the renal function and albuminuria, many important 
risk factors for progression of chronic renal impairment have been identified, - i.e. 
hypertension, hyperglycemia, dyslipidemia, smoking and obesity.21,30-33 However, these 
key risk factors are unable to adequately discriminate between those patients that will 
and will not develop progressive chronic renal impairment. The earlier we detect patients 
at risk, the more important the assessment of individual prognosis is. Currently, risk 
stratification of individual patient prognosis remains a huge challenge. 
Biomarkers may play an important role in overcoming this challenge. A biomarker is 
“a biological characteristic that is objectively measured and evaluated as an indicator 
hoofdstuk 1.indd   13 5-4-12   19:45
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of normal biological processes, pathogenic processes, or pharmacological responses 
to a therapeutic intervention without necessarily being causally related to the clinical 
endpoint”.34 A clinically useful biomarker could allow the early diagnosis of chronic renal 
impairment, the assessment of the future prognosis and potentially even the response to 
therapy. Earlier detection of those with an increased chance of renal impairment or fast-
progressive course could thus help us reduce the incidence of chronic renal impairment 
through selective preventive treatments for patients with the highest risk.35-37 
Aims of the thesis
In this thesis several aspects regarding prediction and prevention of chronic renal 
impairment in high-risk populations were investigated.
Part I: Type 2 Diabetes and Hypertension
In part I, we examine prediction of chronic renal impairment in patients with type 2 
diabetes and hypertension. This research was conducted within the Systems Biology 
towards Novel Chronic Kidney Disease Diagnosis and Treatment (SysKID) consortium. A 
major aim of the SysKID consortium is to identify persons at risk of developing chronic 
renal impairment in the context of diabetes and hypertension.
Increased albuminuria is one of the earliest signs of nephropathy in diabetes and is 
associated with increased risk for development of end-stage renal and cardiovascular 
disease. Early identification of patients at risk for worsening albuminuria allows for start 
or intensification of treatment which may prevent future complications. Many biomarkers 
for the prediction of transition between the stages of albuminuria have been published in 
the last two decades. In chapter 2 we systematically review the validity of biomarkers for 
nephropathy in type 2 diabetes. 
According to current knowledge leakage of excess albumin is a sign of endothelial damage 
and vascular dysfunction. In chapter 3 and 4 we assess whether the micro-vascular 
damage marker Growth-Differentiation Factor-15 (GDF-15) and micronecrosis marker 
high-sensitivity Troponin T (hs-TnT) respectively, precede and have additive predictive 
value in prediction of transition between the stages of albuminuria in patients with type 
2 diabetes and patients with hypertension.
For the prevention of renal complications in patients with diabetes, agents blocking the 
Renin-Angiotensin-Aldosterone System (RAAS) are first choice antihypertensives, as these 
agents not only lower blood pressure but also lower albuminuria. Current guidelines 
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recommend dose-titration of RAAS-blockade on blood pressure response without taking 
responses in albuminuria into account. It is unclear whether the response in blood pressure, 
albuminuria, or their combination should be considered a target for reno-protective 
therapy. In chapter 5 we assess whether the initial treatment responses in albuminuria 
and blood pressure are associated with long-term renal outcome and may thus be used 
in risk management strategies in type 2 diabetes patients with microalbuminuria and 
hypertension. 
For clinical practice, guidelines have been developed regarding screening and treatment 
of albuminuria in high-risk patients based on the current clinical evidence. It remains 
however unclear how well these guidelines are applied in practice. Therefore, in chapter 
6 we assessed the adherence to guidelines for albuminuria screening and treatment in 
patients with type 2 diabetes in a large primary care cohort. 
Part II: Lung transplantation
In part II we examine chronic renal impairment in lung transplantation (LTx) recipients. 
Chronic renal impairment is an important clinical problem after lung transplantation. 
Due to changing acceptance policies, lung transplantation recipients are increasingly 
older and have a higher proportion of ‘co-morbidities’, thus increasing expected renal risk. 
Meanwhile, increased awareness and improved treatment may have counterbalanced the 
increase in risk factors. In chapter 7 we assessed the changes in renal risk factors in the LTx 
population and the incidence of renal function impairment after LTx over time.
Besides the high prevalence of chronic renal impairment, also the prevalence of former 
smoking is relatively high in LTx recipients. We wondered whether, even after smoking-
cessation, smoking history could be relevant for morbidity after LTx, in particular chronic 
renal impairment because of the high prevalences of both chronic renal impairment and 
former smoking. In chapter 8 we assessed the impact of former smoking on the incidence 
of chronic renal impairment and mortality after LTx. 
Lastly, in our cohort, GFR was monitored after LTx using 125-Iothalamate measurements. 
Whereas this method is the gold standard, it is invasive, demanding and costly and is 
therefore not commonly used in most centers to monitor renal function over time. Other 
centers mostly use the more easily available creatinine-based GFR estimations. However, 
these estimations have never been validated in LTx recipients and are likely not very 
accurate in this population, because of the distinct characteristics of the LTx recipients. In 
chapter 9 we aimed to assess how well the more easily available renal function equations 
correlate with gold standard GFR in LTx recipients and to assess the factors of systematic 
bias. 
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Abstract 
Background: Novel biomarkers predicting onset or progression of nephropathy in patients 
with type 2 diabetes have been recently identified. We performed a systematic review 
to assess the validity of biomarkers predicting onset or progression of nephropathy in 
patients with type 2 diabetes in longitudinal studies.
Methods: The methodological quality of the studies was scored using Standards for 
Reporting of Diagnostic accuracy (STARD) criteria and the independent predictive value of 
the biomarkers beyond conventional risk factors was scored according to the adjustment 
for conventional risk factors. Validity of the biomarkers was determined by summarizing 
the methodological quality and the adjustment score.
Results: We identified 15 studies describing 27 biomarkers. Six studies had sufficient 
methodological quality. These studies identified 13 valid and significant markers for 
nephropathy in diabetes: serum interleukin 18, plasma asymmetric dimethylarginine; and 
urinary ceruloplasmin, immunoglobulin G and transferrin were considered valid markers 
predicting onset of nephropathy. Plasma asymmetric dimethylarginine, vascular cell 
adhesion molecule 1, interleukin 6, von Willebrand factor and intercellular cell adhesion 
molecule 1 were considered valid biomarkers predicting progression of nephropathy. 
Plasma high-sensitivity C-reactive protein, E-selectin, tissue-type plasminogen activator, 
von Willebrand factor and triglycerides were considered valid markers predicting onset 
and progression of nephropathy.
Conclusion: Several novel biomarkers for prediction of nephropathy in diabetes have 
been published, which can potentially be applied in future clinical practice and research. 
Because of the heterogeneous quality of biomarker studies in this field, a more rigorous 
evaluation of these biomarkers and validation in larger trials are advocated. 
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Introduction
Diabetic nephropathy is the leading cause of chronic renal failure in the USA and Western 
countries. As such, it is not only associated with considerable morbidity and premature 
mortality but it also negatively affects patient’s quality of life and their social environment, 
and it poses a significant burden on national healthcare budgets.1
Albuminuria is one of the first asymptomatic clinical manifestations of microvascular 
damage in diabetes.2 It has been shown that the presence of micro- or macroalbuminuria 
is associated with progressive renal function loss and an increased risk of cardiovascular 
disease.3 Therefore, screening for, and quantification of albuminuria is recommended in 
all patients with diabetes to identify those who are at risk for long-term complications.4 
In recent years, multiple urinary and serum/plasma biomarkers for the prediction of onset 
of microalbuminuria and for, progression of nephropathy in patients with micro- and 
macroalbuminuria have been investigated in patients with Type 2 diabetes. 
The term ’biomarker‘ describes a characteristic that is objectively measured and evaluated 
as an indicator of normal biological processes, pathogenic processes or pharmacological 
responses to a therapeutic intervention without necessarily being causally related to 
the clinical endpoint (e.g. Troponin T in myocardial infarction).5 Biomarkers can be used 
as diagnostic tools, staging tools, prognostic tools or tools for prediction/monitoring of 
clinical response to an intervention.6 For the latter purpose, certain biomarkers are eligible 
to substitute as clinical endpoints in intervention trials. Such a surrogate marker, also 
referred to as a surrogate endpoint, is expected to predict clinical benefit as evidence exists 
that this marker is associated causally with a certain clinical outcome (e.g. elevated blood 
pressure as a marker for cardiovascular disease). Therefore, only a subset of biomarkers 
will achieve surrogate marker status. 
In this review, we focus on biomarkers for prognosis and risk prediction, which potentially 
can become surrogate markers in future studies. A more prominent role for biomarkers is 
proposed in early non-invasive screening and assessing overall renal risk in patients with 
Type 2 diabetes.7 In this perspective, biomarkers may be important tools in guiding early 
and more aggressive therapy in high-risk patients in order to prevent long-term renal 
complications. 
Before a putative biomarker can be applied in clinical practice as a prediction tool, rigorous 
evaluation is advocated and several criteria should be met.8-12 First of all, biomarkers should 
be tested in longitudinal, methodologically well-designed studies with sufficient power 
in order to ascertain the generalizability of the results.10 The association between the 
biomarker and disease should be independent of potential confounders and should add 
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to risk prediction beyond conventional risk factors.8,11,12 Lastly, results on biomarkers should 
be reproduced in other studies to validate the results.8-10 So far, validity of biomarkers for 
the prediction of onset or progression of nephropathy in patients with diabetes has not 
been critically appraised. 
The objective of this paper was to systematically assess the validity of biomarkers 
predicting onset or progression of nephropathy in patients with Type 2 diabetes on the 
basis of methodological quality of the studies, and by determination of the independent 
predictive value over conventional risk factors. 
Patients and methods
Identification of relevant studies
Relevant studies were identified by searches of Medline via Pubmed, Embase and the 
Cochrane Library database (Cochrane Central Register of Controlled Trials), with relevant 
text words and medical subject headings that consisted of the term “biomarker or 
biological marker” and one of the following terms: “(diabetic) nephropathy”, “(non insulin 
dependent) diabetes mellitus”, “microalbuminuria”, “albuminuria”, “proteinuria”, “chronic 
kidney disease”, “diabetes complications”. The search was limited to longitudinal studies 
on humans and adults, published between 1995 and 2010, without language restrictions. 
We extended our search by reviewing the references from the eligible papers and the 
papers that cited the eligible papers through Web of Science.
Study selection
Studies were considered eligible if they were longitudinal cohort studies or randomized 
controlled trials with at least 20 patients, reporting on biomarkers for the prediction of 
onset or progression of nephropathy in type 2 diabetic patients. We focused on biomarkers 
that can be measured in urine, plasma or serum. Studies on conventional risk factors/
biomarkers were excluded because we were mainly interested in novel biomarkers that 
could potentially improve risk prediction beyond conventional risk markers. Therefore, 
the conventional markers rather served as a basis for quality assessment of the studies 
(see below). The literature search, data extraction, and scoring were carried out by two 
reviewers independently by use of a standardized approach (JK, MEH). Any disagreement 
was resolved by a third reviewer (MR). 
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Terminology
Diabetic nephropathy is histopathologically characterized by several changes in 
the kidney, such as nodular glomerulosclerosis, mesangial expansion, basement 
membrane thickening and interstitial fibrosis. Clinically, diabetic nephropathy is 
usually a constellation of persistent albuminuria, elevated arterial blood pressure, 
and decline in kidney function.13 Changes in albuminuria are considered a hallmark of 
onset or progression of nephropathy. Albuminuria levels have been categorized into 
normoalbuminuria (<30 mg/day or <20 µg/min), microalbuminuria (30-300 mg/day or 
20-200 µg/min) and macroalbuminuria (>300 mg/day or >200 µg/min). Consequently, 
studies often report transition in albuminuria class (from normo- to microalbuminuria 
and from micro- to macroalbuminuria) or doubling of serum creatinine from baseline 
as indicators of nephropathy onset or progression. In our study onset of nephropathy 
was defined as the development of microalbuminuria in previously normoalbuminuric 
patients (early nephropathy). Progression of nephropathy was defined as either the 
transition from normo- or micro- to macroalbuminuria, a longitudinal change in the 
extent of albuminuria or doubling of serum creatinine in micro- and macroalbuminuric 
patients (late nephropathy).
Study analysis
Studies were divided into three groups: studies on biomarkers predicting onset of 
nephropathy in patients with normoalbuminuria (early nephropathy), studies predicting 
progression of nephropathy in patients with micro- or macroalbuminuria (late 
nephropathy), and studies predicting onset and progression of nephropathy in cohorts 
that included patients with normoalbuminuria and microalbuminuria. 
Quality assessment
Studies were assessed for validity using a modified checklist of the STARD criteria (table 
1). The STARD initiative developed a set of 25 criteria for reporting of studies of diagnostic 
accuracy in order to improve the quality.14 For the purpose of this review, we limited the 
quality assessment to 11 items, mainly focusing on methodological quality of the study. 
Items focusing on specific laboratory methods or adverse events of the tests were not 
included in this review. Study quality was considered as “good” if the score was ≥ 10, 
“average” if the score was 8-9, “fair” if the score was 6-7, and “poor” if the score was <6. 
Adjustment score and biomarker validity score
In order to be clinically useful, biomarkers for onset and progression of nephropathy 
should have additional predictive value on top of conventional risk factors (age, sex, race, 
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hypertension, HbA1c, BMI, diabetes duration, hypercholesterolemia, retinopathy, smoking, 
albuminuria and use of RAAS-inhibitors).15-24 As a quality assessment we scored whether 
the studies took conventional risk factors into account. One point was attributed to each 
of the following conventional factors that was adjusted for: Age and sex, blood pressure/
hypertension and/or use of antihypertensive agents, HbA1c or fasting plasma glucose, 
BMI, diabetes duration, total cholesterol and/or HDL cholesterol, retinopathy, smoking, 
use of RAAS-inhibitors, UAER or albumin-to-creatinine ratio (ACR). Race was not applicable 
because all of the studies were conducted in homogenous Asian, Caucasian or 
Native American populations. The maximum adjustment score was 10 points. Adjustment 
was considered “good” if the score was ≥ 9, “average” if the score was 7-8, “fair” if the score 
was 5-6, and “poor” if the score was <5. 
The adjustment score when added to the methodological quality score resulted in a 
combined biomarker validity score. Biomarkers were considered as valid biomarker 
candidates if both the methodological quality score and the adjustment score were at 
least “good” or “average” (biomarker validity score ≥ 15).
Results
The systematic search (performed 1 July 2010) for articles of longitudinal studies on 
biomarkers for prediction of the onset or progression of nephropathy in patients 
with type 2 diabetes resulted in 953 non-duplicate articles of which 841 were not on 
biomarkers other than conventional risk factors for nephropathy in diabetes type 2, and 
were therefore excluded. We also excluded studies on populations with chronic kidney 
diseases other than diabetic nephropathy, studies on nephropathy in patients with 
diabetes type 1, or studies on non-serum and non-urine biomarkers. The remainder of 
the articles (N=112) were reviewed in full text. Of these, only 14 studies met the inclusion 
criteria and were included in the present review.25-38 The main reason for exclusion in this 
phase was cross-sectional study design. Explosion search (the references of the selected 
papers) and forward citation search (all studies referring to the selected papers) resulted 
in identification of one additional paper.39 A flow-chart demonstrating the study selection 
process is shown in figure 1.
The 15 identified studies reported on 27 individual biomarkers, of which 19 were serum/
plasma biomarkers, six were urinary biomarkers and IL-18 was measured in both serum 
and urine (and therefore counted as two individual biomarkers). Four studies reported 
on prediction of the onset of nephropathy in patients with normoalbuminuria,25-28 two 
on progression of nephropathy in micro- or macroalbuminuric patients,29,39 and seven 
hoofdstuk 2.indd   29 5-4-12   20:07
30



















































98 articles excluded 
because no study of 
prediction/progression
98 articles excluded 




113 full-text articles 
selected for detailed 
assessment
841 articles excluded 




168 duplicate studies 
excluded

















Figure 1| Flow chart of the identification process of eligible studies
*In at least one study. 8-oxodG, 8-oxo-7, 8-dihydro-2’-deoxyguanosine; ADMA, asymmetric di-
methylarginine; AGE, advanced glycation end-product; Apo-B, apolipoprotein B; Col-IV, collagen 
IV; CRP, C-reactive protein; hs-CRP, high-sensitivity C-reactive protein; ICAM1, intercellular cell 
adhesion molecule 1; IgG, immunoglobulin G; IL, interleukin; L-PGDS, lipocalin-type D2 synthase; 
MMP9, matrix metallopeptidase 9; NAG, N-acetylglucosaminidase; TGFb; transforming growth 
factor b; TPA, tissue-type plasminogen activator; VCAM1, vascular cell adhesion molecule 1; 
vWF, von Willebrand factor.
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reported biomarkers in combined normo- and microalbuminuric patient cohorts (i.e. onset 
and progression) and thus do not make a distinction between onset and progression.30-36 
Another two studies assessed biomarkers in combined normo- and microalbuminuric 
patient cohorts and report the results for onset and progression of nephropathy 
separately.37,38
Study characteristics
Study characteristics are shown in table 2. Individual study size ranged from 30 to 1103 
patients with a total number of 3529 patients. Mean/median follow-up ranged from 0.5-
9.0 years and mean age of the study populations ranged from 51.8 to 67.5 years. All but one 
study included both men and women in approximately equal proportion.36 Eleven out of 
15 studies were conducted in Asian populations,25-29,32-34,36-38 one study in a Native American 
population,35 and 3 studies in Caucasian populations.30,31,39 In studies assessing biomarkers 
for prediction of onset of nephropathy the transition in albuminuria class (i.e. normo- to 
microalbuminuria) was the endpoint used in all studies. In studies assessing biomarkers 
for prediction of progression of nephropathy the endpoints used were transition in 
albuminuria class (i.e. micro- to macroalbuminuria) in microalbuminuric patients in three 
studies,37-39 and doubling of serum creatinine in macroalbuminuric patients in one study.29 
In studies of mixed normo-, micro- or macroalbuminuric patients the endpoints used 
were very heterogeneous and no distinction was made between onset and progression 
of nephropathy. Therefore, the identified biomarkers are summarized as the separate 
category “onset and progression”. Endpoints used by these studies were change of urinary 
albumin excretion rate over time (without indication of the baseline urinary albumin 
excretion rate),36 the ratio of the urinary albumin excretion rate at baseline and urinary 
albumin excretion rate at end of follow-up,34 development of macroalbuminuria in 
combined normo- and microalbuminuric patients,31,32,35 transition from either normo- to 
microalbuminuria or micro- to macroalbuminuria),33 and transition from normo- to either 
micro- or macroalbuminuria.30 Meta-analysis was not performed because of marked 
heterogeneity in biomarkers analysed, study endpoints, statistical methods used and 
biomarker cut-off levels. 
Methodological quality score, adjustment score, and biomarker validity score
Overall, seven of the 15 studies had good methodological quality, six studies were classified 
as average and two studies as fair. “Average” to “good” adjustment score corresponding to 
an adjustment for at least seven of 10 of the conventional risk factors was only present in six 
studies (table 3). All of these six studies also had good or average methodological quality. 
The biomarkers from these six studies were considered as valid. These studies identified 
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17 valid biomarkers, of which 13 yielded significant results predicting nephropathy. 
Detailed results of all biomarkers are shown in tables 4, 5 and 6. Results were stratified for 
studies reporting on biomarkers predicting the onset of nephropathy, the progression of 
nephropathy, and the onset and progression of nephropathy in combined patient cohorts, 
respectively. 
Biomarkers predicting onset of nephropathy in diabetes (early nephropathy) 
Five urinary biomarkers for prediction of the onset of nephropathy in diabetes were 
evaluated (Table 4).25-27 Of these, urinary IgG, ceruloplasmin, and transferrin were 
predictive of nephropathy onset and had highest validity because of average study design 
and prediction beyond most conventional risk factors. Urinary transferrin was evaluated 
in two studies of good methodological quality, and it was significantly associated with 
onset of nephropathy in both.
Four serum/plasma biomarkers for the onset of nephropathy were evaluated. IL-18 
(a marker of subclinical inflammation) and asymmetric dimethylarginine (ADMA; a 
marker of endothelial dysfunction) could be considered as most promising predictors of 
microalbuminuria, as these were identified in well-designed studies adjusting for (nearly) 
all conventional risk factors. 
Although urinary N-acetylglucosaminidase (NAG) and serum C-reactive protein (CRP) 
were considered valid candidates, results were not significant. The remaining biomarkers 
[matrix metallopeptidase-9 (MMP9) in plasma and lipocalin-type prostaglandin D2 
synthase (L-PGDS) in urine] were not considered valid due to lack of adjustment for 
conventional risk factors.
Biomarkers predicting progression of nephropathy in diabetes (late nephropathy)
Twelve biomarkers for progression of nephropathy in diabetes were evaluated (Table 5). Of 
these, nine plasma biomarkers were evaluated by Persson et al. in patients from the well-
designed randomized control trial ‘Irbesartan MicroAlbuminuria Type 2 Diabetes Mellitus 
in Hypertensive Patients’ (IRMA-2).40 Vascular cell adhesion molecule-1 in serum (sVCAM1), 
interleukin-6 (IL-6), von Willebrand factor (vWf), and intercellular cell adhesion molecule-1 
in serum (sICAM1) were significantly associated with albuminuria progression, whereas 
high sensitive CRP (hs-CRP), transforming growth factor β (TGF-β), fibrinogen, E-selectin, 
and advanced glycation end-product (AGE) peptides were not significant. Interestingly, 
this study also tested the combined z-scores of multiple biomarkers (biomarker panel). 
The panel of markers of endothelial dysfunction (i.e. sVCAM1, vWF, sICAM1 and E-selectin) 
was found as an independent predictor of progression, whilst the panel of inflammation 
markers (i.e. hs-CRP, IL-6 and fibrinogen) was not. The valid biomarker ADMA that was 
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earlier shown to predict onset of nephropathy also predicted progression of nephropathy.38 
In contrast, IL-18 predicted onset but not progression of nephropathy and hs-CRP neither 
predicted onset nor progression of nephropathy in the study by Araki et al.37 Whereas the 
methodological quality of the study on Lipoprotein(a) was good, the study did not address 
adequate correction for conventional risk factors resulting in low overall biomarker 
validity.
Biomarkers predicting onset and progression of nephropathy in diabetes
Fourteen biomarkers were evaluated in seven studies in combined cohorts of normo-, micro- 
and macroalbuminuric patients with variable endpoints (Table 6). Of these studies all but 
one had average to good methodological quality. However, only the study by Stehouwer 
et al. (assessing six biomarkers) performed adequate adjustment for conventional risk 
factors, and identified hs-CRP, E-selectin, tissue-type plasminogen activator (TPA), (vWf) 










































































Araki (38) ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ 10
Bruno (32) □ ■ □ ● ■ □ □ □ □ □ 3
Ebihara (27) □ □ □ □ □ □ □ □ □ □ 0
Fukui (37) □ ■ □ ■ ■ ■ □ ■ ■ □ 6
Hanai (39) ■ ■ ■ ■ ■ □ ■ ■ ■ ■ 9
Hinokio (34) □ ■ □ ■ ■ □ □ □ □ □ 3
Kazumi (26) ■ □ ■ ■ ■ ■ □ ■ ■ □ 7
Looker (36) ■ ■ ■ □ ■ □ □ □ □ □ 4
Nakamura (35) ■ □ □ □ □ □ □ □ □ □ 1
Narita (25) ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ 10
Okazaki (33) □ ■ ■ ■ ■ □ □ □ □ □ 4
Persson (29) ■ □ ■ ■ ■ ■ ■ ■ □ ■ 8
Song (30) ■ □ □ ■ ■ □ □ □ □ □ 3
Stehouwer (31) ■ ■ ■ ■ ■ ■ □ ■ ■ □ 8
Uehara (28) □ □ □ □ □ □ □ □ □ □ 0
 ■, Criterion is met; □ Criterion is not met.
Table 3| Adjustment score
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Discussion
In this systematic review we identified 15 publications on longitudinal studies reporting on 
27 candidate biomarkers for the prediction of nephropathy in type 2 diabetes. We scored 
the methodological quality of the identified studies and we evaluated whether these 
biomarkers add information on risk prediction. Using this approach we demonstrated 
that the overall study quality of these studies is in general modest. This not only limits 
proper assessment of the potential clinical value of the identified biomarkers, it also limits 
the generalizability and comparability of the results. 
Most of the marker molecules identified in this systematic review represent subclinical 
systemic inflammation (CRP, IL-6, IL-18, fibrinogen), endothelial dysfunction (ADMA, vWF, 
VCAM, ICAM1, TPA), extracellular matrix synthesis (TGFb1, laminin, collagen type 4) or 
glomerular and tubular dysfunction (urinary IgG, ceruloplasmin, and transferrin). Due to 
the clear pathophysiological connection between these molecules and nephropathy in 
diabetes it is tempting to utilize these biomarkers in clinical practice. However, before 
these markers can be applied in practice, the clinical applicability of these biomarkers 
needs to be confirmed in high-quality validation studies. 
We would like to highlight several important methodological issues that are relevant 
for the quality of biomarker research. First, we found that studies of predictive markers 
frequently calculated odds ratios or relative risks to demonstrate the strength of 
association between the biomarker and the outcome. However, odds ratios and hazard 
ratios inaccurately predict the risk for individual subjects as the ratios are only a measure 
of association between biomarker and outcome, but do not characterize the ability to 
discriminate between future health or disease.41 
Another limitation of odds ratios and relative risks is that the size of the ratio depends 
on the units of measurement.8 Some form of standardization is necessary, for example 
by division of a continuous measure by its standard deviation. Moreover, even if very 
large odds ratios are reported, one cannot conclude that the marker has good predictive 
power, since each odds ratio could correspond to largely variable true-positive/ false-
positive fractions. Hence, instead of using odds ratios, the additive value of a marker in risk 
prediction should be specified by prediction analyses such as false-positive/true-positive 
fractions, area under the receiver-operator characteristic curve, the net reclassification 
improvement (NRI), integrated discrimination improvement (IDI),42 or the discriminative 
likelihood ratio (dLR).43,44 Only one study included in this review reported an area under the 
ROC-curve,28 and 4 other studies provided sufficient detail for the calculation of sensitivity 
and specificity.25,26,29,33
A second important issue in biomarker research concerns the validation of results of 
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a study in other patient populations. Biomarkers only have clinical value if the results 
are reproducible (external validation). Of the 27 identified biomarkers, the majority was 
evaluated in only one (longitudinal) study, and only 10 markers (plasma VCAM1, hs-CRP, 
vWF, fibrinogen, E-selectin, triglycerides, transferrin, serum IL18, homocysteine and urinary 
transferrin) were analyzed in at least two studies. In nearly all cases results could not be 
replicated (potentially attributable to limited power). 
A last important methodological issue is the heterogeneity of endpoints in some of the 
studies. Moreover, the methods of albumin assessment and the number of albuminuria 
measurements were either not stated or highly heterogeneous between the studies. 
Lastly, the frequently used endpoint “transition in albuminuria class” has crucial 
limitations, e.g. a patient with a rise in albuminuria from 29 to 31 mg/day is defined as 
progressor, while a patient who increases from 31 to 299 mg/day is not. Thus, avoiding 
albuminuria classification itself or introduction of combined relative and absolute 
changes in albuminuria (e.g. class transition and at least 30% increase) may represent a 
valid alternative. This also highlights the importance to reach consensus on definitions of 
endpoints in biomarker research.
Aside from these limitations in study design, several biomarkers showed promising 
results. For the prediction of onset of nephropathy in diabetes, urinary IgG, ceruloplasmin 
and transferrin, serum IL-18 and plasma ADMA were most promising. The results on 
biomarkers for progression of diabetic nephropathy are not conclusive due to differences 
in adjustment for conventional risk factors.
This review has certain limitations due to its focus on longitudinal studies for prediction 
of nephropathy and its focus on methodological quality. We were unable to compare 
the measures of association of the described biomarkers due to marked heterogeneity 
in study endpoints, statistical methods and different cut-offs. Head-to-head comparison 
of biomarkers in a well-designed and sufficiently large longitudinal study is most likely 
the best way to compare biomarkers. Secondly, we did not take into consideration the 
individual time of follow-up in the individual studies. This is of particular importance in a 
slow progressive disease such as nephropathy in diabetes. 
Based on the status of current biomarker research in this field, we recommend that 
future research should be directed at both further biomarker discovery and validation 
of published biomarkers in large well-designed longitudinal studies. Specific prediction 
analyses should be applied to assess the additive predictive value of novel and published 
biomarker candidates beyond conventional risk factors. 
In the end, all effort of biomarker research should be directed towards the development of 
a reliable, accurate, reproducible and robust “Diabetic Nephropathy Biomarker Panel” that 
would compare to the biomarker panel consisting of creatine kinase (CK), CK-MB, Troponin 




Chapter 2Validity of Biomarkers of Nephropathy in Patients with Type 2 Diabetes; A Systematic Review
I and Troponin T currently used in cardiology. Both clinical practice and clinical trials on the 
efficacy of various treatments on renal disease in type 2 diabetic patients would benefit 
of such a biomarker panel, thus developing such a biomarker panel would be a major step 
Conclusions
The fact that many well-designed studies were not able to confirm the results on certain 
biomarkers emphasizes the remaining uncertainty of the clinical utility of many of the 
studied markers despite promising findings. Future research will have to elucidate the 
true value of the current biomarker candidates for prediction of onset and progression 
of nephropathy in diabetes. However, current results prevent us from making clear 
recommendations for clinical practice at this moment.
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Abstract 
Background: Development of micro- or macroalbuminuria is associated with increased 
risk of cardio-renal complications, particularly in diabetes. For prevention of transition 
to micro- or macroalbuminuria more accurate prediction-markers on top of classical 
risk-markers are needed. We studied a new promising marker, Growth-Differentiation 
Factor-15 (GDF-15), to predict transition to increasing stage of albuminuria in type-2 
diabetes (T2DM). In addition, we looked at the GDF-15 potential in non-diabetic subjects 
with hypertension (HT). 
Methods: Cases and controls were selected from the PREVEND-cohort, a large (n=8,592), 
prospective general population study on the natural course of albuminuria, with >10 years 
of follow-up and repeated albuminuria-measurements. We found 24 diabetic and 50 
hypertensive cases transitioning from normo- to microalbuminuria, and 9 diabetic and 25 
hypertensive cases from micro- to macroalbuminuria (average follow-up 2.8 yrs). Controls 
with stable albuminuria were pair-matched for age, gender, baseline albuminuria status 
and diabetes-duration. GDF-15 was measured in samples prior to albuminuria-transition.
Results: Prior to transition, GDF-15 was significantly higher in cases with T2DM than in 
controls (1288[885-1546] vs. 948[660-1016] pg/mL,P<0.001). The odds-ratio for transition 
in albuminuria increased significantly per SD of GDF-15 (2.9 [95%CI 1.1-7.5],P=0.03). GDF-
15 also improved prediction of albuminuria-transition, with significant increases in 
C-statistic (from 0.87 to 0.92, P=0.03) and integrated-discrimination-improvement (0.148, 
P=0.001). In HT, GDF-15 was also independently associated with transition in albuminuria-
stage (2.0[1.1-3.5], P=0.02) and improved prediction significantly.
Conclusions: We identified GDF-15 as a clinically valuable marker for predicting transition 
in albuminuria-stage in T2DM beyond conventional risk markers. These findings were 
confirmed in non-diabetic hypertensive subjects.
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Introduction
The prevalence of chronic kidney disease (CKD) is increasing and has become a major 
public health challenge.1 This increase in CKD is largely due to the rapidly expanding 
epidemic of type 2 diabetes mellitus (T2DM) leading to diabetic nephropathy and 
ultimately end-stage renal disease (ESRD).2 Transition to increasing stages of albuminuria 
(i.e. normo- to microalbuminuria and micro- to macroalbuminuria) is considered a 
hallmark of progression of renal disease in diabetes.3 However, once transitioned from 
normo- to microalbuminuria or to macroalbuminuria, regression of disease is very difficult 
to achieve. Indeed, recent trials in normo-, micro-, and macroalbuminuric diabetic subjects 
showed that early intervention (in normoalbuminuric stage) is more effective than late 
intervention.4 Early markers that detect those that have an increased risk for developing 
micro- or macroalbuminuria could thus help to reduce the number of patients at renal 
risk through selective and appropriate treatment of such patients.5,6 
Many risk factors have been linked to transition from normo- to micro and micro- to 
macroalbuminuria, such as hyperglycemia, hypercholesterolemia and hypertension.7 
However, accurate risk stratification remains challenging. Novel biomarkers may help to 
improve the identification of subjects at risk, as well as improve insight in the underlying 
pathophysiology of the development of micro- or macroalbuminuria. Whereas several 
promising novel biomarkers were described in literature, this had not led to improved risk 
stratification in T2DM.8 
The lack of well-designed prospective studies that first stored samples of individuals 
for novel risk marker analyses and then followed the course of albuminuria over time 
may explain the paucity of knowledge on the prognostic value of novel biomarkers to 
improve risk stratification. We performed a nested case-control study in the large general 
population cohort ‘Prevention of REnal and Vascular End-stage Disease (PREVEND) to 
investigate novel biomarkers that may precede and predict the transition in albuminuria.9
Growth Differentiation Factor-15 (GDF-15), a member of the TGF-β family, is a promising 
novel biomarker, which has been implicated as predictor for cardiovascular and all-cause 
mortality.10-12 Interestingly, it was also associated with renal outcome and a faster decline 
of eGFR as well as mortality in type 1 diabetic patients with macroalbuminuria.13 It is 
unclear whether these findings regarding renal outcome are also applicable to patients 
with type 2 diabetes. In the current study, we investigated whether circulating GDF-15 
levels precede and predict the development of micro- or macroalbuminuria in type 2 
diabetic patients. To test whether this is specific to diabetes, we performed a replication 
study to assess the predictive value of GDF-15 in non-diabetic hypertensive patients. 
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Patients and methods
The present study was performed as a nested case-control study in subjects participating in 
the ‘Prevention of REnal and Vascular End-stage Disease’ (PREVEND) study. This prospective 
community-based cohort study on the natural course of urinary albumin excretion with 
serial follow-up measurements was initiated in 1997. Details of the study protocol have 
been published elsewhere.9 In short, all inhabitants of the city of Groningen aged 28–75 
years were sent a questionnaire and a vial to collect a first-morning-void urine sample. Of 
these individuals, 40,856 responded (47.8%). From these individuals a cohort consisting of 
8,592 subjects was selected (the PREVEND cohort). In this ongoing study participant are 
invited to visit an outpatient clinic for detailed medical examination at ± 3-year intervals. 
At each screening round participants fill out questionnaires on demographics, medical 
history and drug use. Information on drug use is completed with data from community 
pharmacies, including information on class of antihypertensive medication (ACEi/ARB). 
At the study visits participants deliver two 24-hour urine collections, blood pressure is 
measured, anthropometrical measurements are performed, and fasting blood samples 
are taken. 
The PREVEND study was approved by the institutional ethics review board and was 
conducted in accordance with the guidelines of the Declaration of Helsinki. All participants 
provided written informed consent.
Definitions
Normoalbuminuria was defined as urinary albumin excretion (UAE) <30 mg/24h, 
microalbuminuria as UAE 30-299 mg/24h and macroalbuminuria as UAE >300 mg/24h. 
Albuminuria status was based on the average of 2 consecutive measurements in 24-hour 
urine collections. Transition in albuminuria was defined as a transition from normo- to 
micro- or from micro- to macroalbuminuria with at least 30% increase in urinary albumin 
excretion from baseline between two consecutive study visits. T2DM was defined as the 
use of oral anti-diabetic treatment (self-reported or by information retrieved from the 
regional pharmacy database), a fasting plasma glucose >7.0 mmol/L (126 mg/dL) or non-
fasting plasma glucose >11.1 mmol/L (>200 mg/dL). HT was defined as the use of anti-
hypertensive treatment or a systolic/diastolic blood pressure > 140/90 mmHg. 
Selection of cases and controls
For the present study, we selected patients with type 2 diabetes mellitus (T2DM) and 
transition from normo- to microalbuminuria or from micro- to macroalbuminuria. 
As controls, we selected T2DM patients who had persistent normoalbuminuria or 



















































































































Figure 1| Individual courses of urinary albumin excretion in progressors and non-progressors in albuminuria 
(cases and controls)
Individual course of UAE during follow-up for cases (black) and controls (grey) in patients with diabetes (1A) or hypertension (1B) 
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microalbuminuria throughout the same time interval as cases (Figure 1A). As a secondary 
cohort we selected similar cases and controls out of all non-diabetic patients with 
hypertension (Figure 1B). Controls were matched to the cases 1:1 based on diabetes/non-
diabetes, age, gender, baseline normo- or microalbuminuria status, and if applicable 
duration of diabetes. For each subject that showed transition in albuminuria, a matched 
control was selected that most optimally resembled the case on these combined 
parameters. 
Plasma samples of these patients were used from the visit prior to the transition from 
normo- to microalbuminuria, or micro- to macroalbuminuria (baseline). The use of agents 
intervening in the Renin-Angiotensin-Aldosterone system (RAAS) (ACEi/ARB) was allowed, 
but the type of drug and their dose had to remain stable during the study period.
Of the 8592 study participants, 318 had T2DM and 33 of these subjects had unambiguous 
transition in albuminuria and available samples of sufficient quality. Hypertension 
(without diabetes) was present in 1178 participants. Of these participants 75 subjects had 
unambiguous transition in albuminuria and available samples of sufficient quality.
Measurements
Plasma samples were stored at -800C and all samples underwent 1 freeze-thaw cycle. 
Measurements were performed blinded and in duplicate. GDF-15 was measured with a 
novel pre-commercial assay based on the Eclia principle (Roche Diagnostics) with a LLD of 
200 pg/mL and intra-individual CV of 6.7 to 9.2%.
Urinary albumin excretion (UAE) is given as the mean of the two 24-hour urinary 
excretions. Blood pressure was measured twice, in the supine position, every min for 10 
min with an automatic device (Dinamap XLModel 9300; Johnson-Johnson Medical, Tampa, 
FL, USA). eGFR was estimated using the Modification of Diet in Renal Disease (MDRD) 
study equation, using gender, age, race and serum creatinine.14
Urinary albumin concentration was determined by nephelometry (Siemens, Munich, 
Germany). Concentrations of total cholesterol and plasma glucose were measured using 
standard methods. Serum creatinine was measured by dry chemistry (Eastman Kodak, 
Rochester, New York, USA), with intra-assay coefficient of variation of 0.9% and inter-assay 
coefficient of variation of 2.9%. 
Statistical Analysis
 Analyses were performed using STATA version 11.2 (StataCorp LP, Lakeway Drive, Texas, 
USA). A study with 50 patients will provide at least 80% power to detect an odds ratio of 
1.5 assuming a type 1 error of 5% and no residual confounding after matching cases and 
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controls (www.bioconductor.org). Variables with normal distribution are given as mean ± 
standard deviation and variables with skewed distribution as median [inter quartile range 
(IQR)]. Variables with skewed distribution were log-transformed for analyses. Graphical 
methods were used to ascertain normalization of the distribution after transformation. 
Differences between the cases and controls were tested with paired-samples t-test for 
continuous variables and chi-squared test on paired proportions for categorical variables. 
Differences between non-paired groups were tested with independent samples t-test for 
continuous variables and chi-square test for categorical variables. 
To investigate the association between the levels of the markers and transition in 
albuminuria we used conditional logistic regression because of the paired study design. In 
multivariable analyses, we adjusted for differences in baseline urinary albumin excretion 
(UAE) and estimated glomerular filtration rate (eGFR) between cases and controls as these 
two markers are important risk factors for transition in albuminuria stage. We tested for 
interaction between patients who made a transition from normo- to microalbuminuria 
and those who made a transition from micro- to macroalbuminuria by adding an 
interaction term for baseline albuminuria-status and GDF-15 in the model.
To assess whether the markers improved risk prediction and discrimination we determined 
the c-statistic and Integrated Discrimination Improvement (IDI). We calculated the 
c-statistic (discriminatory ability) based on the most important established risk factors 
(UAE, eGFR) and compared those to c-statistics after addition of GDF-15 to the established 
model. Differences in c-statistic were tested with chi-square test. 
In addition to the c-statistic, we calculated the integrated discrimination improvement 
(IDI), another measure of discrimination.15 The IDI is the difference in discrimination 
slopes between cases and controls before and after the addition of the biomarker(s) to 
the model. It assesses the improvement in average sensitivity without sacrificing average 
specificity.16 Calculation of the IDI is done by computing average predicted probabilities 
of the event in cases and controls in models with and without the biomarker(s) 
and subtracting the values from cases and controls from each other. The increase in 
difference between cases and controls after addition of the biomarker(s) is the integrated 
reclassification improvement. The IDI is often more sensitive than the rather conservative 
c-statistic because when several highly predictive markers are in the model, enormous 
odds ratios are required to meaningfully increase the c-statistic.17 For all analyses two-
sided P-values <0.05 were considered statistically significant.
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Type 2 Diabetes Hypertension
Patient Characteristics Cases Controls Cases Controls
Number of patients 33 33 75 75
Demographic Characteristics
   Age - years 62.7 ± 9.2 62.8 ± 9.6 66.3 ± 9.8 65.6 ± 8.7
   Male gender - n (%) 25 (75.8) 25 (75.8) 53 (70.7) 53 (70.7)
   Race - n (%)
     Caucasian 30 (90.9) 31 (93.9) 71 (94.7) 73 (97.3)
     Other 3 (9.1) 2 (6.1) 4 (5.3) 2 (2.7)
Clinical Characteristics
   Smoking - n (%) 6 (18.1) 5 (15.1) 18 (24.0) 13 (17.3)
   BMI - kg/m2 30.0 ± 6.3 27.8 ± 4.2 28.5 ± 4.5 27.9 ± 4.5
   Blood pressure - mmHg
      Systolic Blood Pressure 137 ± 15 134 ± 20 139 ± 19 137 ± 18
      Diastolic Blood Pressure 75 ± 9 75 ± 8 77 ± 8 78 ± 9
   History of Coronary Heart Disease$- n (%) 7 (21.3) 2 (6.1)† 11 (14.9) 9 (12.0)
   Follow-up time 2.7 [2.2-3.8] 2.8 [2.3-4.0] 2.8[2.3-4.0] 2.8 [2.1-3.7]
Laboratory Parameters
  Urinary albumin excretion - mg/24h 22 [17-34] 12 [6-40]* 22 [13-83] 11 [7 -37]‡
  eGFR - mL/min/1.73m2 76 ± 18 80 ± 17 72 ± 21 69 ± 20
  Total Cholesterol - mmol/L 5.0 ± 1.4 5.2 ± 1.4 5.3 ± 1.0 5.4 ± 1.1
  Fasting Plasma Glucose - mmol/L 7.6 ± 1.9 7.2 ± 1.2 5.3 ± 0.8 5.1 ± 0.9
Treatment - n (%)
  Antihypertensive drugs 23 (69.7) 11 (33.3) 75 (100) 75 (100)
  ACEi/ ARB 16 (48.5) 2 (6.1)* 39 (52.0) 39 (52.0)
  Oral antidiabetics 24 (72.7) 24 (72.7) 0 (0) 0 (0)
  Lipid lowering drugs 18 (54.6) 7 (21.2)† 27 (36.0) 20 (26.7)
Baseline UAE status - n (%)
  Normoalbuminuria 24 (72.7) 24 (72.7) 50 (66.7) 50 (66.7)
  Microalbuminuria 9 (27.3) 9 (27.3) 25 (33.3) 25 (33.3)
Median change in UAE - mg/24h  31 [22-151] 0 [-4 - 3]‡ 70 [29-310] 0 [-2 – 8]‡
Median change in UAE - % 164 [106-340] 0 [-23 – 38] 314 [143-668] 5 [-18 – 46]
Table 1| Baseline Characteristics for patients with T2DM and non-diabetic patients with HT
*Cases vs. controls P < 0.05, † Cases vs. controls P<0.01, ‡ Cases vs. controls P<0.001. Plus-minus values are means ± SD 
and non-normally distributed variables are median [inter quartile range (IQR)]. $ Self-reported Coronary Heart Disease. 
T2DM: Type 2 Diabetes Mellitus; HT: Hypertension; BMI: body mass index (weight kg/length m2); eGFR: estimated glo-
merular filtration rate (modification of diet in renal disease-formula); ACEi: angiotensin-converting enzyme inhibitors; ARB: 
angiotensin-2 receptor blockers; UAE: urinary albumin excretion rate. To convert values for serum cholesterol from mmol/L 
into mg/dL multiply by 38.67, to convert values for fasting plasma glucose from mmol/L into mg/dL multiply by 18 and 
to convert values for serum creatinine from µmol/L to mg/dL divide by 88.4.
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Results
In total, 33 cases with type 2 diabetes mellitus (T2DM) and transition from normo- to 
microalbuminuria or from micro- to macroalbuminuria were identified. These cases were 
pair-matched to 33 controls with T2DM and stable albuminuria. 
The baseline characteristics are presented in table 1. Mean age of cases was 62.7 years, 
25 (75.8%) patients were male and the median urinary albumin excretion rate was 18 
[9-44] g/24h. Median follow-up was 2.7 [2.2-3.8] years. Cases had a significantly higher 
baseline UAE than controls, were more frequently treated with lipid lowering treatment 
and more often received ACEi/ARB treatment when compared to matched controls. All 
other parameters were similar. Median follow-up time was 2.7 [2.2-4.0] years.
Change in albuminuria concentrations during follow-up, according to the selection of 
cases and controls, is shown in figure 1A. Patients with transition in albuminuria (cases) 
had a median increase in albuminuria of 31 mg/24h (164%) compared to 0 mg/24h (0%) 
in controls. 
GDF-15 in Type 2 Diabetic Patients
The mean concentration of GDF-15 in cases and for controls, prior to transition in 
albuminuria, is presented in figure 2A. In figure 2B these concentrations are presented 
separately for transition from normo- to micro and micro- to macro. GDF-15 concentrations 
were significantly higher in cases vs. controls (1288 [885-1546] vs. 948 [660-1016] pg/mL, 
P<0.001). The concentrations were lower in normoalbuminuric cases and controls than in 
microalbuminuric cases and controls (910 [737-1162] vs. 1008 [763-1470], P=0.03). 
The odd ratio for transition in albuminuria was 3.58 [95%CI 1.51-8.47] (per standard deviation 
increment in GDF-15) (table 2) and 2.87 [95%CI 1.10-7.53] after adjustment for baseline 
albuminuria and eGFR. There was no statistical significant difference between the odds 
for transition from normo- to microalbuminuria and from micro- to macroalbuminuria 
with each SD increment in GDF-15 (P for interaction=0.55). GDF-15 significantly improved 
the c-statistic on top of a baseline model consisting of UAE and eGFR (increase from 0.87 
to 0.92, P=0.03). GDF-15 also improved the Integrated Discrimination Index (IDI) (0.148, 
P=0.001), indicating that GDF-15 improved discrimination between cases and controls 
beyond baseline UAE and eGFR (table 3).
GDF-15 in non-diabetic Hypertensive Patients
The replication study was a second nested case-control study, which consisted of 75 
(non-diabetic) cases with hypertension (HT) and transition to increasing stages of 
albuminuria that were pair-matched to 75 controls with HT and stable albuminuria (table 
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1). Characteristics of patients with HT were remarkably similar to patients with T2DM, as 
was the median follow-up time (2.8 [2.3-3.9] years in HT vs. 2.7 [2.2-4.0] years in T2DM). 
Cases with HT had a median increase in albuminuria of 70 mg/24h (314%) compared to 
0.2 mg/24h (5%) in controls.
GDF-15 concentration in patients with HT was similar to the concentration in patients 
with T2DM (910 [738-1210] vs. 992 [799-1347] resp.; P=0.63). In cases with HT GDF-15 
concentration was borderline significantly higher than in controls (975 [739-1222] vs. 
872 [726-1172] pg/mL, P=0.09). The odds of transition to micro- or macroalbuminuria 
was significantly increased per SD increment in GDF-15 (1.96 [95%CI 1.12-3.45]). Also in 
patients with HT no difference was observed in the odds for transition from normo- to 
microalbuminuria or micro- to macroalbuminuria with each increment in GDF-15 (p for 
interaction=0.90). Addition of GDF-15 to the prediction model of transition in albuminuria, 
consisting of baseline UAE and eGFR, did not result in significant improvement of the 
c-statistic (from 0.88 to 0.89, P=0.8), but significantly improved IDI (0.059, P=0.04).
Per doubling Per SD increase
Odds ratio 95% Conf. Int. Odds ratio 95% Conf. Int. P-value
Type 2 Diabetes Mellitus
   GDF15 - Crude 7.66 [1.94-30.14] 3.58 [1.51-8.47] 0.004
   GDF15 - Adjusted Model* 5.39 [1.16-25.05] 2.87 [1.10-7.53] 0.03
Hypertension
   GDF15 - Crude 1.58 [0.92-2.73] 1.33 [0.95-1.88] 0.10
   GDF15 - Adjusted Model* 2.94 [1.20-7.20] 1.96 [1.12-3.45] 0.02
Table 2| Odds ratios for GDF-15 and transition in albuminuria  per log-unit increase and per SD 
increase in the level of the biomarker for patients with T2DM and non-diabetic patients with HT
Values were calculated with conditional logistic regression analyses. *Established model: prediction model based 
on urinary albumin excretion and estimated glomerular filtration rate. The biomarkers were modelled as continuous 
(log-transformed) variables. P values are for comparison of the models with the baseline model. GDF-15: Growth-
differentation factor-15; T2DM: Type 2 Diabetes Mellitus; HT: Hypertension.
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Discussion
To the best of our knowledge, this is the first study to indicate that GDF-15 precedes and 
predicts the development of micro- or macroalbuminuria in patients with type 2 diabetes 
mellitus. GDF-15 was not only independently associated with transition in albuminuria 
during a follow-up of ~3 years, it also improved discrimination between patients who did 
and did not develop micro or macroalbuminuria, beyond conventional risk markers. These 
findings were extended and replicated in a cohort of non-diabetic hypertensive patients.
Previous studies mainly implicated GDF-15 as predictor for cardiovascular events and 
all-cause mortality in patients with previous myocardial infarction.10-12 The only previous 
study focusing on GDF-15 and renal outcome was performed by Lajer et. al. in patients with 
type I diabetes mellitus and macroalbuminuria. In this observational study, higher GDF-
15 levels were associated with a faster decline of eGFR and higher risk of development of 
end-stage renal disease.13 Our study extends these latter findings to earlier stages of renal 
disease during which appropriate intervention is most beneficial.
Despite a growing body of literature demonstrating that GDF-15 is a valuable biomarker for 
cardiovascular disease, relatively little is known on the pathophysiological role of GDF-15. 
Its expression is markedly increased in response to injury in various tissues, including heart 
and kidney, and is believed to be a protective factor by reducing apoptosis and influencing 
cellular proliferation.18-20 Higher levels of GDF-15 may thus indicate tissue damage. As 
endothelial cells appear to be a prominent source of GDF-15, the circulating levels of GDF-
15 most likely represent generalized endothelial and microvascular damage.21 The relation 
of GDF-15 with micro-vasculature may explain the link with micro- or macroalbuminuria, 
as increased albuminuria supposedly reflects established microvascular damage in the 
renal and peripheral vasculature.22 Since our cases and controls were at the same stage of 
albuminuria (either normo- or microalbuminuria) at time of GDF-15 measurement, GDF-15 
seems to already be increased before microalbuminuria becomes detectable. Our finding 
that GDF-15 also contributed in identifying subjects at risk for transition in albuminuria 
stage in a non-diabetic hypertensive cohort implies that GDF-15 is not specifically related 
to diabetes. Future research will be necessary to delineate the exact pathophysiological 
role of GDF-15 in diabetes or hypertension and to assess its relation with albuminuria. 
Traditional risk factors associated with transition in albuminuria are age, gender, 
dyslipidemia, insulin sensitivity, hyperglycemia, duration of diabetes, increased blood 
pressure, duration of hypertension, body mass index, and smoking.7,23 Despite identification 
of these important risk factors for transition in albuminuria stage, the ability to stratify 
subjects at risk is still limited. The current data, if confirmed, raise the possibility of 
identification of subjects at risk even when traditional risk factors do not indicate risk, 
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facilitating early identification of those with an increased chance of developing micro- or 
macro- albuminuria. Because early intervention is more effective than late intervention,4 
preventive treatment could thus reduce the risk of renal and cardiovascular events in 
patients with T2DM.5,6 Our findings also applied to non-diabetic hypertensive patients, 
in whom albuminuria is also strongly associated with renal and cardiovascular events.24,25 
We incorporated prediction analyses in the present study to determine GDF-15 could 
add to risk prediction in individual subjects beyond traditional risk markers. Whereas the 
c-static is most commonly used, the c-statistic is not very sensitive in detecting small but 
meaningful contributions of biomarkers in correctly classifying individuals. Hardly any 
improvement of the c-statistic can be reached when the model already includes one or 
several important risk markers.17 Yet, we found improvement in C-statistic in our study in 
T2DM. Because of the insensitivity of the C-statistic, other measures of risk classification 
such as the IDI have recently been proposed.15,16 In our analyses, we also found significant 
improvement in IDI for GDF-15, both in patients with T2DM and non-diabetic subjects 
with hypertension. 
The availability of patient samples from the large general population cohort PREVEND 
was a unique feature of this study. Because this study followed the natural course of 
albuminuria by performing repeated measurements of albuminuria for more than 10 
years, we were able to measure GDF-15 in samples prior to the transition in albuminuria, 
whereas many studies have a cross-sectional design and test biomarkers in patients with 
established increased albuminuria. Other strengths include the well-defined phenotype 
of the population, with albuminuria status based on two consecutive 24-hour urine 
collections, the rigorous definitions for transition in albuminuria stage, and the availability 
of samples that had never been thawed. Because of these strict criteria and the limited 
number of patients with diabetes in this general population cohort we were only able to 
obtain 33 valid cases. 
A limitation of this study was that there was a modest difference in baseline albuminuria. 
This small baseline difference in albuminuria was inherent to the design of the study, as 
the level of albuminuria in itself is related to transition to increasing stages of albuminuria 
and we matched by albuminuria-stage rather than by albuminuria level. Adjustment for 
baseline albuminuria showed that the association of GDF-15 with albuminuria transition 
was independent of baseline albuminuria. A second limitation is the fact that the nested 
case-control design of the study may overestimate the true predictive capacity of the 
models because of the relative high event rate in case-control studies.26 Absolute values 
of the c-statistic should therefore be interpreted with caution. The improvement of the 
c-statistic and the level of significance, however are unaffected by case-control design of 
studies. Lastly, whereas these results are promising and could be confirmed in non-diabetic 
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hypertensive patients, replication of the current results in other studies, preferably large 
prospective cohort studies, is warranted before final conclusions can be reached.
Conclusions
We identified GDF-15 as a marker for prediction of transition in albuminuria in type 2 
diabetic subjects. GDF-15 moreover had significant additive value on top conventional 
risk markers in the prediction of albuminuria-transition. These findings were confirmed 
in non-diabetic hypertensive subjects. If these findings prove to be replicable in other 
studies, GDF-15 might be a valuable marker for individual risk stratification, facilitating 
start or intensification of treatment in high risk patients in order to prevent or delay the 
progression of nephropathy.
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Abstract
Background: Hypertension is an important cause of end-stage renal disease. 
Development of microalbuminuria is the first clinical sign of renal dysfunction, 
progressing to macroalbuminuria and eventually resulting in ESRD. Markers that 
could predict the development of micro- or macroalbuminuria beyond traditional 
risk markers would allow for earlier intervention and better prevention of ESRD. We 
investigated in a case-control study whether circulating levels of the micronecrosis 
marker high-sensitivity TroponinT (hs-TnT) add to predicting the development of micro- 
or macroalbuminuria in hypertensive patients (HT) and performed a replication study in 
type 2 diabetic individuals (T2DM). 
Methods: Cases and controls were extracted from a large (N=8.592) general population 
cohort with long-term follow-up and repeated measurement of albuminuria (PREVEND-
study). Cases were defined by transition in albuminuria stage, i.e. from normo- to micro- 
or from micro- to macro-albuminuria (average follow-up 2.8 yrs). Controls with stable 
albuminuria were pair-matched for age, gender, and albuminuria-status. Hs-TnT was 
measured at baseline in 75 case/control-pairs with HT and 33 case/control-pairs with 
T2DM. 
Results: Prior to transition in albuminuria, hs-TnT was higher in cases than in controls 
(6.6 [3.1-11.6] vs. 5.3 [2.9-8.6] pg/mL, P=0.05). The odds for transition in albuminuria 
increased significantly per SD increase in hs-TnT (2.2[1.2-4.3], P=0.02). In addition, hs-TnT 
improved prediction of albuminuria transition, with significant increases in integrated-
discrimination-improvement (IDI) of 0.048, P=0.02. Similar results were found in the 
T2DM case-control cohort.
Conclusions: We identified hs-TnT as an independent marker predicting the transition 
in albuminuria-stage in HT beyond conventional risk-markers. These findings were 
confirmed in subjects with T2DM.
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Introduction
An increasing number of individuals is recognized to have chronic kidney disease (CKD), 
with hypertensive nephropathy second only to diabetes as a leading cause of progressive 
CKD.1 Microalbuminuria, starting from levels of 30 mg/day and on, is an established and 
important risk factor of hypertensive renal disease with progressive CKD.2-4 Especially 
levels of albuminuria >300 mg/day are associated with fast-progressive CKD and 
ultimately end-stage renal disease that requires dialysis or renal transplantation.2-4
It is obvious that effective therapeutic strategies for progressive CKD should include 
prevention of micro- or macroalbuminuria.1 Early markers that detect those that have an 
increased chance for developing micro- or macroalbuminuria could thus help us reduce the 
number of patients at renal risk through selective preventive treatments of such patients.5,6 
Many risk factors have been linked to development of micro- or macroalbuminuria, such 
as hyperglycemia, hypercholesterolemia and hypertension.7 However, these risk factors 
insufficiently discriminate those that will develop increased albuminuria from those that 
will not. Novel early biomarkers may help to improve the identification of subjects at risk, 
as well as lead to a better understanding of the underlying pathophysiology of transition 
in albuminuria. 
A lack of well-designed prospective studies that first stored samples of individuals for 
novel risk marker analyses and then followed the course of albuminuria over time may 
explain the paucity of knowledge on the value of novel biomarkers to improve risk 
stratification. The ‘Prevention of REnal and Vascular End-stage Disease’ (PREVEND) study is 
a large prospective study on the natural course of albuminuria in the general population, 
with to date five repeated measurements of albuminuria with 3-year intervals in 8.592 
subjects.8 This cohort offers a unique opportunity to prospectively study the predictive 
power of biomarkers for morbidity and/or mortality events. 
The micronecrosis marker high-sensitivity Troponin T (hs-TnT) is increasingly recognized 
as a strong predictive marker for vascular events.9-13 Interestingly, hs-TNT appeared to be 
an independent risk factor prediction the progression of diabetic nephropathy in patients 
with type 1 diabetes.14 We aimed to investigate whether hs-TNT levels precede and predict 
the development of micro- or macroalbuminuria in subjects with hypertension and to 
compare and confirm findings in subjects with type 2 diabetes (T2DM). We therefore 
performed a nested case-control study in the PREVEND-cohort. 
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Methods
The present study was performed as a nested case-control study in subjects participating 
in the Prevention of REnal and Vascular End-stage Disease (PREVEND) study. This 
prospective community-based cohort study with serial follow-up measurements was 
initiated in 1997 to investigate the natural course of urinary albumin excretion and its 
relation to renal and cardiovascular disease in a predominantly Caucasian population. 
Details of the study protocol have been published elsewhere.8 In short, all inhabitants 
of the city of Groningen aged 28–75 years were sent a questionnaire and a vial to collect 
a first-morning-void urine sample. Of these individuals, 40 856 responded (47.8%). From 
these individuals a cohort consisting of 8592 subjects was selected (the PREVEND cohort). 
In this ongoing study participant are invited to visit an outpatient clinic for detailed 
medical examination at ± 3-year intervals. At each screening round participants fill out 
questionnaires on demographics, medical history and drug use. Information on drug use 
is completed with data from community pharmacies, including information on class of 
antihypertensive medication (ACEi/ARB). At the study visits participants deliver two 24-
hour urine collections, blood pressure is measured, anthropometrical measurements are 
performed, and fasting blood samples are taken. 
The PREVEND study was approved by the institutional ethics review board and was 
conducted in accordance with the guidelines of the Declaration of Helsinki. All participants 
provided written informed consent.
Definitions
Normoalbuminuria was defined as urinary albumin excretion (UAE) <30 mg/24h, 
microalbuminuria as UAE 30-299 mg/24h and macroalbuminuria as UAE >300 mg/24h. 
Albuminuria status was based on the average of 2 consecutive measurements in 24-hour 
urine collections. Transition in albuminuria was defined as a transition from normo- to 
micro- or from micro- to macroalbuminuria with at least 30% increase in urinary albumin 
excretion from baseline between two consecutive study visits. HT was defined as the use of 
anti-hypertensive treatment or a systolic/diastolic blood pressure > 140/90 mmHg. T2DM 
was defined as the use of oral anti-diabetic treatment (self-reported or by information 
retrieved from the regional pharmacy database), a fasting plasma glucose >7.0 mmol/L 
(126 mg/dL) or non-fasting plasma glucose >11.1 mmol/L (>200 mg/dL). 
Selection of cases and controls
For the present study, we selected patients with HT and progression from normo- to 
microalbuminuria or from micro- to macroalbuminuria, and patients with type 2 diabetes 
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mellitus (T2DM) and progression in albuminuria-stage as cases. As controls, we selected HT 
or T2DM patients who had persistent normoalbuminuria or microalbuminuria throughout 
the same time interval as the selected cases. Controls were matched to the cases 1:1 based 
on hypertension/diabetes, age, gender, baseline normo- or microalbuminuria status, and 
duration of diabetes. For each subject that showed transition in albuminuria-stage, a 
matched control was selected that most optimally resembled the case on these combined 
parameters. Plasma samples of these patients were used from the visit prior to the 
transition from normo- to microalbuminuria, or micro- to macroalbuminuria (baseline). 
The use of agents intervening in the Renin-Angiotensin-Aldosterone system (RAAS) (ACEi/
ARB) was allowed, but the type of drug and their dose had to remain stable during the 
study period.
Of the 8592 study participants, hypertension was present in 1178 participants. Of these 
participants 75 subjects had unambiguous transition in albuminuria and available 
samples of sufficient quality. Of the 8592 study participants, 318 had T2DM and 33 of these 
subjects had unambiguous transition in albuminuria and available samples of sufficient 
quality.
Measurements
Plasma samples were stored at -800C and all samples underwent 1 freeze-thaw cycle. 
Measurements were performed blinded and in duplicate. Hs-TnT was measured with a 
novel highly sensitive assay, Elecsys® high-sensitivity Troponin T (Roche Diagnostics) with 
a lower limit of detection (LLD) of 3 pg/mL and intra-individual coefficient of variation (CV) 
of 0.7 to 5.6%. For the purpose of meaningful data-analyses, values below the LLD were 
conservatively set at a value of 2.9 pg/mL. 
Urinary albumin excretion (UAE) is given as the mean of the two 24-hour urinary 
excretions. Blood pressure was measured twice, in the supine position, every min for 10 
min with an automatic device (Dinamap XLModel 9300; Johnson-Johnson Medical, Tampa, 
FL, USA). eGFR was estimated using the Modification of Diet in Renal Disease (MDRD) 
study equation, using gender, age, race and serum creatinine.15
Urinary albumin concentration was determined by nephelometry (Siemens, Munich, 
Germany). Concentrations of total cholesterol and plasma glucose were measured using 
standard methods. Serum creatinine was measured by dry chemistry (Eastman Kodak, 
Rochester, New York, USA), with intra-assay coefficient of variation of 0.9% and inter-assay 
coefficient of variation of 2.9%. 
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Figure 1| Individual courses of urinary albumin excretion in progressors and non-progressors in albuminuria 
(cases and controls)
Individual course of UAE during follow-up for cases (black) and controls (grey) in patients with hypertension (1A) or type 2 diabetes 
(1B) stratified for albuminuria-status at baseline (left: normoalbuminuria; right: microalbuminuria). T2DM: Type 2 Diabetes Mellitus; 
HT: Hypertension.  
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Statistical Analysis
 Analyses were performed using STATA version 11.2 (StataCorp LP, Lakeway Drive, Texas, 
USA). A study with 50 patients will provide at least 80% power to detect an odds ratio of 
1.5 assuming a type 1 error of 5% and no residual confounding after matching cases and 
controls (www.bioconductor.org). Variables with normal distribution are given as mean ± 
standard deviation and variables with skewed distribution as median [inter quartile range 
(IQR)]. Variables with skewed distribution were log-transformed for analyses. Graphical 
methods were used to ascertain normalization of the distribution after transformation. 
Differences between the cases and controls were tested with paired-samples t-test for 
continuous variables and chi-squared test on paired proportions for categorical variables. 
Differences between non-paired groups were tested with independent samples t-test for 
continuous variables and chi-square test for categorical variables. 
To investigate the association between the levels of the markers and transition in 
albuminuria we used conditional logistic regression because of the paired study design. In 
multivariable analyses, we adjusted for the differences in baseline characteristics between 
the groups: urinary albumin excretion (UAE) and estimated glomerular filtration rate 
(eGFR) (the latter only borderline significantly different), both also important risk factors 
for transition in albuminuria-stage.16,17 We tested for interaction between patients who 
made a transition from normo- to microalbuminuria and those who made a transition 
from micro- to macroalbuminuria by adding an interaction term for baseline albuminuria 
status and hs-TnT in the model.
To assess whether the marker improved risk prediction and discrimination we determined 
the c-statistic and Integrated Discrimination Improvement (IDI). We calculated the 
c-statistic (discriminatory ability) of a model including UAE and eGFR (established model) 
and compared those to c-statistics after addition of hs-TnT to the established model. 
Differences in c-statistic were tested with the chi-square test. 
In addition to the c-statistic, we calculated the integrated discrimination improvement 
(IDI) as described by Pencina et al., another measure of discrimination.18 The IDI is the 
difference in discrimination slopes between cases and controls before and after the 
addition of hs-TnT to the model. It assesses the improvement in average sensitivity 
without sacrificing average specificity. Calculation of the IDI is done by computing average 
predicted probabilities of the event in cases and controls in models with and without 
hs-TnT. The prediction probabilities of models with and without hs-TnT are subtracted 
in cases and controls respectively. The increase in difference between cases and controls 
after addition of the biomarker is the integrated reclassification improvement. The IDI is 
often more sensitive than the rather conservative c-statistic because when several highly 
predictive markers are in the model, enormous odds ratios are required to meaningfully 
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 Hypertension  Type 2 Diabetes
Patient Characteristics Cases Cases Cases Controls
Number of Patients 75 33 33 75
Demographic Characteristics
   Age - years 66.3 ± 9.8 62.7 ± 9.2 62.7 ± 9.2 65.6 ± 8.7
   Male Gender - n (%) 53 (70.7) 25 (75.8) 25 (75.8) 53 (70.7)
   Race - n (%)
     Caucasian 71 (94.7) 30 (90.9) 30 (90.9) 73 (97.3)
     Other 4 (5.3) 3 (9.1) 3 (9.1) 2 (2.7)
Clinical Characteristics
   Smoking - n (%) 18 (24.0) 6 (18.1) 6 (18.1) 13 (17.3)
   BMI - kg/m2 28.5 ± 4.5 30.0 ± 6.3 30.0 ± 6.3 27.9 ± 4.5
   Blood Pressure - mmHg
      Systolic Blood Pressure 139 ± 19 137 ± 15 137 ± 15 137 ± 18
      Diastolic Blood Pressure 77 ± 8 75 ± 9 75 ± 9 78 ± 9
   History of Coronary Heart Disease$- n (%) 11 (14.9) 7 (21.3) 7 (21.3) 9 (12.0)
   Follow-up time - years 2.8[2.3-4.0] 2.7 [2.2-3.8] 2.7 [2.2-3.8] 2.8 [2.1-3.7]
Laboratory Parameters
  Urinary Albumin Excretion - mg/24h 22 [13-83] 22 [17-34] 22 [17-34] 11 [7 -37]‡
  eGFR - mL/min/1.73m2 72 ± 21 76 ± 18 76 ± 18 69 ± 20
  Total Cholesterol - mmol/L 5.3 ± 1.0 5.0 ± 1.4 5.0 ± 1.4 5.4 ± 1.1
  Fasting Plasma Glucose - mmol/L 5.3 ± 0.8 7.6 ± 1.9 7.6 ± 1.9 5.1 ± 0.9
Treatment - n (%)
  Antihypertensive Drugs 75 (100) 23 (69.7) 23 (69.7) 75 (100)
  ACEi/ ARB 39 (52.0) 16 (48.5) 16 (48.5) 39 (52.0)
  Oral Antidiabetics 0 (0) 24 (72.7) 24 (72.7) 0 (0)
  Lipid Lowering Drugs 27 (36.0) 18 (54.6) 18 (54.6) 20 (26.7)
Baseline UAE status - n (%)     
  Normoalbuminuria 50 (66.7) 24 (72.7) 24 (72.7) 50 (66.7)
  Microalbuminuria 25 (33.3) 9 (27.3) 9 (27.3) 25 (33.3)
Median change in UAE - mg/24h  70 [29-310] 31 [22-151] 31 [22-151] 0 [-2 – 8]‡
Median change in UAE - % 314 [143-668] 164 [106-340] 164 [106-340] 5 [-18 – 46]
     *Cases vs. controls P < 0.05, † Cases vs. controls P<0.01, ‡ Cases vs. controls P<0.001. Plus-minus values are means ± SD 
and non-normally distributed variables are median [inter quartile range (IQR)]. $ Self-reported Coronary Heart Disease. 
T2DM: Type 2 Diabetes Mellitus; HT: Hypertension; BMI: body mass index (weight kg/length m2); eGFR: estimated glo-
merular filtration rate (modification of diet in renal disease-formula); ACEi: angiotensin-converting enzyme inhibitors; ARB: 
angiotensin-2 receptor blockers; UAE: urinary albumin excretion rate. To convert values for serum cholesterol from mmol/L 
into mg/dL multiply by 38.67, to convert values for fasting plasma glucose from mmol/L into mg/dL multiply by 18 and to 
convert values for serum creatinine from µmol/L to mg/dL divide by 88.4.
Table 1| Baseline Characteristics for patients with T2DM and non-diabetic patients with HT
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increase the c-statistic.19 For all analyses two-sided P-values <0.05 were considered 
statistically significant.
Results 
In total, 75 cases with hypertension (HT) and progression from normo- to microalbuminuria 
or from micro- to macroalbuminuria were available. These cases were pair-matched to 75 
controls with HT and stable albuminuria.
The baseline characteristics of these cases and controls are presented in table 1. Mean 
age of the patients with HT was 64.9 years, 176 (72%) patients were male, and the median 
urinary albumin excretion rate was 18 [9-44] g/24h. Cases had a significantly higher 
baseline UAE than controls. All other parameters were similar. Median follow-up time 
was 2.8 [2.3-3.9] years. The changes in albuminuria during the follow-up for both cases 
and controls are shown in figure 1. Patients with transition in albuminuria had a median 
increase in albuminuria of 70 mg/24h (314%) compared to 0.2 mg/24h (5%) in controls.
Hs-TnT in Hypertensive Patients
The baseline (before albuminuria-stage transition) hs-TnT concentrations are presented 
in figure 2, stratified by cases and controls and presented separately for transition from 
normo- to micro and micro- to macro. Hs-TnT concentration was below the lower limit 
of detection (LLD, 3.0 pg/mL) in in 24 (32%) cases and in 18 (24%) controls (P=0.28). Hs-
TnT concentrations were higher in cases vs. controls (6.6 [3.1-11.6] vs. 5.3 [2.9-8.6] pg/mL; 
P=0.05), and marker concentrations were lower in normoalbuminuric cases and controls 
than in microalbuminuric cases and controls (4.4 [2.9-7.8] vs. 5.4 [2.9-11.3], P=0.04).
The adjusted odds for transition in albuminuria per standard deviation increment in hs-
TnT was significantly increased (2.2 [95%CI 1.2-4.3]. There was no statistically significant 
difference between the odds for transition from normo- to microalbuminuria and from 
micro- to macroalbuminuria with each SD increment in hs-TnT (P for interaction=0.58). 
We calculated the c-statistic and integrated discrimination improvement (IDI) to test 
whether the markers had additive value on top of UAE and eGFR in discriminating 
between patients with and without transition in albuminuria (table 3). Addition of hs-TnT 
to the baseline model gave non-significant improvement in c-statistic (from 0.88 to 0.91, 
P=0.2), but significant improvement of IDI (0.048, P=0.02).
 
Hs-TnT in Type 2 Diabetic Patients
The replication study was a second nested case-control study, which consisted of 33 cases 
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with diabetes (T2DM) and progression of albuminuria, which were again pair-matched 
to 33 controls with T2DM and stable albuminuria. Average follow-up in T2DM patients 
was 2.7 [2.2-4.0] years, which was very similar to the follow-up in patients with HT. 
Baseline characteristics are presented in table 1. The patients with T2DM and transition 
in albuminuria had a median increase in albuminuria of 31 mg/24h (164%) compared to 
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Figure 2| Hs-TnT levels in progressors and non-progressors in albuminuria (cases and controls)
Hs-TnT levels (pg/mL) (mean ± SE) in cases and controls and cases and controls stratified for baseline albuminuria for hypertension 
(upper panels) or type 2 diabetes (lower panels). * P<0.05. T2DM: Type 2 Diabetes Mellitus; HT: Hypertension.  
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Per doubling Per SD increase
Odds ratio 95% Conf. Int. Odds ratio 95% Conf. Int. P-value
Hypertension
   Hs-TnT - Crude 1.51 [0.99-2.32] 1.39 [0.95-2.03] 0.09
   Hs-TnT - Adjusted Model* 2.83 [1.23-6.50] 2.24 [1.17-4.31] 0.02
Type 2 Diabetes Mellitus
   Hs-TnT - Crude 5.66 [1.19-26.80] 3.39 [1.28-8.97] 0.01
   Hs-TnT - Adjusted Model* 3.51 [0.62-19.90] 2.00 [0.70-5.68] 0.16
             
Values were calculated with conditional logistic regression analyses. T2DM: Type 2 Diabetes Mellitus; HT: Hyper-
tension.
Table 2| Odds ratios for hs-TnT and transition in albuminuria-stage per log-unit increase and 
per SD increase in the level of the biomarker for patients with HT and patient with  T2DM     
C-statistic 95% Conf. Int. P-value IDI 95% Conf. Int. P-value
Hypertension
   Established Model* 0.88 [0.82-0.94] ref ref ref
   Established Model + hs-TnT 0.91 [0.86-0.95] 0.2 0.048 [0.009-0.086] 0.02
Type 2 Diabetes Mellitus
   Established Model* 0.87 [0.78-0.96] ref ref ref
   Established Model + hs-TnT 0.89 [0.81-0.97] 0.13 0.059 [0.001-0.117] 0.04
           * Established model: prediction model based on urinary albumin excretion and estimated glomerular filtration rate. The 
biomarkers were modeled as continuous (log-transformed) variables. P values are for comparison of the models with the 
baseline model. T2DM: Type 2 Diabetes Mellitus; HT: Hypertension.
Table 3| C-statistics and integrated discrimination improvements (IDI) for logistic regression models 
predicting transition in albuminuria  for patients with HT and patient with T2DM
Mean hs-TnT concentrations were significantly lower in T2DM compared to HT (2.9 [2.9-
5.3] vs. 5.5 [2.9-10.4]; P<0.001). Hs-TnT concentration was below the lower limit of detection 
in 24 (73%) controls and 14 (42%) cases (P=0.01). Like in HT, hs-TnT concentrations were 
higher in cases vs. controls in T2DM (4.0 [2.9-7.2] vs. 2.9 [2.9-3.1] pg/mL; P=0.002).
The adjusted odds for transition in albuminuria in T2DM patients per standard deviation 
increment in hs-TnT was numerically similar to HT, although in T2DM the odds ratio 
did not reach statistical significance (2.00 [95%CI 0.70-5.68]) (table 2). No difference 
was observed in the odds for transition from normo- to microalbuminuria or micro- to 
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macroalbuminuria with each increment in hs-TnT (P=0.70 for hs-TnT). Lastly, addition of 
hs-TnT to the baseline model consisting of UAE and eGFR did not significantly improve 
the c-statistic (from 0.87 to 0.89, P=0.13), but did result in significant increase in IDI (0.059, 
P=0.04).
Discussion
In this study, we found that hs-TNT predicts progression of albuminuria-stage in subjects 
with hypertension. This predictive property is independent of baseline albuminuria and 
improves discrimination between cases and controls beyond conventional renal and 
cardiovascular risk markers. In a smaller sample of cases and controls with T2DM, we 
confirmed these findings, albeit at a lower offset level of hs-TNT.
Traditional risk factors associated with transition in albuminuria are age, gender, 
dyslipidemia, hypercholesterolemia, insulin sensitivity, hyperglycemia, duration of 
diabetes, increased blood pressure, duration of hypertension, body mass index and 
smoking.7,20 Despite identification of these important risk factors for transition in 
albuminuria, the ability to stratify subjects at risk is still limited. The current data, if 
confirmed by other studies, raise the possibility of identification of subjects at risk even 
when traditional risk factors do not indicate risk, facilitating early identification of those 
with an increased chance of developing micro- or macroalbuminuria. Because early 
intervention is more effective than late intervention,21 preventive treatment could thus 
reduce the risk of renal and cardiovascular events in patients with HT and T2DM.1 
Previous studies mainly implicated hs-TnT as predictor for cardiovascular events and 
all-cause mortality in various populations,9-12 and only one study previously reported 
on hs-TnT and renal outcome in T1DM.14 TnT has generally been considered a marker for 
cardiomyocyte necrosis. However, hs-TnT has also been detected in non-cardiac conditions, 
including renal failure, pulmonary hypertension, pulmonary embolism, sepsis and dialysis, 
albeit in substantially lower concentrations.13,22-26 The findings of hs-TnT levels in this 
low range in conditions other than cardiac ischemia, indicate that even the low levels 
may confer prognostic information. The exact mechanisms for the release of low levels 
of TnT remain unclear. Amongst the mechanisms suggested are systemic inflammatory 
processes and microvascular changes.27,28 Of note, the baseline levels of hs-TnT were higher 
in HT than in T2DM, suggesting that increased cardiac work-load or structural remodeling 
in hypertension might, at least in part, be responsible for the enhanced release of hs-TnT. 
Our findings also applied to patients with type 2 diabetes. Transition in albuminuria-stage 
in type 2 diabetes is considered a hallmark of progression of renal disease and increases 
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the risk for cardiovascular events.16,17 Early identification of subjects at risk and appropriate 
treatment in type 2 diabetic patients is at least of equal importance as in subjects with 
hypertension. In this respect hs-TnT is a candidate marker that now requires validation in 
larger cohorts. 
Our use of samples of a large prospective cohort study with repeated measurements 
of albuminuria aiming primarily focusing on albuminuria as pathophysiological 
phenomenon and predictor of cardiovascular and end-stage renal disease was a 
unique feature of this study. Other strengths include the well-defined phenotype of the 
population, with albuminuria status based on two consecutive 24-hour urine collections, 
the rigorous definitions for transition in albuminuria, and the availability of samples 
that had never been thawed. Because of these strict criteria and the limited number of 
patients with diabetes or hypertension in this general population cohort we were only 
able to obtain 75 cases of HT with progression of albuminuria and 33 cases of T2DM with 
albuminuria. 
A limitation of this study was the modest difference in baseline albuminuria between cases 
and matched controls. The difference in baseline albuminuria was inherent to the design 
of the study as the level of albuminuria in itself is related to transition in albuminuria and 
we did not match subjects on their baseline albuminuria but on albuminuria-stage (i.e. 
normoalbuminuria or microalbuminuria at baseline). To account for the modest difference 
in baseline albuminuria we adjusted the regression analyses for the baseline albuminuria 
level and showed that hsTnT independently contributed in identifying individuals at 
risk for transition in albuminuria-stage. A second limitation is the fact that the nested 
case-control design of the study may overestimate the true predictive capacity of the 
models because of the relative high event rate in case-control studies.29 Absolute values 
of the c-statistic should therefore be interpreted with caution. The level of significance 
of improvement of the c-statistic however, is unaffected by the case-control design of 
the study. Nevertheless, as with all biomarker studies, replication of the current results in 
other studies, preferably large prospective cohort studies, is warranted. 
Conclusions
We identified hs-TnT as marker for prediction of progression in albuminuria in 
hypertension. As hs-TnT had significant additive value on top conventional risk markers 
to predict albuminuria progression, hs-TnT may contribute to the early identification of 
patients at risk for progression of to hypertensive nephropathy and also for progression 
to diabetic nephropathy. We performed a confirmation study of our findings in diabetic 
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patients. If these findings are replicated in other studies it could facilitate studies that test 
whether start or intensification of treatment in high risk patients will prevent or delay the 
progression of nephropathy in HT as well as T2DM.
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Abstract 
Background: We aimed to investigate the individual impact of initial responses in urinary 
albumin excretion (UAE) and systolic blood pressure (SBP) to Angiotensin-II-Receptor-
Blocker (ARB) treatment on long term renal outcome in patients with type 2 diabetes and 
microalbuminuria.
Methods: In a post-hoc analysis of the IRMA-2 trial we first assessed the individual 
variability in UAE and SBP-response (0-6 months) in 531 subjects. Subsequently, we 
analyzed the individual effect of both response parameters on renal outcome defined as 
change in estimated glomerular filtration rate (eGFR) during 2 years of follow-up.
Results: The median reductions in UAE and SBP in the population were -18% and -11mmHg 
respectively. In Irbesartan treated patients, 85 (24.4%) had a robust (>median) reduction 
in UAE but not in SBP (discordant SBP-response) and 67 (19.3%) had a robust (>median) 
reduction in SBP but not in UAE (discordant UAE-response). The degree of reduction in 
UAE was independently associated with the rate of eGFR decline (p=0.0037). SBP showed 
a similar trend (P=0.087). The relation between a larger UAE-reduction and a slower rate 
of renal function decline was present in both the cohort with a SBP-change above and 
below the median. 
Conclusions: Within an individual, UAE response to ARB-therapy may be discordant from 
SBP-response. The initial change in UAE was independently associated with eGFR slope: 
the more UAE reduction the less eGFR decline, irrespective of the SBP-change. These 
results suggest that in microalbuminuric patients with type 2 diabetes, UAE should be 
monitored after initiation of therapy and a separate target for renoprotective therapy.
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Introduction
Current treatment strategies in diabetes separately target risk factors for micro- and 
macro-vascular complications. HbA1c is targeted with anti-diabetic agents, cholesterol 
levels with statins and blood pressure (BP) with antihypertensive agents. Agents blocking 
the Renin-Angiotensin-Aldosteron-System (RAAS) are first choice antihypertensives 
in patients with diabetes as these agents not only lower blood pressure but also lower 
urinary albumin excretion (UAE), another important renal risk factor.1, 2 Current guidelines 
recommend dose-titration of RAAS-blockade on BP response to achieve a systolic blood 
pressure (SBP) below 130 mmHg, without taking the response in UAE into account.3 
It is known that the initial response in proteinuria during RAAS blockade independently 
determines renal outcome in patients with diabetes and proteinuria.4 Moreover, recent 
studies have illustrated that within an individual, the response in BP is not always paralleled 
by a response in proteinuria or vice-versa.5 These so-called discordant responses allow a, 
albeit retrospective, look at whether the response of BP, proteinuria, or their combination, 
is the driving parameter for renoprotection. Data in patients with proteinuria have 
demonstrated that long-term renoprotection is mainly achieved in those patients with an 
initial fall in proteinuria irrespective of the BP response. Accordingly, this suggests that a 
treatment approach solely focusing on BP reduction may not be the most efficacious way 
to achieve renoprotection.6-8 Whether responses in albuminuria irrespective of BP relate 
to long-term renoprotection in patients with microalbuminuria have not been published. 
We therefore performed a post-hoc analysis in the Irbesartan in Patients with Type 2 
diabetes and Microalbuminuria (IRMA-2) trial,9 investigating the variability in initial 
treatment responses in UAE and SBP in patients with type 2 diabetes and microalbuminuria. 
Secondly, we aimed to determine the impact of different UAE and SBP responses on renal 
outcome. This should provide insight as to whether albuminuria should be considered a 
target for renoprotective therapies in addition to BP in microalbuminuric patients.
Patients and methods
The IRMA 2 study was a 2-year multi-center, randomized, double-blind trial in patients 
with type 2 diabetes and microalbuminuria comparing Irbesartan (150 or 300 mg once 
daily) versus placebo on top of conventional antihypertensive treatment. The design of the 
study has been reported elsewhere.9 In brief, eligible patients had their antihypertensive 
agents discontinued during the run-in period and replaced by placebo. After three weeks 
patients were randomly assigned to receive Irbesartan 150, 300 mg, or matching placebo 
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once daily. A total of 590 patients were followed for 2 years for the development of overt 
nephropathy. Patients were seen at month 3, 6, and every 6 months thereafter. Additional 
blood pressure lowering medication, apart from Angiotensin-Converting Enzyme 
inhibitors (ACEi) and Angiotensin-II-Receptor Blockers (ARBs), was allowed to reach the 
target blood pressure of 135/85 mmHg. The study protocol was in accordance with the 
declaration of Helsinki and was approved by all local institutional review boards. All 
patients gave written informed consent.
Patients
IRMA-2 enrolled hypertensive patients with type 2 diabetes, ranging in age from 30 to 
70 years. All patients had persistent microalbuminuria which was defined as a urinary 
albumin excretion rate of 20 to 200µg/min in at least two out of three consecutive, 
sterile, overnight urine samples. The main exclusion criteria were a serum creatinine 
concentration >1.5mg/dL (133µmol per liter) for men and >1.1mg/dL (97µmol per liter) for 
women, non-diabetic kidney disease, cancer, life-threatening disease with death expected 
to occur within two years, and an indication for Angiotensin-converting–enzyme inhibitors 
(ACEi) or Angiotensin-II–receptor blockers (ARBs). 
Measurements
The urinary albumin concentration was determined by nephelometry at a central 
laboratory.10 The serum creatinine concentration was determined by Jaffe reaction with 
the use of a Hoffmann–LaRoche kit.11 Glomerular filtration rate (eGFR) was estimated with 
the Modification of Diet in Renal Disease (MDRD) equation.12 The lowest arterial blood 
pressure during a 24-hour period (Korotkoff phase I/V) was measured twice in the sitting 
position after at least 10 minutes of rest. 
Urinary albumin excretion and blood pressure response
This post-hoc analysis focuses on the urinary albumin excretion (UAE) and systolic blood 
pressure (SBP) change from baseline to month 6. A robust decline in UAE or SBP was 
defined as a decline in UAE or SBP more than the population median. This approach was 
aimed at identifying subgroups with identical number of patients to increase the power 
of the analysis while minimizing the risk of bias. UAE change at month 6 for each patient 
was calculated as 100*log(UAE at 6 months/UAE at baseline). SBP change was calculated 
as the difference between the month 6 and baseline value. The month 6 values were 
chosen for two reasons: 1) the treatment effects were considered to be fully present at 
month 6, and 2) this was the earliest time-point at which most variables of interest were 
available. 
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Patients were divided into groups according to the median of UAE and SBP change from 
baseline to month 6. Patients with both UAE change and SBP change above or below the 
median were considered to have a concordant response, whereas patients with either 
a UAE change or SBP change above the median were considered to have a discordant 
response.
Renal endpoints
Transition from micro to macroalbuminuria (development of overt nephropathy) was 
the primary efficacy measure in the IRMA-2 trial which was defined as UAE >200µg/
min and at least 30% higher than baseline level of UAE on at least two out of three 
consecutive samples. Since the initial reduction in albuminuria induced by ARB treatment 
is directly related to the primary efficacy measure (which includes the long term change 
in albuminuria), we decided to use the course of decline in eGFR from month 6 to end of 
follow-up as our primary renal endpoint. We looked at development of overt nephropathy 
in a secondary analysis.
Statistical Analysis
Categorical variables are reported as frequencies and percentages. Variables with 
normal distribution are presented as mean with standard deviation (SD) and variables 
with a skewed distribution are presented as median with interquartile range [IQR]. 
Non-normally distributed variables were log-transformed before analyses. Graphical 
methods and normality tests were used to ascertain normalization of the distribution 
after transformation. Differences between groups were tested with Fishers Exact Test for 
categorical variables and ANOVA for continuous variables, followed, where applicable, 
by post-hoc Bonferroni correction for multiple testing. A multivariate mixed model with 
random intercepts and random slopes was used to assess the relationship between the 
magnitude of UAE and SBP change and the rate of eGFR decline. Such a model calculates 
renal function decline over time within and between individuals also taking into account 
the correlation within individuals and time. For exploration of the relationship between 
the month 6 change in UAE and eGFR decline, the change in UAE was categorized 
according to quartiles and related to eGFR decline from month 6. The multivariate 
mixed model included the following baseline covariates: age, gender, log transformed 
UAE, SBP and DBP, eGFR, HbA1c, duration of diabetes, total cholesterol, smoking, BMI, 
and treatment allocation. A multivariate Cox-proportional Hazards model was used to 
assess the relationship between the magnitude of UAE and SBP change from baseline to 
6 months and time to development of overt nephropathy from 6 months to the end of 
follow up. The multivariate Cox-proportional Hazards model included the same covariates 
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Concordant Discordant Discordant Concordant
(Negative)  (Positive)
UAE < Median* UAE < Median* UAE > Median* UAE > Median*
Characteristics SBP < Median** SBP > Median** SBP < Median** SBP > Median**
Number of Patients 153 112 120 146
Changes 0-6 Months
   Median [IQR] change UAE - % 35 [7 to 92] 35 [0 to 85] -48 [-63 to -33] -51 [-68 to -37]
   Median [IQR] change SBP - mmHg 0 [-7 to 5] -21 [-28 to -15] -5 [-9 to 5] -21 [-28 to -16]
Demographic Characteristics
Age - yrs 58.3 ± 8.1 58.7 ± 8.6 57.9 ± 7.5 57.1 ± 8.2
Male Sex - n (%) 104 (68.0) 82 (73.2) 77 (64.2) 100 (68.5)
Race - n (%)
   White 148 (96.7) 110 (99.1) 117 (98.3) 141 (96.6)
   Nonwhite 5 (3.3) 1 (0.9) 2 (1.7) 2 (1.4)
 
Clinical Characteristics
Body Mass Index 29.9 ± 4.2 29.9 ± 4.1 30.4 ± 4.2 30.0 ± 4.2
Known Duration of Diabetes > 5 yrs - n (%) 112 (73.2) 80 (71.4) 82 (68.3) 100 (68.5)
Smoking - n (%) 24 (15.7) 22 (19.6) 20 (16.7) 31 (21.2)
Laboratory Variables
Glycated Hemoglobin - % 7.4 ± 1.7 7.1 ± 1.6 7.1 ± 1.7 7.2 ± 1.7
Blood Pressure  - mmHg
   Systolic 149 ± 13# 158 ± 15 149 ± 13# 158 ± 13
   Diastolic 88 ± 8$ 92 ± 10 89 ± 8$ 92 ± 10
Urinary Albumin Excretion - µg/min 68.8 ± 42.5 56.3 ± 35.1 68.9 ± 41.6 66.1 ± 39.3
eGFR (MDRD) - mL/min 74 ± 14 71 ± 14 70 ± 13 72 ± 13
Cholesterol - mg/dL
   Total 216 ± 41 224 ± 43 230 ± 60 225 ± 43
   Low-density Lipoprotein 137 ± 36 141 ± 33 142 ± 53 140 ± 40
   High-density Lipoprotein 43 ± 11 44 ± 12 43 ± 12 44 ± 12
Negative concordant indicates no robust (i.e. more than median) response in neither UAE and SBP, positive concordant indicates a 
robust (i.e. more than median) response in both parameters. UAE, Urinary Albumin Excretion; SBP, Systolic Blood Pressure; eGFR, 
estimated Glomerular Filtration Rate; MDRD, Modification of Diet in Renal Disease study equation. *Median UAE response was 
18% decline, **Median SBP response was 11mmHg decline, # P<0.001 versus patients with UAE < median & SBP > median and 
patients with UAE > median & SBP > median$ P<0.01 versus patients with UAE < median & SBP > median and patients with UAE 
> median & SBP > median.
Table 1| Baseline characteristics of the patients stratified by groups of change in albuminuria and systolic 
blood pressure from baseline to month 6
as the above mentioned multivariate mixed model. The initial fall in eGFR after start of 
treatment may reflect a hemodynamic response and may be associated with long-term 
renoprotection.13,14 Since the month 6 change in eGFR was not associated with the initial 
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change in UAE and SBP we considered the initial eGFR change not a potential confounder 
in our analyses. Relative risk reductions are described in the text as percentage reductions 
([1–hazard ratio]× 100). P-value of <0.05 indicated statistical significance. Data were 
analyzed with SPSS version 18.0 (SPSS Inc., Chicago, IL) and SAS (SAS Institute, Cary, NC).
Results
Systolic blood pressure and urinary albumin excretion change
A total of 531 out of 590 randomized patients had urinary albumin excretion (UAE) and 
systolic blood pressure (SBP) measurements available at baseline and at six months post-
randomization and were included in this post-hoc analysis. The median responses in UAE 
and SBP in the population were 18% and 11 mmHg respectively. We subsequently divided 
the population according the median response in these parameters, defining a robust 
response as a response more that the population median. The median decline in UAE and 
SBP in each subgroup is reported in table 1. In Irbesartan treated patients, 24.4% had a 
robust reduction in UAE but not in SBP (discordant SBP response) and 19.3% had a robust 
reduction in SBP but not in UAE (discordant UAE response).
The baseline characteristics according to UAE and SBP response are shown in table 2. 
There were no differences in baseline characteristics except that patients with a robust 
reduction in SBP, irrespective of the UAE response, had a higher average baseline systolic 
and diastolic blood pressure compared to patients without robust SBP decline. 
Renal outcome
We assessed whether the degree of change in UAE and SBP was associated with a 
different slope of renal function loss. A larger decrease in UAE during the first 6 months 
was independently associated with a slower rate of renal function decline during the 
follow up time (P=0.0037; figure 1). A robust decrease in SBP showed a similar trend of a 
slower rate of long-term eGFR decline, but was not significant (P=0.087).
The rate of eGFR decline according to combined change in UAE and SBP and adjusted for 
other risk variables is presented in figure 2A. A robust UAE reduction resulted in a slower 
rate of eGFR decline, also in those patients who did not have a robust SBP reduction. The 
combination of a robust response in UAE and SBP resulted in the lowest rate of progressive 
renal function loss. 
For completeness, we determined the impact of changes in UAE and SBP on the risk for 
development of overt nephropathy in a secondary analysis. It should be reminded that 
the initial change in UAE is directly related to the development of overt nephropathy. The 
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Albuminuria Response > Median 
(Reduction >18%)

















   (N=353)
(%)
   SBP response > median 
   (Reduction > 11mmHg)
69 (19.5) 56 (15.9) 35.4 35 (9.9) 33 (9.3) 19.3 55
   SBP response < median
    (Reduction < 11mmHg)
40 (11.3) 46 (13) 24.4 45 (12.7) 29 (8.2) 21.0 45
   Total (%) 60 40
Conventional Treatment
   (N=178)
   SBP Response > median
    (Reduction >11mmHg)
7 (3.9) 17 (9.6) 13.5 21 (11.8) 22 (12.4) 24.2 38
   SBP Response < median
    (Reduction < 11mmHg)
16 (9.0) 14 (7.9) 16.9 32 (18.0) 49 (27.5) 45.5 62
   Total (%) 30 70
Median UAE response was 18% decline, Median SBP response was 11mmHg decline.
Table 2| Distribution of the Irbesartan and conventional treatment group (number of patients and % of total in 
parentheses) according to change in albuminuria and systolic blood pressure from baseline to month 6
Figure 1| Long-term annual decline in estimated GFR from 6-24 months, per quartile urinary albumin excre-
tion change from baseline to month 6
Long-term annual decline in estimated GFR from 6-24 months, per quartile urinary albumin excretion change from baseline to 
month 6 (P=0.0037) and per group of systolic blood pressure change from baseline to month 6 (divided over the median change) 
(P=0.087) in 531 type 2 diabetic patients with microalbuminuria.
P=0.0037 P=0.087
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risk reduction for development of overt nephropathy was 44%(95%CI 39 to 59%; P<0.001) 
and 9%(95%CI 19 to +2%; P=0.098) per 50% reduction in UAE and 5 mmHg SBP reduction 
respectively. The risk for development of overt nephropathy according to combined 
change in UAE and SBP and adjusted for other risk variables is presented in figure 2B.
Figure 2| Renal outcome for groups of urinary albumin excretion and systolic blood pressure change 
A: Decline in eGFR from 6-24 months for groups of urinary albumin excretion and systolic blood pressure change, in 531 type 2 
diabetic patients with microalbuminuria. B: Hazard ratios for overt nephropathy from 6-24 months for groups of urinary albumin 
excretion and systolic blood pressure change, in 531 type 2 diabetic patients with microalbuminuria.
A
B
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Discussion
The results of this study show that the response to ARB therapy varies for both UAE and 
SBP even within the microalbuminuric hypertensive patient. The rate of long-term renal 
function decline showed a clear dependence on the initial response in UAE irrespective 
of SBP response. The results of this microalbuminuria study confirm a previous study 
reporting on proteinuria in which similar individual variations in response to ARB 
(Losartan) were observed, and in which the reduction in proteinuria was independently 
associated with renal outcome in type 2 diabetic patients with nephropathy.5 Combining 
the results of that study and the current study, we conclude that monitoring therapy-
induced changes in UAE in individual diabetic patients is important in addition to 
monitoring blood pressure, since therapy induced changes in both parameters do not run 
in parallel and both parameters were independently associated with the effectiveness to 
achieve renal protection.
The reduction in albuminuria achieved during the initial months of RAAS blockade is a 
critical step to achieve renoprotection. Trials conducted in populations with and without 
diabetes showed that agents intervening in the RAAS confer additional renoprotection 
beyond other antihypertensive regimens. Although in most trials BP control was slightly 
better in the RAAS-treatment arm, the clinical benefit exceeded that what could be 
attributed to improved BP control.9,15,16 In addition, the reduction in UAE during the initial 
months of therapy is the most important determinant of long-term renoprotection. This 
observation was initially made in diabetic renal disease by Rossing et al.17 and in non-
diabetic renal disease by Apperloo et al.14 investigating long term eGFR decline, and later 
on confirmed in analyses from large randomized controlled trials looking at hard renal 
endpoints.4,5,7,18 It should be noted that the aforementioned observations are derived 
from studies enrolling patients with macroalbuminuria (UAE >300 mg/day) and/or eGFR 
levels below 60ml/min/1.73m2. Importantly, the results of the present study extend these 
findings to the patient population with levels of UAE within the microalbuminuric range 
(UAE 30–300 mg/day) and eGFR levels above 60ml/min/1.73m2.
An important question is whether changes in albuminuria can be used as a surrogate 
endpoint in clinical trials. The distinct advantage is that trials with surrogate endpoints 
require fewer patients, require shorter follow-up, are less expensive and facilitate drug 
development. To obtain surrogacy status definitive evidence is required demonstrating 
that the surrogate endpoint is causally related to the clinical endpoint. It has been pointed 
out that the evidence for albuminuria as a surrogate endpoint is reasonably robust in 
patients with diabetes and macroalbuminuria but limited data are available in patients 
with UAE.19,20 This study is the first to show that even in the low albuminuria range the 
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initial anti-albuminuric response to ARB treatment is an important independent indicator 
of renoprotection. This suggests that also in patients with microalbuminuria, albuminuria 
may be a potential candidate as a surrogate endpoint.
Prospective randomized controlled trials will be necessary to obtain definitive evidence 
that an approach of targeting UAE confers renoprotection within the microalbuminuria 
range. These trials should be designed to compare the long-term clinical effect of different 
predefined UAE targets. Such a design isolates the role of UAE as an independent target for 
therapy and establishes the clinical relevance of targeting UAE for renal or cardiovascular 
protection. In this respect, a recent study by Ruggenenti et al. in diabetic and non-diabetic 
nephropathies compared the efficacy of a treatment strategy specifically targeting UAE 
with a historical cohort targeting only blood pressure.21 The results showed that targeting 
UAE is feasible and translates into substantial risk reductions for End Stage Renal Disease 
(ESRD). Interestingly, again the reduction in UAE was the only variable in multivariate 
analyses that was associated with a lower risk of ESRD. The obvious limitation is that the 
comparisons published in this report were not randomized. The ROAD study is the only 
randomized controlled trial testing a treatment strategy specifically targeting proteinuria. 
This trial showed that optimal anti-proteinuric dosages of RAAS blockade is feasible and 
resulted in a substantially larger reduction in proteinuria and slower rate of renal function 
decline in non-diabetic patients.22 Prospective studies confirming these results in diabetic 
patients with microalbuminuria and proteinuria are needed. 
One can only speculate about possible mechanisms underlying the discordant blood 
pressure and UAE responses. One possibility is that clinical blood pressure and overnight 
albumin excretion measurements are subject to large random variability and thus do not 
accurately reflect true UAE and BP. However, patients allocated to Irbesartan more often 
have a robust decline in UAE compared with patients treated with conventional treatment 
only (60 vs. 30%, table 1.) Hence, a clear difference in discordant response pattern can 
be deduced, indicating that the ARB treatment responses are not solely due to random 
variability. 
Another possible explanation for the discordant treatment responses is that the intra-
individual discordance in UAE and SBP responses is accounted for by differences in 
systemic and local RAAS-activity or differences in the extent of tissue penetration of 
RAAS-blockade. It is hypothesized that the UAE response depends on the extent of intra-
renal RAAS-blockade while the SBP response depends on systemic vasculature RAAS-
inhibition. In support of this hypothesis, pre-clinical studies have shown that inhibition of 
extra-renal RAAS plays an important role in mediating blood pressure control.23 However, 
further research is needed to elucidate the exact mechanisms.
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It is noteworthy that this is a post-hoc analysis of clinical trial data and the results are 
no longer based on randomized comparisons. Although we adjusted for a large range of 
potential confounders, unmeasured confounding may have influenced our results. The 
results can therefore only be interpreted as hypothesis generating.
Conclusions
Our data show that ARB induced responses in blood pressure and urinary albumin 
excretion are discordant within a large proportion of patients. This underscores the 
recommendation of treatment guidelines of diabetes associations to regularly assess 
both blood pressure and urinary albumin excretion in individual patients with diabetes. 
Importantly, the response in urinary albumin excretion individually determined renal 
outcome, regardless of the blood pressure response. This implies that renoprotective 
strategies in microalbuminuric patients with type 2 diabetes should not only target blood 
pressure but also urinary albumin excretion. 
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Abstract
Background: Failure of diagnosing and treatment of albuminuria plays a role in high 
morbidity and mortality in type 2 diabetes (T2DM). We evaluated guideline adherence 
and factors associated with albuminuria screening and treatment in T2DM patients in 
primary care.
Methods: Guidelines recommend annual measurement of albuminuria and if increased 
appropriate treatment with Renin-Angiotensin-Aldosterone-System (RAAS)-blockers. We 
performed a cohort study of T2DM patients managed by 182 Dutch general practitioners 
(Groningen Initiative to Analyse Type 2 diabetes Treatment database), and evaluated 
guideline adherence in the years 2007-2009. We assessed whether demographic, clinical 
or organizational factors determined guideline adherence with multivariable multilevel-
analyses.
Results: Data were available for 14,120 T2DM patients (47.6% male, mean age 67.3 ±11.7 
years, median diabetes duration 6 [IQR: 3-10] years). Albumin-creatinine-ratio (ACR) was 
measured in 45.2% in 2007, 57.4% in 2008, and 56.8% in 2009. Only 23.7% of patients 
were measured every year and 21.4% was never measured. ACR was more often measured 
in patients below 75 years, with a previous ACR-measurement, using anti-diabetic 
medication and receiving additional care by a diabetes support facility. RAAS treatment 
was prescribed to 78.4% patients with prevalent micro/macroalbuminuria, 66.5% in 
incident micro/macroalbuminuria, 58.2% in normoalbuminuria and 52.1% of those 
without ACR measurements. In those not treated with RAAS-blockers, it was initiated in 
14.3, 12.8, 3.0 and 2.3%, respectively. Presence of micro/macroalbuminuria, blood pressure 
and treatment with antihypertensive medication were determinants of RAAS-treatment 
initiation.
Conclusions: Guideline implementation regarding management of albuminuria in T2DM 
patients in primary care should be further improved.
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Introduction
Type 2 diabetes mellitus (T2DM) is an increasing public health problem due to the ageing 
population, increasing trend in obesity and changes in lifestyle. In parallel, the costs 
associated with diabetes care and the disease burden for patients are increasing.1 One 
of the major complications of diabetes is diabetic nephropathy. Microalbuminuria is one 
of the earliest signs of diabetic nephropathy, and is associated with increased risk for 
end-stage renal disease, cardiovascular disease and all-cause mortality.2,3 Agents blocking 
the Renin-Angiotensin-Aldosterone System (RAAS) lower albuminuria and prevent 
worsening of albuminuria beyond their blood-pressure lowering effect.4-6 Because of the 
risks associated with increased albuminuria, clinical guidelines recommend screening 
for albuminuria in patients with T2DM with sufficient life expectancy.7,8 In patients with 
T2DM and confirmed elevated albuminuria RAAS-blockers are the preferred treatment 
option irrespective of concomitant blood pressure levels.7, 8 
However, despite these therapeutic options, morbidity and mortality is still high in type 
2 diabetes. This could be partly due to the fact that the current interventional protocol or 
strategies do not sufficiently take care of all the risk in these patients. Alternatively, the 
implementation of such strategies in practice may be partly failing. Discrepancies have 
been reported between recommended diabetes care by clinical guidelines and observed 
diabetes care in practice.9 Much attention has been paid to the quality of risk factor 
monitoring and treatment of conventional risk factors for diabetic renal and cardiovascular 
complications, such as blood glucose, blood pressure and cholesterol levels.10-18 Few studies 
have focused on the quality of screening for and treatment of elevated albuminuria,19-22 
even though this is among the strongest cardio-renal risk factors.23
Therefore, our aim was to assess adherence to clinical guideline recommendations with 
respect to albuminuria management in Dutch primary care patients with T2DM, and 
to identify demographic, clinical or organizational factors associated with guideline 
adherence. 
Patients and Methods
Study population and setting 
For this observational study, we used data from patients with type 2 diabetes obtained 
from 182 general practitioners (150 practices) that collaborated in the Groningen 
Initiative to ANalyse Type 2 diabetes Treatment (GIANTT) project. GIANTT provides quality 
assessments for most general practitioners (GPs) in Groningen province, The Netherlands.11 
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The included practices covered a total population of over 500,000 persons in 2008. The 
patient population for this study consisted of all patients who had been diagnosed with 
type 2 diabetes for at least 1 year on January 1st 2007, were still alive on July 1st 2010, did not 
leave the practice before July 2010, did not object to the data collection (<1%), and were 
primarily managed by their GP (n=14,120). In our study region, a regional diabetes facility 
offers support to GPs. Patients can be referred to this facility for laboratory tests and 
physical examination. The results are reported back to the GPs who remain responsible 
for further management and treatment decisions. Patients who were primarily managed 
by a specialist for their diabetes, as indicated by the GP, were excluded from this study 
(n=2,933).
Data collection
We used data on demographic characteristics, organizational factors, clinical 
characteristics, laboratory parameters and prescribed medication from the GIANTT 
database. This database contains anonymized data extracted from structured tables and 
free text parts of electronic medical records using an automated and validated method.24 
For research with anonymous medical record data no ethics committee approval is 
required in The Netherlands.
Guideline Recommendations
The Dutch primary care guideline recommends yearly albuminuria screening in all 
diabetes patients with sufficient life expectancy (at least 10 years).8 For the yearly 
albuminuria-screening, measurement of albumin-creatinine-ratio (ACR) is favoured over 
urinary albumin concentration.25 If the measurement indicates the presence of micro- or 
macroalbuminuria this has to be confirmed by a repeat measurement within the next few 
months. According the guideline, all patients with confirmed micro- or macroalbuminuria 
should be prescribed RAAS-treatment (Angiotensin-Converting-Enzyme Inhibitors (ACEi)/ 
Angiotensin II Receptor Blockers (ARB) even if their blood pressure readings are in the 
normal range. For the treatment of hypertension in patients with normoalbuminuria, 
thiazide-diuretics are first-choice antihypertensives, followed by RAAS-treatment.
Definitions
Patients’ ACR-values were classified as normoalbuminuria, microalbuminuria or 
macroalbuminuria. Microalbuminuria was defined according gender specific cut-offs, 
being ACR > 2.5 mg/mmol in men and > 3.5 mg/mmol in women.26 Macroalbuminuria 
was defined as ACR > 25 mg/mmol in men and > 35 mg/mmol in women. We clustered 
patients with micro and macroalbuminuria for analyses on guideline adherence because 
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the evaluated guideline recommendations are equal for micro- and macroalbuminuria. 
These patients are all denoted as having increased albuminuria.
Based on the ultimate ACR measurement in the period 2007-2009 (index measurement) 
patients were classified into patients without any measurements, patients with 
normoalbuminuria and patients with increased albuminuria. The patients with increased 
albuminuria were subdivided into patients with incident increased albuminuria and 
patients with prevalent increased albuminuria. Based on the prior ACR measurement, 
patients with repeated increased albuminuria were denoted as having prevalent increased 
albuminuria.
Treatment with RAAS-blockers was defined as any prescription of an agent intervening 
in the RAAS-system in the year before the index ACR measurement. A repeat ACR 
measurement was defined as a second measurement of ACR within 100 days from the 
index measurement. Initiation of RAAS-treatment was defined as start of RAAS-treatment 
within 100 days after the index ACR measurement or within 100 days of the repeat 
measurement of ACR after at least 1 year without prescription of any RAAS-treatment. 
Determinants of guideline adherence
As potential patient-related determinants of guideline adherence we considered 
demographic characteristics (age >75 years, gender), organizational factors (additional 
care by a diabetes support facility), clinical characteristics (known duration of diabetes, 
having ACR measurements in the preceding 12 months, prior ACR status (unknown, 
normoalbuminuria, increased albuminuria), body mass index, systolic and diastolic blood 
pressure), laboratory parameters (glycosylated haemoglobin, serum creatinine, estimated 
glomerular filtration rate according to Modification of Diet in Renal Disease (MDRD)-study 
equation,27 low-density lipoprotein, high-density lipoprotein) and medication (none, use of 
oral antidiabetics, use of oral antidiabetics and insulin and use of antihypertensive agents 
in the 12 months before the index ACR measurement, number of antihypertensives used, 
use of RAAS). For the clinical and laboratory parameters we used the most recent value in 
the 12 months before the index ACR measurement if available and the most recent value 
in the 12 months before a random date generated according to a similar date distribution 
otherwise. 
Statistical Analysis
We performed the analyses with STATA version 11.2 (STATACorp LP, Texas, USA). We 
calculated in what proportion of patients an ACR measurement was recorded in each 
calendar year. Differences in patient characteristics between patients with and without 
ACR measurement in 2009 were compared with students’ t-test for continuous variables 
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and chi-squared test for categorical variables. For all groups of patients we calculated what 
proportion of patients received RAAS-treatment and in what proportion RAAS-treatment 
was initiated and, if applicable, ACR measurement was repeated. The descriptive analyses 
Registration Degree Overall ACR measured ACR not measured
N (%) N=14120 8025 (56.8%) 6095 (43.2%) P-value
Demographic Characteristics
Age – years 14120 (100) 67.3±11.7 66.5±11.3 67.7±12.5 <0.001
Age >75 years 14120 (100) 4107 (29.1) 2166 (27.0) 1941 (31.9) <0.001
Male sex 14120 (100) 6722 (47.6) 3948 (49.2) 2774 (45.5) <0.001
Organizational Factors
Support care by diabetes facility 14120 (100) 4825 (34.2) 3120 (38.9) 1705 (28.0) <0.001
Clinical Characteristics
Known duration of diabetes – years 14120 (100) 6 [3-10] 6 [3-10] 6 [3-9] <0.001
Body Mass Index – kg/m2 9902 (70) 30.2±5.5 30.2±5.5 30.2±5.6 ns
ACR measured previous 12 months 14120 (100) 8111 (57.4) 5621 (70.0) 2490 (40.9) <0.001
Blood Pressure - mmHg 
   Systolic 12381 (88) 143+19 143±19 142±20 <0.001
   Diastolic 12381 (88) 79±10 79±10 78±10 <0.001
Laboratory Parameters
Glycosylated hemoglobin - % 12803 (91) 7.0±1.0 7.0±0.9 6.9±1.0 <0.001
Serum Creatinine - mmol/L 12223 (87) 93±30 92±26 94±35 <0.001
eGFR (MDRD) - ml/min 12223 (87) 60±18 61±17 60±18 ns
Cholesterol - mg/dl
   Low-density lipoprotein 11751 (83) 2.4±0.9 2.3±0.9 2.5±0.9 <0.001
   High-density lipoprotein 11793 (84) 1.2±0.3 1.2±0.3 1.2±0.3 ns
Albumin to creatinine ratio - mg/mmol 8025 (57) 1.2 [0.5-2.7] 1.2 [0.5-2.7] - n/a
Medication
Diabetes Regulating medication 14120 (100) 12037 (85.3) 7175 (89.4) 4862 (79.8) <0.001
   Oral antidiabetics 14120 (100) 11165 (79.1) 6753 (84.2) 4412 (72.4) <0.001
   Insulin 14120 (100) 2768 (19.6) 1539 (19.2) 1229 (20.2) <0.001
Blood pressure regulating medication 14120 (100) 10882 (77.1) 6356 (79.2) 4526 (74.3)
   Number of antihypertensives 14120 (100) 2 [1-2] 2 [1-2] 2 [0-2] ns
   RAAS-treatment 14120 (100) 8479 (60.0) 5028 (62.7) 3441 (56.5) <0.001
   Beta-blockers 14120 (100) 5642 (40.0) 3271 (40.8) 2371 (38.9) <0.001
   Calcium antagonists 14120 (100) 3088 (21.9) 1819 (22.7) 1269 (20.8) <0.001
   Diuretics 14120 (100) 6607 (46.8) 3831 (47.7) 2776 (45.5) <0.001
    Other 14120 (100) 319 (2.3) 181 (2.3) 138 (2.3) ns
Table 1| Baseline characteristics overall and stratified by ACR measurement
Data are presented as n(%) or mean±sd or median[iqr]. Abbreviations: ACR: Albumin-to-creatinine ratio; eGFR estimated Glomerular Filtra-
tion Rate; MDRD: Modification of Diet in Renal Disease study equation;  ACEi: Angiotensin-Converting-Enzyme Inhibitors; ARB: Angiotensin II 
Receptor Blockers.
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are also presented stratified by age below and over 75 years, and repeated using longer 
time periods in which the ACR measurement could be documented or the RAAS-treatment 
could be initiated. Multilevel analyses clustering patients by GP were used to assess which 
patient level factors were associated with ACR measurement. We determined whether 
random slopes significantly improved model fit with the likelihood ratio test and used 
a forward selection procedure adding variables to the baseline model (containing age 
and sex) one at the time, based on the Wald-statistic. To allow analyses with all available 
patients and to minimize bias, we used multiple imputation of missing values. We used the 
same multilevel modeling strategy to assess which patient level factors were associated 
with RAAS-treatment initiation in all patients, including increased albuminuria (increased 
vs. not increased or not determined) as determinant, and in four subgroups divided by 
albuminuria status (without ACR measurement, with normoalbuminuria, with incident 
and with prevalent increased albuminuria). For all analyses we considered a P-value <0.05 
statistically significant.
Results
Data between 2007 and 2010 were available from 182 general practitioners with a total 
of 14,120 patients with T2DM. Of the 14,120 patients, 47.6% were male, the mean age was 
67.3±11.7 years and the median duration of diabetes was 6 [IQR 3-10] years (Table 1). 
ACR-measurement
ACR was measured at least once in 6,377 patients (45.2%) in 2007, in 8,111 patients (57.4%) 
in 2008, and in 8,025 patients (56.8%) in 2009. Extending the interval from 12 to 15 months 
increased these percentages to 53.9%, 65.0% and 61.5% respectively (figure 1). In the 3-year 
period between 2007 and 2010, 11,106 patients (78.7%) had at least one measurement, 
3,351 patients (23.7%) had at least one ACR measurement all three consecutive years, and 
3,014 patients (21.4%) did not have any ACR measurement. 
ACR was more frequently measured in patients below than above 75 years (58.9 vs. 
52.7% in 2009, p<0.001), and in patients receiving care at the diabetes support facility as 
compared to receiving routine diabetes care in the GP practice (64.7% vs. 52.8%, p<0.001). 
Differences in characteristics between patient with and without ACR measurement 
are shown in table 1. In a multivariable multilevel model (Table 2), the most important 
determinants of ACR measurement were age, previous ACR measurement, additional care 
by the diabetes support facility, and use of antidiabetic medication. 
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Prevalence of increased albuminuria
Looking at the most recent ACR measurement before 2010 (N=11,106) 8,823 patients 
(79.4%) had normoalbuminuria, 1,970 patients (17.7%) had microalbuminuria, and 313 
patients (2.8%) had macroalbuminuria. The guideline makes a distinction between 
actions needed for incident and prevalent increased albuminuria and we therefore 
used the before-last measurement to distinguish between incident and prevalent 
increased albuminuria. Of the patients with increased albuminuria (presence of micro- or 
macroalbuminuria, N=2283) 1,360 patients (59.6%) also had increased albuminuria on the 
prior ACR measurement, indicating prevalent increased albuminuria. 923 patients (40.4 
%) did not have increased albuminuria on the prior ACR measurement or did not have a 
prior measurement, indicating incident increased albuminuria. 
Repeat measurements and RAAS-treatment 
Of patients with prevalent increased albuminuria 78.4% received RAAS-treatment in the 
year up to the index measurement, compared to 66.5% of patients with incident increased 
albuminuria, 58.2% of patients with normoalbuminuria and 52.4% of patients without 
any ACR measurements.
In patients with incident and prevalent increased albuminuria not receiving RAAS-
treatment, the guidelines recommend further action. The appropriate steps differ 
Figure 1| ACR Measurement distribution over time between 2007 and 2010 for each year independently
Horizontal dotted lines indicate the percentage of patients with at least one ACR measurement from beginning of 2007, 2008 and 
2009 respectively.  The population selected was stable (N=14120) throughout this time-interval, the percentage of patients with at 
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between patients with incident increased albuminuria and patients with prevalent 
increased albuminuria (Figure 2).
Of the 294 patients with prevalent increased albuminuria not on RAAS-treatment, RAAS-
treatment was initiated in 42 patients (14.3%) (Figure 2). 
In patients with incident increased albuminuria, the albuminuria status merits 
confirmation by a repeat measurement. Of the 309 patients with incident increased 
albuminuria not on RAAS-treatment, ACR measurement was repeated in 41 (13.3%) 
patients, and in 37 (12.0%) patients RAAS-treatment was initiated without confirmatory 
ACR measurement. In 231 (74.8%) patients no action was undertaken. Of the 41 
confirmatory measurements, in 28 (68.3%) patients increased albuminuria status was 
confirmed and in 1 of these patients RAAS-treatment was subsequently initiated (Figure 
2). Overall, RAAS-treatment was initiated in 38 patients (12.3%) with incident increased 
albuminuria. In total, appropriate action (i.e. repeat measurement performed and/
or RAAS-treatment initiation) was undertaken in 51 patients (16.5%). In comparison, in 
patients with normoalbuminuria not receiving RAAS-treatment, treatment was initiated 
in 108 patients (3.0%) after the most recent ACR measurement, and in patients without 
any ACR measurements RAAS-treatment was initiated in 33 patients (2.3%). RAAS-
treatment initiation was thus more common in patients with increased albuminuria vs. 
patients without increased albuminuria (13.6% vs. 2.8%, P<0.001)
Extending the interval for initiation of RAAS-treatment from 100 days after the index 
ACR measurement to 200 days of the index measurement, did not substantially increase 
the number of new RAAS-prescriptions in patients with increased albuminuria (data not 
shown). 
The proportion of patients receiving RAAS-treatment was similar in patients with 
increased albuminuria below and above 75 years (73.3 vs. 72.6%, P=0.13), and appropriate 
action in patients with increased albuminuria was undertaken in similar numbers of 
patients 15.0% vs. 13.3% (P=0.34) below and above 75 years respectively. 
Factors determining RAAS-treatment initiation
In the overall multivariate analysis, increased albuminuria status, blood pressure and 
number of antihypertensives (other than those intervening in the RAAS) that were already 
used were important determinants of RAAS-treatment initiation (Table 2). Looking at the 
subgroups, we found that amongst patients without any ACR measurement and patients 
with normoalbuminuria the most important determinants of RAAS-treatment initiation 
were blood pressure and/or number of antihypertensive agents that were already used 
(Table 2). In patient with increased albuminuria, the number of antihypertensive agents 
appeared to be a determinant next to presence of increased albuminuria.
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Discussion
An ACR measurement was observed in less than 60% of T2DM patients in Dutch primary 
care in 2009, even in patients below 75 years of age. ACR measurement was more common 
in patients with earlier ACR measurements, more concomitant medication use, and 
receiving additional care by a diabetes support facility. Patients with increased albuminuria 
were frequently treated with RAAS-treatment (78.4% in prevalent albuminuria and 66.5% 
in incident albuminuria). In patients with increased albuminuria not on RAAS-treatment 
the actions considered appropriate according to the guideline were applied in only a small 
proportion of patients (<15%). 
Albuminuria screening was lower than anticipated based on published screening rates 
of other renal/cardiovascular risk factors.10-12 Although the proportion of patients being 
screened increased when the interval was extended beyond 12 months, as proposed in a 
recent study,22 this was a marginal increase leaving more than a third of patients not being 
screened in 2009. Also, limiting the patients to those who have a longer life expectation 
did not substantially increase the ACR screening rate. One possible reason for the low 
screening rates could be that patients did not frequently visit their GP or even avoided 
care, although this is not plausible as 3 monthly visits are common for patients with 
T2DM in The Netherlands. In addition, more than 90% of the included patients had their 
HbA1c checked at least once yearly in our study period and the number of care avoiders 
in this cohort is estimated to be less than ~5% on the basis of other available visit data 
and measurements.11 It is therefore unlikely that care avoidance contributed considerably 
to the low proportion of ACR screening. Another reason, brought forward by some GPs, 
are logistical issues regarding albuminuria screening (i.e. instruction first morning void, 
requirement of specific urine cups, inadequate patient recall system). This may explain 
why additional care by a diabetes support facility was an important determinant of ACR 
measurement, as they may be more attentive of laboratory procedures and providing 
necessary patient instruction and thus may be better equipped to provide optimal 
diabetes care. In further support of this, additional support by diabetes care facilities has 
previously been shown to contribute to improve hypertension management in diabetes.28
Of the patients who had prevalent or incident micro/macroalbuminuria, a substantial 
proportion already received RAAS-treatment. It is unclear to what extent RAAS-treatment 
was prescribed to these patients because of increased albuminuria or because of (previous) 
uncontrolled blood pressure. Given the fact that RAAS-treatment was also common 
in patients without any ACR measurements and patients with normoalbuminuria, it 
is tempting to assume that in many patients the main indication for RAAS-treatment 
was uncontrolled blood pressure rather than increased albuminuria. This suggestion is 
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further supported by our finding that blood pressure and number of antihypertensive 
drugs used (other than RAAS) were determinants of RAAS-treatment initiation in patients 
with unknown albuminuria or normoalbuminuria. Furthermore, RAAS-treatment was 
also more likely to be initiated in patients with increased albuminuria when they already 
used more antihypertensive drugs, suggesting that initiation of RAAS-treatment in these 
patients is also partly depending on pre-existing high blood pressure. This may indicate 
that establishment of increased albuminuria in itself is insufficiently recognized as an 
indication for starting RAAS-treatment. 
Across all groups the proportion of patients that was started on RAAS-treatment was 
highest in patients with prevalent increased albuminuria followed by patients with 
incident increased albuminuria. Increased albuminuria was an important trigger for 
RAAS-treatment initiation. Nevertheless, the proportion of patients that was prescribed 
RAAS after increased albuminuria measurement was disappointingly low (~13%). 
How does the Dutch guideline and clinical practice relate to international guidelines and 
practice? The Dutch primary care guideline differs in some aspects from the standards 
of medical care by the American Diabetes Association (ADA).7 The main discrepancy 
between the Dutch primary care guideline and the ADA guideline is that RAAS-treatment 
is only recommended in patients with increased albuminuria, whereas the ADA guideline 
recommends RAAS-treatment in all hypertensive patients with T2DM irrespective of their 
albuminuria status. This may to some extent limit the direct extrapolation of our results, 
although similar problems regarding attention for increased albuminuria may occur in 
other primary care settings. 
With respect to screening for albuminuria and its treatment in other parts of the world, 
a study from the UK reported on the quality of diabetes care and presented data on 
albuminuria screening and treatment thereof.9 In this population 75% of patients with 
T2DM were screened for increased albuminuria in a 15 months period in 2006 which 
was also lower as compared to other risk factors. Of patients with a diagnosis of micro/
macroalbuminuria 86.4% was treated with an ACEi or ARB but no information was 
presented on subsequent RAAS-treatment initiation. Both the proportion of patients 
screened and the proportion of patients treated with RAAS-treatment were modestly 
higher in the UK-setting than we observed in the Dutch setting. The higher proportion of 
screened patients in the UK study can partly be explained by the longer study period (15 
as opposed to 12 months) and the measurement in ‘high quality data’ general practices. 
Also, the higher rates of screening and treatment in the UK may be positively influenced 
by the implementation of the quality and outcomes framework in 2004.9 In our study, 
we observed improvement in albuminuria screening in 2008-2009 compared to 2007. As 
the current guideline dates from 2006, this improvement illustrates that new guideline 
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recommendations may take time and extra effort before they are fully implemented in 
practice.29,30
It is widely recognized that there can be many barriers and incentives contributing to 
the implementation of guidelines in practice.31 We looked at several external factors, 
including patient characteristics and organizational factors. However, barriers at the 
level of the health care professional may also be important. There can be cognitive and 
attitudinal barriers which may explain inertia.31 A questionnaire among European general 
practitioners (GPs) showed such internal barriers with respect to albuminuria guideline 
implementation. A repeat ACR test in T2DM patients with incident microalbuminuria was 
deemed necessary by only 45-77% (depending of the country) GPs. Even more worrisome 
was that only 23-50% of GPs would prescribe RAAS-treatment in a T2DM patient with 
confirmed microalbuminuria. These findings, together with our data, show that awareness 
and implementation of guidelines regarding albuminuria screening and treatment in 
primary care need to be improved.32
A limitation of this study is that we looked at the most recent ACR measurement and 
the subsequent actions, whereas some patients may have a history of previous events or 
outcomes which may influence these actions. To take this into account, we included a wide 
range of potential patient-related determinants when assessing guideline adherence. 
Another limitation is that we only looked at new prescriptions of RAAS-treatment and 
not at changes in RAAS-treatment such as dose-adjustment. This may underestimate the 
proportion of patient in whom action is undertaken regarding RAAS-treatment on the 
basis of the ACR measurement. For assessing guideline adherence in our study, however, 
these patients were considered to be adequately managed. An important strength of 
this study is that the data reflect a large longitudinally followed group of T2DM patients 
treated in primary care. All collected data were registered during regular care and this 
process was unaffected by this study. Data collection and registration have been validated 
in prior studies underscoring the robustness of the results.24 
Conclusions
In the primary care setting, the adherence to guidelines with respect to albuminuria 
screening and treatment was modest and should be further improved in order to 
accomplish optimal risk management in patients with type 2 diabetes. It is well recognized 
that albuminuria is one of the strongest cardio-renal risk markers, and early screening 
and appropriate treatment have the potential to substantially reduce the risk of cardio-
renal complications. Nevertheless, in comparison to the management of other risk factors 
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in T2DM albuminuria receives little attention. Better support systems for regular ACR 
measurement and more attention for albuminuria as a risk factor beyond blood pressure 
may improve albuminuria screening and treatment in primary care. 
 
Sources of funding
The research leading to these results was funded by the European Community’s Seventh 
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Abstract
Background: Impaired renal function is a frequent complication after lung transplantation 
(LTx). Since the early days of LTx, recipient eligibility criteria slowly became less strict, while 
treatment regimens evolved. These developments may have had opposing effects on the 
risk for impaired renal function. We aimed to study changes in recipient characteristics 
in conjunction with incidence of impaired renal function in consecutive series of lung 
transplant recipients ( LTRs).
Methods: 340 Adult LTRs (mean age 45±12, 50.3% male, median follow-up 3.4[1.0-7.1]
yrs) were divided into 4 consecutive patient series in time: 1990-1996 (n=93), 1997-2001 
(n=79), 2002-2005 (n=89), 2006-2008 (n=79). Primary endpoint was cumulative incidence 
of doubling of serum creatinine (DSC), taking into account the competing risk of death. 
Measured GFR (mGFR, 125I-Iothalamate) was assessed as a secondary endpoint.
Results: Mean age at transplantation (P=0.001), prevalence of hypertension (P=0.005), 
packyears of former smoking (P=0.001) and BMI (P=0.05) increased across the consecutive 
series. Cumulative incidence of DSC at 24 months after LTx was 43%, 37%, 35% and 29% 
resp. in the consecutive series (P=0.01). Despite higher prevalence of renal risk factors, 
there was lower adjusted risk of DSC in the consecutive series, with resp. HRs[95%CI] of 
0.62[0.34-1.15], 0.50[0.25-0.98] and 0.31[0.154-0.67] compared to the series of 1990-1996. 
In line, mGFR at 24 months after LTx was 51±17, 53±17, 57±21 and 63±21ml/min/1.73m2 in the 
consecutive series (P=0.002).
Conclusions: Despite higher prevalence of renal risk factors in more recently transplanted 
patients, renal outcome after LTx has improved over time. Nevertheless, impaired renal 
function remains a frequent complication after LTx.
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Introduction
Impaired renal function is a common complication after lung transplantation (LTx).1-3 Renal 
function declines progressively in the majority (>90%) of lung transplant recipients (LTRs).2 
At five years after LTx, cumulative incidence of chronic renal failure has been reported to be 
more than 15%.2,4 A large proportion (~50%) of these patients ultimately progresses to end 
stage renal disease (ESRD), requiring renal-replacement therapy.2,4,5  Since its introduction 
more than 20 years ago, the field of lung transplantation has evolved considerably. Due to 
changing acceptance policies LTRs are increasingly older and have a a higher proportion 
of ‘co-morbidities’.6 Yet, patient and graft survival after LTx have gradually improved.7, 8 The 
increasing age, higher prevalence of co-morbidities and the longer overall survival may all 
be suspected to adversely impact on incidence of impaired renal function and ESRD after 
LTx.9 These factors may, however, be opposed by a “learning curve” in management of LTRs 
and decreased nephrotoxicity of the novel immunosuppressive strategies.2,10,11 Whether 
these developments over time have affected the risk for renal function impairment after 
LTx has not been systematically assessed. In the current study therefore, we evaluated 
the changes in population characteristics that occurred over time in consecutively 
transplanted series of LTx patients, as well as the incidence of renal function impairment 
after LTx in these patients, in a large single-center cohort .
Patients and methods
In total 348 lung and 22 heart-lung/lung-liver transplantations were performed between 
1990 and 2008 at the University Medical Center Groningen (UMCG), the Netherlands. We 
excluded 17 pediatric and 13 re-transplantations, leaving 340 primary adult lung or heart-
lung transplantations to be included in the present study. Patients were divided into four 
consecutive patient series with similar numbers of patients: 1990-1996, 1997-2001, 2002-
2005 and 2006-2008. 
Clinical information on all individuals was obtained at baseline (before transplantation) 
and post-transplantation during follow-up visits. There was no loss of follow-up. From all 
patients consent for the use of their data was obtained prior to transplantation. 
Data collection
The following parameters were collected for all patients: recipient gender, age of the 
recipient at transplantation, pulmonary diagnosis, type of transplantation, intra-operative 
use of cardiopulmonary bypass, immunosuppressive regimen, history of smoking, number 
hoofdstuk 7.indd   129 5-4-12   20:50
130
Chapter 7 Impaired Renal Function after Lung Transplantation 
of packyears, diabetes pre-transplantation (antidiabetic treatment), hypertension pre-
transplantation (anti-hypertensive treatment), body-mass-index (BMI) , 24-hour creatinine 
excretion and measures of renal function. 
Measures of renal function
Renal function was assessed at baseline and regularly during follow up by serum creatinine 
(SCr). We also assessed true GFR at baseline and with intervals during follow-up by means 
of the 125I-Iothalamate and 131I-Hippuran infusion method.12-14 This method is considered a 
gold standard method for GFR measurement and used for the development of novel renal 
function equations.15 The 125I-Iothalamate and 131I-Hippuran clearances are calculated as 
(U*V)/Piot and (I*V)/Phipp ,respectively. U*V represents urinary excretion of the tracer; I*V, the 
infusion rate of the tracer, which equals clearance from plasma during steady state. GFR is 
calculated as the urinary clearance of 125I-Iothalamate, corrected for voiding errors: (U*V/P)
corr. Height and weight were measured in every patient before investigation. Body surface 
area (BSA) was calculated as 0.007184 · weight0.425 · length0.725, and GFR was expressed per 
1.73 m2 of BSA.16
Endpoints
Outcome measure for this study was doubling of serum creatinine (DSC). This is an 
acknowledged endpoint in clinical studies on chronic renal function impairment, including 
LTx.4,17-19 Accordingly DSC was defined as the first SCr value twice the baseline value, 
confirmed by a similar second value at least four weeks after the initial doubling. Baseline 
SCr was the mean of available measurements in the month prior to transplantation. SCr 
was measured at all outpatient visits during follow-up. Measured glomerular filtration 
rate (mGFR) was used as a secondary outcome. From 2004 onwards, mGFR measurements 
were performed with lower frequency, allowing less resolution in time, and incomplete 
data in the more recently transplanted patients. We therefore refrained from using mGFR 
as primary outcome variable for our study.
Medication 
Immunosuppressive protocols used over time are described in more detail elsewhere.20
In short, induction consisted of rATG (Thymoglobulin; Sanofi Pasteur, Lyon, France) 
until 2001 and Basiliximab induction thereafter (Simulect, Novartis Pharma, Basel, 
Switzerland). Maintenance immunosuppression consisted of a calcineurin inhibitor 
(CNI) based immunosuppressive regimen combined with Prednisolone and Azathioprine 
(Immuran; GlaxoSmithKline, Brentford, UK) or Mycophenolate Mofetil (Cellcept; Roche, 
Basel, Switzerland). 
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Cyclosporine (Neoral; Novartis Pharma, Basel, Switzerland) was the CNI used until 2001 
(target levels: whole blood trough levels 400ng/mL initially, tapered to 150 ng/mL within 
the first three weeks), tacrolimus (Tacrolimus, Prograft; Astellas Pharma, Staines, UK) was 
the CNI used from 2001 onwards (target levels: 20ng/mL during the first three weeks, 
15ng/mL until the third month and 10-12ng/mL thereafter and from 2004 until present 
target levels 15-18ng/mL during the first three weeks, 12-15ng/mL until the third month, 
and 10-12ng/mL thereafter).
All patients furthermore received P.Jiroveci prophylaxis (co-trimoxazole), Herpes 
prophylaxis (aciclovir) and from 2001 all patients at risk received standard CMV–
prophylaxis (ganciclovir).
Statistical analysis
Results were analyzed with SPSS version 18.0 and STATA version 11.0. Continuous variables 
are reported as means with standard deviations, and categorical variables as frequencies 
with percentages. Recipient characteristics are shown according to the four transplant 
series. Categorical characteristics of the groups were compared with Chi square test, and 
continuous characteristics were compared with ANOVA for linear trend. Results were 
considered significant at two-sided P<0.05. 
Follow-up was measured from date of transplantation. Patients were censored at date 
of last follow-up. Death was regarded as a competing endpoint for DSC and cumulative 
incidence of DSC was calculated taking the competing risk of death into account. Strata of 
the consecutive patient series were compared with the Gray’s log-rank test for competing 
risks data. We used a cause-specific hazards model for the multivariable regression analyses 
to model the risk of DSC in the different time-series.21 In the multivariable analyses, we 
adjusted for demographics, significant differences between patient series and established 
renal risk factors in LTRs (age, sex, pulmonary diagnosis, type of transplantation, use of 
cardiopulmonary bypass, hypertension, diabetes, packyears of smoking, serum creatinine, 
BMI, and creatinine excretion). In addition, we performed a secondary analysis looking at 
the consecutive pharmacologic eras (Csa, Tac and Tac-low). Hazard ratios (HR) are reported 
with 95% confidence interval [CI]. 
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1990-1996 1997-2001 2002-2005 2006-2008 P-value
Number of Patients 93 79 89 79
Age at Transplantation - years 42.9 ± 11.1 44.0 ± 11.1 46.0 ± 12.4 48.9 ± 12.7 0.001
Male Sex - n (%) 55 (59.1) 35 (44.3) 48 (53.9) 33 (41.8) 0.08
Pulmonary Diagnosis  - n (%) 0.004
   Chronic Obstructive Pulmonary Disease 16 (17.2) 14 (17.7) 21 (23.6) 28 (35.4)
   α-1-Antitrypsine Deficiency 30 (32.3) 18 (22.8) 13 (14.6) 8 (10.1)
   Cystic Fibrosis 15 (16.1) 21 (24.1) 19 (21.3) 12 (15.2)
   Primary Pulmonary Hypertension 8 (8.6) 3 (3.8) 5 (5.6) 2 (2.5)
   Secondary Pulmonary Hypertension 6 (6.5) 6 (7.6) 6 (6.7) 5 (6.3)
   Bronchiectasis 9 (9.7) 4 (5.1) 6 (6.7) 2 (2.5)
   Pulmonary Fibrosis 9 (9.3) 15 (18.1) 17 (16.8) 19 (21.3)
   Other 0 (0) 0 (0) 3 (3.4) 4 (5.1)
Type of Transplantation  - n (%) 0.10
   Unilateral 18 (19.4) 14 (17.7) 20 (22.5) 24 (30.4)
   Bilateral 74 (79.6) 58 (73.4) 62 (69.7) 50 (63.6)
   Combined organ 1 (1.1) 7 (8.9) 7 (7.9) 5 (6.3)
Cardiopulmonary Bypass - n (%) 69 (74.2) 48 (60.8) 53 (59.6) 34 (40.5) <0.001
Immunosuppressive Regimen - n (%) 0.001
    Cyclosporin 93 (100) 63 (79.7) - -
    Tacrolimus - 16 (20.3) 38 (42.7) -
    Tacrolimus-low - - 51 (57.3) 79 (100)
History of Smoking  - n (%) 54 (60.7) 42 (54.5) 47 (53.4) 49 (63.6) 0.30
    Number of packyears 17 ± 14 17 ± 11 22 ± 14 26 ± 17 0.001
Hypertension - n (%) 8 (8.7) 12 (15.2) 23 (25.8) 21 (26.6) 0.005
Diabetes Mellitus - n (%) 9 (9.8) 6 (7.6) 7 (7.9) 10 (12.7) 0.67
Body Mass Index (BMI - kg/m2) 21.8 ± 3.4 21.7 ± 3.4 22.1 ± 3.7 22.9 ± 4.1 0.05
Creatinine Excretion (mmol/24h) 11.0 ± 3.3 9.0 ± 4.3 8.8 ± 4.1 8.9 ± 3.0 0.001
Renal Function Measurements
   Pre-transplantation sCr - µmol/L 100 ± 23 96 ± 20 101 ± 21 97 ± 24 0.12
   Estimated GFR (MDRD) - ml/min/1.73m2 68 ± 20 68 ± 22 64 ± 18 73 ± 25 0.38
   Estimated GFR (CKD-EPI) - ml/min/1.73m2 76 ± 21 75 ± 22 71 ± 20 78 ± 23 0.79
   Glomerular Filtration R ate (GFR) - ml/min/1.73m2 100 ± 22 105 ± 26 94 ± 24 95 ± 25 0.05
Table 1| Baseline patient characteristics per series of lung transplant recipients
Abbreviations: MDRD: Modification of diet in renal disease study equation, CKD-EPI: Chronic Kidney Disease–Epidemiology Collabo-
ration equation.
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Results 
Baseline characteristics for the four consecutive transplant series are shown in table 1. 
Mean recipient age at transplantation increased from 42.9±11.1 yrs between 1990 and 
1996 to 48.9±12.7 yrs between 2006 and 2008 (P=0.001). Primary diagnosis gradually 
shifted from α 1-antitrypsin deficiency as largest group towards chronic obstructive 
pulmonary disease and pulmonary fibrosis as largest groups (P=0.004). The proportion 
of other pulmonary diagnoses as well as the type of transplantations remained relatively 
constant over time. The use of cardiopulmonary bypass decreased over time. Importantly, 
CsA was replaced by Tac as the standard calcineurin inhibitor (CNI) in 2001. 
Concerning renal risk factors, prevalence of hypertension before transplantation increased 
from 8±9% between 1990 and 1996 to 21±276% between 2006 and 2008 (P=0.005), 
and also the number of LTRs with a history of heavy smoking gradually increased over 
time, with average number of packyears of former smoking increasing from 17±14 yrs to 
26±17 yrs (P=0.001). Prevalence of diabetes remained stable. Interestingly, recipient BMI 
increased in the consecutive series from 21.8±3.4 to 22.9±4.1 kg/m2 (P=0.05) whereas 24-
hour creatinine excretion, a measure of total muscle mass,22 decreased in the consecutive 
series over time from 11.0±3.3 to 8.9±3.0 mmol/24h (P<0.001).
Baseline serum creatinine (SCr) and eGFR assessed by the Modification of Diet in Renal 
Disease (MDRD) and Chronic Kidney Disease–Epidemiology Collaboration (CKD-EPI) 
equations were not different between the consecutive series in time. However, the more 
accurate mGFR shows that both equations underestimate mGFR and that baseline renal 
function decreased in the consecutive series in time from 100±22 to 95±25 ml/min/1.73m2 
(P=0.05). The lower baseline mGFR over time corresponds to the higher age of the LTRs 
and the increased prevalence of renal risk factors. Survival and cumulative incidence of 
bronchiolitis obliterans syndrome were at least equal in the consecutive series of LTRs 
(data not shown).
The overall cumulative incidence of doubling of serum creatinine (DSC) was 27.6% at 1 
year after LTx. For the four respective time-series, the cumulative incidence of DSC at 1 
year after LTx was 28.0%, 26.6%, 27.0% and 22.7% (P=0.01). For the series 1990-1996, 1997-
2001 and 2002-2005 overall cumulative incidence of DSC 48 months after LTx was 46.7% 
and the cumulative incidences for the respective series were 53.8, 46.8 and 42.2% (figure 
1, P=0.01). 
In univariable regression analysis, the most recent cohort (2006-2008) was associated 
with lowest risk for DSC (HR[95%CI]=0.48[0.29-0.82]), compared to the cohort 1990-
1996 (reference) and series 1996-2001 and 2002-2005 were associated with intermediate 
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risk (HRs of 0.70[0.47-1.03], and 0.61[0.41-0.91] resp.) (table 2). In multivariable 
regression analyses with adjustment for age, sex, type of LTx, pulmonary diagnosis, use 
of cardiopulmonary bypass, hypertension, diabetes, packyears, serum creatinine, BMI 
and creatinine excretion, the HRs compared to cohort 1990-1996 were 0.62[0.34-1.15], 
0.50[0.25-0.98] and 0.31[0.15-0.67] for the series of 1997-2001, 2002-2005 and 2006-2008 
respectively. 
Model 1 Model 2
Transplant Series HR [95%CI] HR (95%CI)
1990-1996 1.00 (reference) 1.00 (reference)
1997-2001 0.70 [0.47-1.03] 0.62 [0.33-1.13]
2002-2005 0.61 [0.41-0.91] 0.50 [0.25-0.98]
2006-2008 0.48 [0.29-0.82] 0.31 [0.15-0.67]
Model 1: Crude model. Model 2: Adjusted for potential confounders: Age, sex, 
pulmonary diagnosis, type of transplantation, hypertension, diabetes, packyears of 
former smoking, serum creatinine, BMI, creatinine excretion and use of cardiopulmo-
nary bypass. HR: Hazard Ratio, CI: Confidence Interval.
Table 2| Cause-specific hazards regression for DSC
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Cumulative incidence of doubling of serum creatinine after lung transplantation  for the consecutive time-series of lung transplant 
recipients. Numbers of patients still at risk for DSC at the various time points after LTx are indicated below the graph.
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In a secondary analysis looking at the consecutive pharmacological eras (CsA, Tac and 
Tac-low respectively), respective cumulative incidences of DSC were 27.6, 27.8 and 23.0% 
(P=0.04) at 12 months after LTx, 41.0, 35.2 and 31.4% (P=0.04) at 24 months after LTx and 
50.6, 44.4 and 39.1% at 48 months after LTx (P=0.04). In a multivariable adjusted Cox-
regression analysis, HRs for DSC were 0.63[0.33-1.22] and 0.46[0.26-0.81] for Tac and Tac-
low respectively, compared to CsA. We found no significant difference between low versus 
high dose Tac (HR=0.72 [0.36-1.45], P=0.36).
As a secondary outcome we analyzed decline in mGFR as well as residual mGFR at 24 and 
48 months after LTx (48 months follow-up was not available for the cohort 2006-2008) 
(figure 2). For the consecutive transplant series mean decline in mGFR was 46, 49, 42 and 
30% respectively (P=0.005) at 24 months after LTx and 51, 49 and 42% respectively (P=0.07) 
at 48 months after LTx. The long-term renal function decline seems to be less pronounced 
in the more recent transplant series (figure 2). For the four consecutive transplant series 
the mean residual mGFR was 51±17, 53±17, 57±21 and 63±21 ml/min/1.73m2 respectively 
(P=0.002) at 24 months after LTx and 45±18, 52±18, 53±17 (P=0.02) at 48 months after LTx. 
End-stage Renal Disease (ESRD)
A total of 16 patients progressed to ESRD. In the four consecutive time series, numbers 
were 11 (11.8% during 6.8[1.6-12.6] years of follow-up), 1 (1.3% during 7.1[0.8-9.0] years), 4 
(4.5% during 4.1[3.0-5.5] years) and 0 (0% during 1.5[0.4-2.1] years) respectively. By default, 
follow-up is longest the earliest time series. Together with the low absolute number of 
ESRD, this renders it virtually impossible to perform meaningful statistical analyses and 
draw reliable conclusions on a possible change in the incidence of ESRD over time. We 
























































Figure 2| Decline in mGFR and residual mGFR after lung transplantation 
Left panel: percentage mGFR decline from baseline for the stacked time-intervals 0-12 months, 12-24 months and 24-48 months, 
per series of LTRs. Right panel: Residual mGFR before transplantation and 12, 24 and 48 months after Lung Transplantation per 
series of LTRs. Follow-up of 48 months was not available for cohort 2006-2008.
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Discussion
In this study we assessed the change in patient characteristics of consecutive series of 
LTRs between 1990 and 2008 in our center, and the course of renal function after LTx. First, 
patient characteristics changed considerably over time, resulting in a higher prevalence 
of risk factors in the more recently transplanted patients. Nevertheless, the two-year 
cumulative incidence of DSC decreased in the consecutive transplant series and the risk 
for DSC was lower in each consecutive series. Thus, renal outcome has ameliorated over 
time despite a worse renal risk profile at baseline. These results are further supported by 
the lower mGFR decline and higher residual mGFR at all time points after LTx in the more 
recent series of LTRs.
The overall cumulative incidences of DSC found in this study of 37% at 2 years after LTx and 
47% at 4 years after LTx were in agreement with the cumulative incidence of 53% at 4 years 
after transplantation in a small study with 45 patients in Italy21 and cumulative incidences 
of 43% at 2 years and 53% at 5 years after LTx in a larger study with 219 patients in the 
US.4 The characteristics of our population compare well to the population in these two 
studies with respect to age, pulmonary diagnoses, BMI, prevalence of diabetes, and renal 
function at baseline. These data support the generalizability of our single center data to 
other populations. Yet, differences were also present, mainly the proportion of bilateral 
transplantations, the prevalence of hypertension and the use of Tacrolimus, which were 
all higher in our population.
The current results confirm our earlier observation of a non-linear decline in renal function 
over time, with a large initial drop that gradually levels off thereafter, in an early subgroup 
of our LTx cohort.23 Despite the decreasing incidence in DSC over time, the marked non-
linearity of the decline was present in all patient series (figure 1). Interestingly, we found 
no difference in baseline GFR estimated with the MDRD and CKD-EPI equation, whereas 
a difference was observed in baseline mGFR measured with 125I-Iothalamate. In addition, 
both equations substantially underestimated GFR. The discrepancy between eGFR and 
mGFR may relate to the observed difference in creatinine excretion, which is a measure 
of muscle mass. This again stresses the limitations of creatinine-based GFR estimation 
in a population as LTRs with large variation in muscle mass and muscle mass changes 
after LTx.24 Despite the lower baseline GFR in the consecutive series, we did not only find 
a significantly lower percentage of GFR decline over time, but also a higher residual GFR 
during follow-up in the more recent series.
One of the factors that has likely played a role in the amelioration of renal function 
impairment after LTx over time is the switch from CsA to Tac as standard calcineurin 
inhibitor in 2001. It has previously been shown in other solid organ transplant populations 
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that Tac, in the dosages used, was less nephrotoxic than CsA.2 In LTRs, results of studies 
comparing nephrotoxicity of CsA and Tac have been inconclusive, possibly due to these 
weaknesses in study design. One study defined CNI use use during >80% of the post-
transplant course, and others looked at initial CNI regimen.2,10,11 These study designs 
rendered the studies susceptible to bias because deterioration of renal function is often 
one of the reasons for change of one CNI-regimen into another.25 Our findings provide 
support for the assumption that also in LTRs Tac could be less detrimental on renal 
function than CsA.
Other factors that may have influenced the reduced incidence of renal function impairment 
are the evolvement of immunosuppressive regimens, improved surgical techniques and 
post-operative management, increased awareness about renal function impairment and 
increased experience in the management of LTRs and renal function impairment in LTRs.
The increased awareness about renal function impairment may also be exemplified 
by how use of CNIs and blood pressure management evolved. During the era in which 
cyclosporine was used as CNI, targeted levels were maintained, even in case of worsening 
renal function. When, however, Tacrolimus appeared to be a more potent CNI, gradually 
lower trough levels were accepted in case of worsening renal function. For blood pressure 
management, parallel changes occurred. In the early 90’s the targeted blood pressure was 
<160/95, and this was gradually lowered towards the contemporary target of <140/90. In 
addition, use of ACE-inhibitors in case of worsening renal function increased over time, 
which are currently first choice antihypertensive agents.
A limitation of this study was that it was an observational and single-center analysis. 
This could limit the generalizability of our finding to other LTx populations. Nevertheless, 
the similarity with previously published literature on cumulative incidence of DSC is 
remarkable. Another limitation of this study is the use of a creatinine-based endpoint. 
However, DSC is the most frequently used endpoint in research on this topic, facilitating 
comparison between studies.11,19 Our results are strengthened by the parallel findings with 
the gold standard 125I-Iothalamate GFR measurements.13 Another strength of this study 
was the large and well-characterized cohort of LTRs, including all patients transplanted in 
our center since the start of the program, without any loss to follow-up. 
Conclusions
Lung transplant recipient characteristics changed over the last two decades, with higher 
prevalence of renal risk factors and worse overall condition of lung transplant recipients. 
Yet, prevalence of renal function loss decreased across consecutive series of a large 
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cohort of lung transplant recipients. Despite the improvements in overall renal outcome, 
impaired renal function remains an important complication after lung transplantation 
and exposition of the lung transplant recipients to unnecessary additional renal risks 
remains to be avoided as much as possible. 
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Abstract 
Background: Chronic kidney disease (CKD) is a common complication after lung 
transplantation (LTx). Smoking is a risk factor for many diseases, including chronic kidney 
disease (CKD). Smoking cessation for >6 months is required for LTx-enlistment. However, 
the impact of smoking history on CKD development after LTx remains unclear. We 
investigated the effect of former smoking on CKD and mortality after LTx. 
Methods: CKD was based on glomerular filtration rate (GFR) (125I-iothalamate-
measurements). GFR was measured before and repeatedly after LTx. 
Results: 134 recipients never smoked and 192 recipients previously smoked for a median 
of 17.5 pack years. At 5 yrs after LTx, overall cumulative incidences of CKD-III, CKD-IV and 
death were 68.5, 16.3 and 34.6% respectively. Compared to never smokers, former smokers 
had a higher risk for CKD-III (hazard ratio (HR) - 95%-confidence interval [95%CI]=1.69 
[1.27-2.24]) and CKD-IV (HR=1.90 [1.11-3.27]), but not for mortality (HR=0.99[0.71-1.38]). 
Adjustment for potential confounders did not change results. 
Conclusions: Despite cessation, smoking history remained a risk factor for CKD in LTx 
recipients. Considering the increasing acceptance for LTx of older recipients with lower 
baseline renal function and an extensive smoking history, our data suggest that the 
problem of post-LTx CKD may increase in the future.
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Introduction
Chronic kidney disease (CKD) is a serious complication after lung transplantation (LTx). 
In most LTx-recipients renal function deteriorates progressively, often resulting in CKD.1 
Progression from CKD to end-stage renal disease (ESRD) currently develops in between 3 
and 10% of LTx recipients.2-4 Recipient age and life expectancy after LTx are increasing, so 
it is likely that the a priori risk for CKD after LTx is increasing concomitantly, with possible 
consequences for the number of LTx recipients that develop ESRD on the long term.5
Approximately 60% of LTx recipients have a history of smoking.6 This is the highest rate 
reported among recipients of solid organs: former smokers account for 51-54% of renal-
transplant recipients,7,8 42-50% of liver-transplant recipients,9 and 45% of heart-transplant 
recipients.5 Moreover, many former smokers amongst LTx recipients smoked heavily, as 
around 40-45% of them undergo LTx because of end-stage pulmonary emphysema, which 
is largely attributable to heavy smoking.6 Pulmonary emphysema, cardiovascular disease 
and lung cancer are well-known complications of smoking.10-12 It may be less well-known 
that smoking is also a risk factor for CKD.13, 14 We wondered whether, even after smoking 
cessation, smoking history could be relevant for morbidity after LTx, in particular CKD, 
because of the high prevalence of both CKD and former smoking in LTx recipients.
Transplant centers, including our own, commonly require that patients have stopped 
smoking for at least six months before being enlisted for LTx.15,16 In the current study, we 
analyzed the potential association between smoking history before LTx and development 
of CKD after LTx in a large single center cohort of LTx recipients. In addition, we analyzed 
the impact of past smoking on mortality and causes of death after LTx.
Patients and methods
A total of 370 lung transplantations, of which 22 heart-lung transplantations were 
performed at the University Medical Center of Groningen (UMCG), the Netherlands 
between 1990 and 2008. Pediatric transplantations (n=17) and re-transplantations (n=13) 
were excluded. Quantitative data on smoking history were obtained from patient records. 
We excluded 14 patients of the remaining 340 patients from further analyses because 
of lack of data on smoking history, leaving a total of 326 patients eligible for evaluation. 
Further clinical information of all individuals was gathered at baseline and during 
follow-up. Consent for the use of patient data was obtained from all patients prior to 
transplantation.
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Smoking history
Smoking cessation for at least 6 months is a requirement for LTx enlistment. Returning 
to active smoking after LTx is very strongly disapproved and occurs, to the best of our 
knowledge, only exceptionally. Smoking history prior to transplantation was quantified 
by number of pack years. One pack year is defined as 20 cigarettes (one pack) smoked per 
day for one year. Patients were categorized into never and former smokers and the latter 
were further categorized according to number of pack years: 1-10, 11-25 and >25 pack years.
GFR measurements
Glomerular filtration rate (GFR) measurements were performed by constant infusion 
of radiolabelled tracers 125I-Iothalamate and 131I-Hippuran as described before.17-19 This 
method is considered a gold standard method for GFR measurement, has a day-to-day 
coefficient of variation of 2.5%19 and is used for the development and validation of novel 
renal function equations.20 Height and weight were measured in every patient before 
every GFR measurement. Body surface area (BSA) was calculated as 0.007184*weight0.425*
length0.725,21 and GFR was expressed per 1.73 m2 of BSA. GFR measurements were performed 
routinely at outpatient basis, before transplantation and at regular time-intervals after 
transplantation.
Endpoints of the study
Primary endpoints of the study were CKD-III and CKD-IV. CKD-III and CKD-IV were defined 
as GFR<60 ml/min/1.73m2, and GFR<30 ml/min/1.73m2 respectively, according to the cut-
off values in the NKF K/DOQI guidelines.22
We used GFR measurements by radiolabelled Iothalamate for the definition of CKD 
because in LTx recipients creatinine-based GFR estimations are biased by the large 
variation in muscle mass.23 For the primary analyses, definition of CKD was based on the 
first GFR measurement below the cut-off values defining the stages of CKD. We did this 
because beyond 2 years after LTx we measured GFR with 2-year intervals. Consequently, a 
proportion of patients with one measurement below the CKD-threshold lacked follow-
up until a confirmatory measurement. Defining CKD based on at least 2 measurements 
below the CKD-threshold would result in underestimation of true cumulative incidence 
of CKD. Moreover, in patients that had a GFR measurement below the cut-off, only 2.4% 
the second GFR measurements were inconsistent with the former measurements. This 
assured us that use of this definition for endpoints was appropriate. However, to consent 
with the NKF K/DOQI guidelines that indicate CKD should be confirmed by a second 
measurement >90 days later, we performed secondary analyses with the endpoints 
defined as such. We furthermore performed a secondary analysis with doubling of serum 
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creatinine (DSC) as alternative renal endpoint to check consistency across renal endpoints. 
DSC was defined as a doubling of serum creatinine, confirmed by a similar value >90 days 
after the initial doubling.
ESRD was defined as the requirement of renal replacement therapy. We recorded 
occurrence of ESRD and death until January 2010. Causes of death were coded according 
to the International Classification of Diseases (ICD-9). 
Immunosuppressive Regimens
Immunosuppressive protocols used over time are described in more detail elsewhere.24 
In short, maintenance immunosuppression consists of a calcineurin inhibitor (CNI) 
based immunosuppressive regimen, combined with steroids and azathioprine (Immuran; 
GlaxoSmithKline, Brentford, United Kingdom). Cyclosporine (Neoral; Novartis, Basel, 
Switzerland) was the CNI used until 2001. The targeted whole blood trough level of 
CsA was initially 400 µg/L, tapering to 150 µg/L within the first three weeks. Tacrolimus 
(Prograft; Astellas, Staines, United Kingdom) was the CNI used from 2001 onwards. 
Between 2001-2004 target trough levels were 20 µg/L during the first three weeks, 15 
µg/L until the third month and 10-12 µg/l thereafter. Lower peri-operative tacrolimus 
trough levels were targeted from 2004: 15-18 µg/L during the first three weeks, 12-15 µg/L 
until the third month, and 10-12 µg/L thereafter. We further decreased target levels to 8-10 
µg/L in the case of EBV-reactivation.24
Prednisolone dose was 0.2 mg/kg/d until the third month and 0.1 mg/kg/d thereafter. 
Azathioprine dose was 1.5-3 mg/kg/d. Induction consisted of ATG (Thymoglobulin; Sanofi-
Pasteur, Lyon, France) until 2001 and Basiliximab induction thereafter (Simulect; Novartis, 
Basel, Switzerland). We switched some patients from Azathioprine to Mycophenolate 
Mofetil (Cellcept; Roche, Basel, Switzerland). Patients received P. Jiroveci prophylaxis, 
Herpes prophylaxis and CMV-prophylaxis (at-risk patients only, from 2001 onwards). 
Statistical analysis
Data were analyzed with SPSS version 18.0 (IMB, New York, USA), STATA version 11.2 
(STATACorp LP, Texas, USA) and R version 2.12.0 (CRAN, Wien, Austria). The data were 
obtained from pre-existent databases and from patient chart review. Categorical variables 
are reported as frequencies and percentages. Variables with normal distribution are 
presented as mean with standard deviation (SD) and variables with a skewed distribution 
are presented as median with interquartile range [IQR]. 
Recipient characteristics are shown according to categories of smoking habits prior 
to transplantation. We divided patients into never smokers and former smokers and 
subdivided the latter category into three categories according to number of pack 
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years. Differences between groups were tested by one-way ANOVA for linear effects 
for continuous variables and Chi Squared-test for categorical variables. We performed 
adjustment for multiple comparisons over time using Bonferroni correction. 
CKD-III, CKD-IV and all-cause mortality were endpoints in this study. Cumulative incidences 
of CKD-III and CKD-IV were calculated for never smokers and groups of former smokers 
using competing risk analysis. Differences between smoking exposure groups were tested 
with Gray’s test for competing risks data.25,26 We calculated population attributable risk 
as (proportion exposed*((adjusted hazard ratio-1)/adjusted hazard ratio)*100%.27 The 
association of former smoking with CKD-III and IV was modeled with Cox cause-specific 
hazards regression,28 and the association with mortality with standard Cox proportional 
hazards regression. Variables that we selected as covariates in multivariable analyses 
were patient demographics, variables that were different between the smoking exposure 
groups at baseline and variables previously found to be risk factors with renal risk after 
LTx.29,30 Linearity of continuous covariates was assessed using multivariable fractional 
polynomials. Optimal model-fit for GFR was obtained by a 1000/GFR transformation, 
whereas age, BMI and pack years were either best fitted in a linear non-transformed way 
or did not contribute to the model. We therefore used a 1000/GFR-transformation of GFR 
in the analyses. To assess dose-dependency, the number of pack years was analyzed as 
continuous variable.
We performed secondary analyses without the never smokers and stratified for age (< 47 
and > 47 years, population median) and for diagnosis (COPD vs. non-COPD) to rule out that 
(dose) effects were solely based on the differences in characteristics of never smokers and 
former smokers. Moreover, in further secondary analyses, we repeated the multivariable 
analyses with CKD-III and CKD-IV confirmed by a second measurement >90 days later and 
with doubling of serum creatinine, also confirmed by a second measurement >90 days 
later as alternative renal endpoints. Lastly, as body dimensions may change substantially 
after LTx we performed a secondary analysis with body surface area as time-dependent 
variable. Possible interactions between variables were also assessed. Hazard ratios (HR) are 
reported with 95% confidence interval [95%CI]. Final results were considered significant 
at a level <0.05.
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Number of Patients 134 62 74 56
Pack Years 0 ± 0 6.5 ± 3.0 18.1 ± 4.7 38.7 ± 12.1
Male Sex - n, % 73 (54.3) 26 (41.9) 40 (54.1) 27 (48.2) 0.37
Recipient Age* - years 36.8 ± 12.5 48.5 ± 8.2 50.7 ± 6.9 55.1 ± 5.6 <0.001
Race  0.88
    Whites 131 (99.3) 62 (100) 73 (98.6) 56 (100)
    Blacks 3 (0.7) 0 (0) 1 (1.4) 0 (0)
Glomerular Filtration Rate - mL/min/1.73m2 108 ± 26 98 ± 18 101 ± 15 93 ± 17 0.04
Pre-transplantation SCr - μmol/L 77 ± 19 80 ± 18 79 ± 15 79 ± 16 0.68
Body Mass Index (BMI) - kg/m² 21.0 ± 3.5 22.1 ± 3.6 23.3 ± 4.0 23.2 ± 3.2 <0.001
Hypertension - n, % 26 (19.5) 15 (24.2) 13 (17.6) 8 (14.3) 0.59
Diabetes Mellitus - n, % 23 (17.3) 2 (3.2) 4 (5.4) 2 (3.6) 0.002
Pulmonary Diagnosis - n, % <0.001
    COPD 4 (3.0) 10 (16.1) 25 (33.8) 39 (69.6)
    α1-antitrypsin-deficiency (AAT) 2 (1.5) 23 (37.1) 31 (41.9) 10 (17.9)
    Cystic Fibrosis (CF) 61 (45.5) 3 (4.8) 1 (1.4) 0 (0)
    Pulmonary Hypertension (PH) 20 (14.9) 9 (14.6) 4 (5.4) 3 (5.4)
    Pulmonary Fibrosis (PF) 28 (20.9) 12 (19.4) 10 (13.5) 4 (7.1)
    Other 19 (14.1) 5 (8.1) 3 (4.1) 0 (0)
Type of Transplantation - n, % <0.001
    Unilateral 21 (15.7) 14 (22.6) 15 (20.3) 19 (33.9)
    Bilateral 100 (74.6) 46 (74.2) 57 (77.0) 36 (64.3)
    Combined organ 13 (9.7) 2 (3.2) 2 (2.7) 1 (1.8)
Immunosuppressive Regimen - n, % 0.045
    CsA-based 57 (42.5) 35 (56.5) 39 (52.7) 16 (28.6)
    Tac-based 77 (57.5) 27 (43.5) 35 (47.3) 40 (71.4)
Transplant Series - n, % 0.043
    1990-1996 23 (17.2) 10 (16.1) 10 (13.5) 5 (8.9)
    1997-2000 34 (25.4) 24 (38.7) 24 (32.4) 11 (19.6)
    2001-2004 37 (27.6) 16 (25.8) 15 (20.3) 12 (21.4)
    2005-2008 40 (29.9) 12 (29.7) 22 (29.7) 28 (50)  
Recipient age at time of transplantation. **mL/min/1.73m2). sCr: serum creatinine, COPD: Chronic obstructive pulmonary disease, 
CsA: Cyclosporin, Tac: Tacrolimus. Differences between groups were tested by one-way ANOVA for linear effects.
Table 1| Baseline patient characteristics of never smokers and former smokers subdivided in categories 
according to number of pack years
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Results
Quantitative data on previous history of smoking were available in 326 (96%) patients: 134 
(41.1%) patients had never smoked and 192 (58.9%) patients had smoked a median [IQR] 
of 17.5 [10-30] pack years. Baseline characteristics of never smokers and former smokers 
stratified for number of pack years are shown in table 1. 
Overall, the former smokers were older, had higher BMI, more often had pulmonary 
diagnoses chronic obstructive pulmonary disease (COPD) or α1-antitrypsine-deficiency 
(as opposed to cystic fibrosis, pulmonary fibrosis or pulmonary hypertension in never 
smokers), more often underwent unilateral lung transplantation and had lower GFR 
before transplantation. Comparing subgroups of former smokers the patients with higher 
numbers of pack years were found to be older, were more often transplanted for COPD 
and more often received Tacrolimus-based maintenance immunosuppression. A relatively 
large proportion of heavy former smokers was transplanted in the most recent stratum. 
This reflects recent changes in acceptance policy for LTx enlistment. Other characteristics 
were similar for the smoking exposure groups. Cyclosporine and Tacrolimus trough levels 
were similar for never smokers and all groups of former smokers in all time-intervals 
during follow-up after transplantation (table 2). 
Mean baseline GFR was 102±22 ml/min/1.73m2. Baseline GFR was higher in never smokers 
than in former smokers, but this difference did not persist after adjustment of GFR for 
recipient age. Renal function declined considerably after LTx, on average -43±24% within 
2 years after LTx. The decline was particularly steep in the first 6 months after LTx, slowly 
leveling off beyond 12 months after LTx (figure 1). 
Cyclosporin (ng/mL) 0-1 month N 1-6 months N 6-24 months N >24 months N
Never smokers 0        Pack years 293 ± 53 56 195 ± 56 53 177 ± 41 45 182 ± 28 39
Former smokers 1-10   Pack years 299 ± 40 34 175 ± 25 32 166 ± 30 27 170 ± 28 25
11-25 Pack years 294 ± 43 37 180 ± 25 31 175 ± 34 28 165 ± 45 25
>25    Pack years 280 ± 35 16 180 ± 28 16 172 ± 22 15 172 ±17 10
Tacrolimus (ng/mL)
Never smokers 0        Pack years 14.9 ± 2.8 71 10.9 ± 2.3 55 10.2 ± 1.7 55 9.8 ± 1.3 40
Former smokers 1-10   Pack years 14.8 ± 2.0 26 10.8 ± 1.6 22 10.7 ± 2.0 21 10.1 ± 1.4 14
11-25 Pack years 15.2 ± 2.1 33 11.4 ± 1.9 32 10.7 ± 2.3 31 10.0 ± 1.8 18
 >25    Pack years 14.3 ± 1.9 35 10.7 ± 1.7 29 10.3 ± 1.5 28 9.8 ± 1.2 20
Table 2| Median Cyclosporin and Tacrolimus whole blood trough levels (ng/mL) per time interval after lung
transplantation according to groups based on number of pack years
P > 0.05 for Cyclosporin and Tacrolimus trough levels in never smokers and groups of former smokers at all time-intervals after lung transplan-
tation. Differences between groups were tested by one-way ANOVA for linear effects. 
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The slope of GFR decline in the first year after LTx was steeper in former smokers than 
in never smokers (-34±20 and -25±18% resp., P=0.005). Former smokers generally had a 
significantly lower mean GFR than never smokers from 6 months after LTx onwards. The 
former smokers with a history of >25 pack years of smoking had lowest mean GFR at all 
time points. 
The overall cumulative incidence of CKD-III at 5 years after LTx, taking competing risk of 
death into account, was 68.5%, with a cumulative incidence of 58.2% in never smokers vs. 
74.4% in former smokers (P<0.001). This cumulative incidence was 72.6%, 74.7% and 75.8% 
(P<0.001) in former smokers with a history of 1-10, 11-25 and >25 pack years of smoking, 
respectively. The overall cumulative incidence of CKD-IV at 5 years after LTx, taking 
competing risk of death into account, was 16.3% with a cumulative incidence of 10.7% in 
never smokers vs. 20.2% in former smokers (P=0.004). This cumulative incidence of CKD-
Figure 1| Glomerular filtration rate after lung transplantation according to number of pack years 
Means with standard error of GFR relative to body-surface-area per group according to groups based on number of pack 
years (0 Pack years, 1-10 Pack years, 11-25 Pack years, >25 Pack years). Differences between groups were tested by one-
way ANOVA for linear effects.  §P<0.05, NS after Bonferroni correction, *P<0.006, significant after Bonferroni correction # 
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increase in risk of CKD-III per group according to number of pack years, with HRs of 1.57 
[1.09-2.25], P=0.015; 1.65 [1.15-2.36], P=0.006 and 1.92 [1.32-2.79], P=0.001 for patients with 
a history of 1-10, 11-25 and >25 pack years of smoking respectively, compared to never 
smokers. The same was true for CKD-IV, with HRs of 1.30 [0.63-2.70], P=0.48; 1.96 [1.04-
3.71], P=0.04 and 2.78 [1.41-5.46], P=0.003 for the respective categories of former smokers 
compared to never smokers (Figure 2).
IV at 5 years after LTx was 15.0%, 20.4% and 26.9% (P=0.004) in former smokers with a 
history of 1-10, 11-25 and >25 pack years of smoking, respectively. 
Fifteen (5% of total) patients (mean age at LTx 38±13 years) progressed to ESRD at a mean 
follow-up of 7.2±4.1 years. Of those patients, 7 had COPD and 7 had cystic fibrosis. Current 
average follow-up of patients alive is 5.3±4.2 years; hence, the proportion of ESRD might 
increase with longer follow-up. We refrained from further (multivariable) analyses on 
determinants of ESRD, because of the small number of patients with ESRD.
In univariable Cox proportional Hazard analyses, former smokers had an increased risk of 
CKD-III (HR [95%Confidence Interval(CI)]=1.69 [1.27–2.24], P=0.001) and CKD-IV (HR=1.90 
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Figure 2| Cumulative incidences of CKD-III and CKD-IV according to number of pack years 
Cumulative incidences of CKD-III (left, (P<0.001)) and CKD-IV (right, (P<0.001)) according to groups based on number of pack 
years (0 Pack years, 1-10 Pack years, 11-25 Pack years, >25 Pack years). Differences between groups were tested with grays test 
for competing risks data. *Per 10 pack years. All analyses are multivariable cause-specific hazards regression analyses for pack 
years and CKD-III and CKD-IV.
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In analyses with pack years of smoking as a continuous variable, the HRs per 10 pack years 
of smoking for CKD-III and-IV were 1.19 [1.09–1.28], P<0.001 and 1.40 [1.20-1.62], P<0.001 
(table 3). In the multivariable analyses this dose-dependent relation remained significant 
for both CKD-III (HR 1.25 [1.10–1.42], P<0.001) and CKD-IV (HR 1.46 [1.17–1.83], P<0.001) 
(table 3). The corresponding adjusted population-attributable risks of former smoking (i.e. 
the CKD-rate reduction if all patients would have been never smokers) were 11.8% for CKD-
III and 18.6% for CKD-IV.
In secondary analyses, the dose-dependent increase in renal risk persisted after exclusion 
of the never smokers from the analysis (table 4). Results of the analyses stratification by 
age (<47 and >47 years, population median) and diagnosis (COPD vs. non-COPD) are also 
displayed in table 4. As can be seen, hazard ratios were relatively high in patients < 47 
years and in patients with diagnoses other than COPD. To investigate whether the risk was 
different between stratification groups, we tested for interaction between strata and pack 
years in the fully adjusted model. There was no significant interaction between age-strata 
and pack years for CKD stage III (P=0.92) and CKD stage IV (P=0.81). For diagnosis strata, 
there was a trend towards interaction for CKD stage III (P=0.18) and significant interaction 
for CKD stage IV (P=0.04). These data are consistent with pack years of smoking being a 
risk factor for CKD both in patients with COPD and in patients without COPD, but highest 
risk in patients without COPD as primary diagnosis. As a total, the results are consistent 
and point towards former smoking increasing the risk for CKD. 
We found that if analyses were repeated with CKD confirmed by a second value overall, 
cumulative incidences of CKD-III and CKD-IV after 5 years of follow-up were lower, with 
cumulative incidences of 57.8 and 10.4% for CKD-III and CKD IV respectively. The results of 
analyses of smoking as a risk factor for CKD remained essentially unchanged though, with 
CKD stage III CKD stage IV
 HR [95%CI] P-value HR [95%CI] P-value
Stratified by age
  < 47 years Pack years* 1.30 [0.88-1.93] 0.19 2.31 [1.01-5.32] 0.05
  > 47 years Pack years* 1.21 [1.05-1.40] 0.008 1.36 [1.07-1.72] 0.04
Statified by diagnosis
  COPD Pack years* 1.18 [1.02-1.38] 0.03 1.36 [1.07-1.72] 0.01
  other than COPD Pack years* 1.50 [1.11-2.01] 0.008 2.20 [1.17-3.97] 0.01
Former smokers only Pack years* 1.23 [1.06-1.42] 0.005 1.42 [1.11-1.81] 0.005
 
 
Table 4| Secondary analyses stratified by age and pulmonary diagnosis and in former smokers only
*Per 10 pack years. All analyses are multivariable cause-specific hazards regression analyses for pack years and CKD-
III and CKD-IV.
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Chapter 8Former Smoking and Chronic Kidney Disease after Lung Transplantation
HRs of 1.17 [1.03–1.33], P=0.02 and 1.63 [1.25-2.13], P<0.001 per 10 pack years of smoking for 
CKD-III and CKD-IV respectively in the fully adjusted model. Likewise, former smoking was 
dose-dependently associated with doubling of serum creatinine as renal endpoint, with 
a HR of 1.28 [1.10-1.49], P=0.002 per 10 pack years in the fully adjusted model. Lastly, we 
performed multivariable analyses with body surface area as a time-dependent variable, 
yielding HRs of 1.22 [1.08-1.39], P=0.002 for CKD-III and 1.48 [1.18-1.85], P=0.001 for CKD-IV. 
The overall cumulative incidence of all-cause mortality at 5 years after LTx was 34.6%, with 
a cumulative incidence of 32.9% never smokers vs. 37.2% in former smokers (P=0.4). In 
univariable Cox-regression analysis, former smokers’ risk of mortality was similar to that 
of never smokers (HR = 0.99 [0.71–1.38], P=0.9). We found that the main causes of death 
were graft failure (34.2%, after mean 3.8±3.4 years) and malignancy (17.1%, after a mean 
of 5.0±4.0 years). Only a small proportion of patients died of cardiovascular causes (6.2%, 
after a mean of 4.6±4.6 years). Former smokers more often died of malignancy than never 
smokers did (23% vs. 8.5% resp., P=0.03). There were no other significant differences in 
causes of death between former smokers and never smokers (Table 5).
Cause of death
Total Never smokers   Former smokers  
P-valueN (%) N (%)  N (%)
Peri-operative death 17 (11.8) 8 (13.6) 11 (12.6)
Multi-organ failure 12 (8.3) 8 (13.6) 4 (4.6)
Infection 19 (13.2) 7 (11.9) 12 (13.8)
Cardiovascular 9 (6.3) 2 (3.4) 7 (8.0)
Malignancy 25 (17.4) 5 (8.5) 20 (23) 0.03
Transplant failure 50 (34.7) 25 (42.4) 25 (28.7)
Other 12 (8.3) 4 (6.8) 8 (9.2)
  
Table 5| Causes of death after lung transplantation according to number of pack years
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Discussion 
This study shows for the first time that former smoking is associated with increased risk 
of CKD-III and CKD-IV after LTx. We found the increased risk of former smoking on CKD 
to be independent of potential confounders, including baseline GFR, recipient age and 
pulmonary diagnosis. The association between former smoking and CKD was further 
supported by evidence of dose-dependency. 
The difference in renal function between never and former smokers starts early after 
transplantation. Whereas both never smokers and former smokers had a steep initial 
decline in GFR, the initial decline in GFR was more pronounced in former smokers, and 
even more marked in former smokers with higher number of pack years. After the early 
rapid decrease in GFR, the rate of decline gradually leveled-off over time, but differences 
between groups clearly persisted.  
Our results suggest that former smoking primes the kidneys for accelerated decline in GFR 
after LTx. The renal susceptibility to accelerated decline in GFR was not accounted for by 
adjustment for pre-transplant GFR. Nevertheless, it remains possible that former smokers 
have pre-existent renal damage. This is not necessarily captured by GFR as kidneys are 
known to have a certain amount of reserve capacity. This allows kidneys to maintain 
GFR at a certain level by compensating for damage and/or nephron loss. Consequently, 
substantial renal damage can be present without any measurable effect on GFR. In 
addition, it has been demonstrated that intra-renal vascular pathology (myointimal 
hyperplasia, arteriolar hyalinosis, glomerular sclerosis) in renal biopsies of former smokers 
is more prominent than in never smokers without an apparent difference in renal 
function.31 Thus, renal damage related to prior smoking can be present in the kidney after 
smoking cessation without being reflected in GFR. Interestingly, it has been observed that 
renal histological lesions (including myointimal hyperplasia and arteriolar hyalinosis) 
amplify the nephrotoxic effects of CNIs in renal transplant recipients.32 Accordingly, renal 
vascular lesions induced by prior smoking might well be involved in our observations that 
former smokers are more susceptible to post-transplantation CKD, despite that they no 
longer smoke. Further research will need to clarify whether these suggested mechanisms 
indeed play a role in the accelerated decline of GFR in former smokers. 
Various mechanisms could underlie the persistence of smoking-associated damage after 
smoking cessation. Recently it was found that smoking-induced changes in epigenetics of 
blood platelets can persist for more than 10 years after smoking cessation, showing that 
distant effects of smoking can last for many years.33,34 These findings are corroborated by 
data of persisting increases in risk of smoking-associated conditions long after cessation 
of smoking, e.g. the risk of lung cancer remains increased 15-fold in men and 9-fold in 
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women for at least ten years after smoking cessation.35 Our study is the first to identify 
former smoking as a risk factor for CKD in lung transplant recipients. The risk was not 
explained by clinical renal parameters, notwithstanding gold standard renal function 
measurements. This is of substantial clinical significance, as it means that reliable smoking 
history could aid in risk-assessment. In a general sense, the association between former 
smoking and the risk for CKD is very sparsely documented, and so far, data in populations 
with a high renal risk are lacking altogether. 
We did not observe any relationship between former smoking and mortality after LTx, 
although former smokers more frequently died of malignancy. This would be consistent 
with the increased risk of malignancy in smokers in the general population. In the general 
population, smoking is furthermore associated with cardiovascular disease. However, 
no association between former smoking and cardiovascular death was observed in this 
study. Importantly, the chances of finding an association between former smoking and 
cardiovascular disease were small because LTx recipients generally are relatively young 
and thoroughly screened on cardiovascular status prior to transplantation. They are 
therefore unlikely to develop cardiovascular disease within several years. Moreover, despite 
the development of cardiovascular risk factors due to the use of immunosuppressants 
(hypertension, hyperlipidemia, hyperglycemia etc.), LTx recipients are more likely to 
die of other transplantation-related causes (such as transplant failure or infection). 
This is supported by the high mortality due to transplant failure and low numbers of 
cardiovascular death in our population. 
Our study has several limitations. First, several differences in baseline characteristics 
existed between the never smokers and former smokers. The former smokers more often 
had pulmonary emphysema and were relatively old, whereas the never smokers often had 
cystic fibrosis, pulmonary fibrosis or pulmonary hypertension and were relatively young. 
To ensure that the results of our analyses were less likely to be confounded by these 
differences, we adjusted for recipient age, gender, baseline GFR, BMI, pulmonary diagnosis, 
type of transplantation, medication-regimen, hypertension, diabetes and transplantation 
year. We also performed several sensitivity analyses to check the consistency. Even so, the 
associations persisted. 
In secondary analyses we found that in patients with diagnoses other than COPD, pack 
years of former smoking was associated with highest risk for CKD. It should be noted that 
this group contains relatively many younger patients and patients with cystic fibrosis, 
whom differ in many aspects from patients with COPD (e.g. glomerular hyper filtration 
making kidneys more susceptible to CNI-toxicity, higher prevalence of diabetes after LTx, 
higher prevalence of chronic rejection, higher doses of immunosuppression after LTx, all 
risk factors for CKD). It is possible that the difference between diagnosis strata is due 
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to residual confounding, however, it is also possible that this reflects a difference in 
susceptibility of kidneys to the noxious effects of former smoking between the diagnosis 
groups. 
In addition, it is hard to exclude that some patients have resumed smoking after LTx, 
despite very strong discouragement. Sobering data on smoking resumption after LTx 
have recently been published, showing that some 11% of patients had resumed smoking 
– without informing their doctors.15 Nevertheless, we believe it is unlikely that our 
conclusions are affected by an undetected sub-cohort that resumed smoking. First of all, 
others have reported much lower numbers of patients resuming smoking after LTx.16,36 
Also, smoking resumption is more likely after an abstinence period of <6 months. Our 
center requires an abstinence period of at least 6 months before enlistment. Moreover, a 
random sample of patients from our population was recently tested for exhaled carbon 
monoxide levels and we found no evidence for smoking resumption. Last, whereas we 
cannot fully exclude smoking resumption in a minority of patients, it is unlikely that the 
presence of a small sub-cohort could lead to the clear dose-dependent effect of former 
smoking on CKD observed here in the whole cohort. Another limitation of the study is the 
lack of data on behavior, socio-economic status, presence of other co-morbid conditions 
and environmental factors. These parameters could be confounding the association 
between former smoking and CKD. While it would have been appropriate to adjust for 
these factors, such factors were not documented in the current study and could not be 
taken into account, resulting in potential unmeasured confounding. 
A major strength of our analysis is the use of 125I-Iothalamate GFR measurements for 
baseline and follow-up. This method is considered a gold standard method for GFR 
measurement and provides a very reliable measurement.18 This measurement is superior 
especially in populations such as LTx, where long-term changes in muscle-mass confound 
creatinine-based renal function estimates.23 A comparison of this method with the more 
widely available eGFR calculations was published in an early subgroup (N=40) from this 
cohort in 2000,23 showing that renal function loss is underestimated by creatinine-derived 
renal function estimates in LTx recipients. Another strength of this study is the availability 
of serial CNI trough levels in never smokers and groups of former smokers. These levels 
were similar for never smokers and former smokers, indicating similar CNI exposure and 
making confounding by CNI toxicity unlikely. Furthermore, this study shows data on a 
large cohort of LTx recipients with a good representation of all kinds of LTx recipients with 
long follow-up, without loss to follow-up. 
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Conclusions
The number of pack years of prior cigarette smoking was dose-dependently associated 
with an increased risk of both stage-III and stage-IV CKD, but not all cause mortality in a 
large cohort of LTx patients, independent of potential confounders. 
These findings are reason for concern. Waiting times for LTx have continued to increase due 
to expanding recipient criteria. Likewise, donation criteria have also expanded. Patients 
as well as organs transplanted are generally in worse condition now than several years 
ago and LTx recipients are therefore at increased risk of complications after LTx, amongst 
which CKD.37 If the association of former smoking and CKD after LTx were confirmed in 
other studies, it would be relevant to gain further insight in the biology of this association. 
For the moment, it would seem prudent to consider former smokers at increased renal risk 
and avoid additional renal risks as much as possible. 
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Abstract 
Background: Various creatinine-based equations are available to estimate GFR. Lung 
transplant recipients (LTR) frequently have abnormal body composition that may affect 
performance of the equations. Therefore, specific validation of the creatinine-based 
equations in LTR is needed. 
Methods: CG, MDRD and CKD-EPI equations for estimated GFR (eGFR) were compared with 
2092 assessments of 125Iothalamate-measured GFR (mGFR) in 301 LTR, up to 16 years after 
transplantation. We assessed performance precision, bias and accuracy), determinants of 
bias, stability of bias over time and accuracy in monitoring renal function deterioration 
over time.
Results: CG, MDRD and CKD-EPI underestimated mGFR, with 13.8, 28.8 and 22.7%, 
respectively. Precision and accuracy were modest. In all equations, bias was larger (i.e. 
more underestimation) for higher values of mGFR, in female patients and in recipients 
with cystic fibrosis or emphysema. BMI determined bias of CG and age bias of MDRD. Bias 
was stable over time. All equations underestimated long-term slope of GFR-decline with 
±35% and sensitivity/specificity in detecting fastest progressors was 88-90/68-70%. 
Conclusions: The performance of creatinine-based renal function equations is modest in 
LTR, with average underestimation of GFR, limited precision/accuracy and underestimation 
of long-term course of GFR. Creatinine-based equations thus have important shortcomings 
in accurate determination and long-term monitoring of renal function in individual LTR. 
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Introduction
Progressive renal function deterioration is common after lung transplantation (LTx),1-3 and 
requires close monitoring. Glomerular Filtration Rate (GFR) is accepted as the best overall 
measure of renal function and represents the overall filtering capacity of the kidneys.4 
GFR can be measured as the urinary and plasma clearance of ideal filtration markers, such 
as radiolabelled 125I-Iothalamate, to give a reliable reflection of renal function.5 
However, because the GFR measurements with ideal filtration markers are complex, 
demanding and costly, the use of these methods to monitor renal function in lung 
transplant recipients (LTR) is often not feasible in clinical practice. Therefore, renal function 
is generally monitored by serial estimates of GFR using creatinine-based renal function 
equations. Serum creatinine-based GFR equations are superior to using serum creatinine 
alone as an index for renal function because these equations take into account certain 
patient-specific biometrical indices that affect creatinine generation and excretion (age, 
gender, race, weight). However, the equations have important shortcomings as they 
frequently underestimate gold standard measured GFR (mGFR), especially in the high- 
and high-normal range, and lack sensitivity in detecting progressive renal function loss.6-8
In patients with abnormalities in body composition the estimate is affected even more 
substantially.9,10 Of note, renal function equations have been validated almost exclusively 
for their cross-sectional performance. The sparse data on their longitudinal performance 
show that renal function loss over time can be underestimated, in some patients 
substantially.6,9,11 
LTR frequently have abnormal body composition prior to transplantation and 
substantial changes in body composition frequently occur after transplantation (e.g. 
due to improvement of pulmonary status and prolonged steroid use).12 In addition, renal 
hemodynamics may be altered due to the pulmonary disease and calcineurin inhibitor 
use.13 14 Performance of creatinine-based renal function equations may be hampered by 
all of these factors. However, little data on performance of the creatinine-based renal 
function equations are available in this specific group of patients.13, 15 An early study from 
our group, demonstrated a change in bias during follow up after LTx, hampering the use of 
estimated GFR for monitoring renal function over time with underestimation of the rate of 
renal function loss.13 However, only a small number of patients was analyzed in this study 
and the duration of follow-up was limited to the first two years after transplantation. 
Moreover, at the time this study was performed the nowadays most frequently used eGFR 
equations (abbreviated MDRD and CKD-epi) were not yet available. Therefore, validation 
of the renal function equations for determination and long term longitudinal monitoring 
of renal function after LTx is needed. 
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In the current study, we analyzed how various frequently used creatinine-based renal 
function equations perform compared to 125I-Iothalamate GFR in a large cohort of LTR, and 
assessed the determinants of the systematic error. In addition, we assessed longitudinal 
change of the systematic error and the accuracy in monitoring renal function deterioration 
over time. 
Materials and methods
Between 1990 and 2008 in total 370 lung transplantations and heart-lung transplantations 
were performed at the University Medical Center of Groningen (UMCG), the Netherlands. 
We included all adult lung transplant recipients whom had at least 1 measurement of GFR 
and serum creatinine measurement at the same day for the analysis of performance of 
the creatinine-based GFR estimations in lung transplantation recipients. Consent for the 
use of patient data was obtained from all patients prior to transplantation.
GFR measurements
Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured 
simultaneously by constant infusion of radiolabelled tracers 125I-Iothalamate and 
131I-Hippuran as described before.16-18 In short, the method was as follows: after drawing 
a blank blood sample, the priming solution containing 0.04 mL/kg body weight of the 
infusion solution (0.04 MBq of 125I-iothalamate and 0.03 MBq of 131I-hippurate per mL saline) 
plus an extra of 0.6 MBq of 125I-iothalamate was given, followed by constant infusion at 12 
mL/h. To attain stable plasma concentrations of both tracers, a 2 hour stabilization period 
followed, after which the clearance period started.
Clearances of 125I-Iothalamate and 131I-Hippuran are measured over the next 2 hours and 
calculated as (U*V)/P and (I*V)/P, respectively. U*V represents the urinary excretion of the 
tracer, I*V represents the infusion rate of the tracer and P represents the tracer value in 
plasma at the end of each clearance period. GFR is calculated from U*V/P of 125I-iothalamate 
and corrected for voiding errors by multiplying the urinary clearance of 125I-iothalamate 
with the ratio of the plasma and urinary clearance of 131I-Hippuran. This correction method 
is based on the fact that, during steady state, the plasma clearance of 131I-Hippuran equals 
it urinary clearance when urine collection is perfect. This GFR measurement has a day-
to-day coefficient of variation of <2.5%18 and is considered a gold standard method for 
GFR measurement and used for the development and validation of novel renal function 
equations.19 
Serum creatinine was determined in blood samples drawn at the start of the GFR 
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measurement. Height and weight were measured in every patient before investigation. 
The GFR measurement procedure was unaltered over the duration of the observation 
period. Renal function was measured routinely at out-patient basis before transplantation, 
1, 6, 12, 18, 24 months after transplantation and every 6-24 months thereafter. For patients 
screened at another center or patients transplanted with high urgency no pre-LTx 
measurement was available. 
Renal function equations
GFR was estimated using the 3 most frequently used renal function equations. The first 
creatinine-based renal function equation we used was the Cockcroft-Gault (CG)-formula.20 
The CG-formula was calculated as follows (in ml/min):
 
CG = (140-age) * weight/(72 x serum creatinine in mg/dl) * (0.85 if female)
Secondly, we used the abbreviated, re-expressed, four variable Modification of Diet in 
Renal Disease-study (MDRD) equation for standardized serum creatinine samples.21 
Because none of the patients were blacks; no correction for ethnicity was applied. MDRD 
equation was therefore calculated as follows (in ml/min/1.73m2):
MDRD = 175 * (serum creatinine in mg/dl)-1.154 * (age)-0.203 * (0.742 if female)
The third equation we used was the more recently developed CKD-EPI equation.19 This 
equation is calculated gender-specific and stratified by creatinine levels. It was developed 
especially to provide a better performance in the mildly impaired, normal and higher 
range.22 The following calculations were used (in ml/min/1.73m2):
Female with serum creatinine ≤ 0.7 mg/dL: GFR = 144 * (0.993)age * (serum creatinine / 0.7)-0.329
Female with serum creatinine > 0.7 mg/dL: GFR = 144 * (0.993)age * (serum creatinine / 0.7) -1.209
Male with serum creatinine ≤ 0.9 mg/dL: GFR = 141 * (0.993)age * (serum creatinine / 0.9) -0.4111
Male with serum creatinine > 0.9 mg/dL: GFR = 141 * (0.993)age * (serum creatinine / 0.9) -1.209
From here, GFR estimates by these above mentioned equations are referred to as estimated 
GFR (eGFR). GFR measured by the 125I-Iothalamate method are referred to as measured GFR 
(mGFR). mGFR and eGFR estimated by the Cockcroft Gault formula were normalized to 
body surface area (BSA) by dividing the values by 1.73/BSA. BSA was calculated according 
to the formula of DuBois and DuBois 23 as follows: 
BSA = 0.007184 * weight in kg0.425 * · height in cm0.725
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Calibration of serum creatinine 
Serum creatinine was measured by Jaffé alkaline picrate assay, on the MEGA (Merck KGaA, 
Darmstadt, Germany) until the 1st March 2006. After this date, serum creatinine was 
measured by enzymatic assay on the Roche Modular (Roche, Basel, Switzerland). Large 
differences exist in calibration of the serum creatinine assays across center and within 
centers over time. Therefore, both methods used in this center were calibrated to the 
reference standard, i.e. Cleveland Clinic Laboratory measurements, as proposed by Coresh 
et al.24
The calibration procedure was described in more detail elsewhere.6 In short, 177 samples 
drawn before 1st March 2006 and 339 samples drawn after 1st March 2006 with a broad 
range of creatinine values were sent to the Cleveland Laboratory and led to the following 
calibration equations: Calibrated serum creatinine = [-0.300 + 1.217 * (UMCG Jaffé 
creatinine values in mg/dL)] for measurements before 1st March 2006 and [0.011 + 1.087 
* (UMCG Roche creatinine values in mg/dL)] for measurements after 1st March 2006. CG, 
MDRD, and CKD-EPI equations were all three calculated with calibrated creatinine values.
Medication 
Immunosuppressive protocols used over time are described in more detail elsewhere.25 In 
short, induction consisted of rATG (Thymoglobulin; Sanofi Pasteur, Lyon, France) until 2001 
and Basiliximab (Simulect, Novartis Pharma, Basel, Switzerland) induction thereafter. 
Maintenance immunosuppression consisted of a calcineurin inhibitor (CNI) based 
immunosuppressive regimen combined with Prednisolone and Azathioprine (Immuran; 
GlaxoSmithKline, Brentford, United Kingdom) or Mycophenolate Mofetil (Cellcept; Roche, 
Basel, Switzerland). 
Cyclosporine (Neoral; Novartis Pharma, Basel, Switzerland) was the CNI used until 2001 
(target levels: whole blood trough levels 400ng/mL initially, tapered to 150 ng/mL within 
the first three weeks), tacrolimus (Tacrolimus, Prograft; Astellas Pharma, Staines, United 
Kingdom) was the CNI used from 2001 onwards (target levels: 20ng/mL during the first 
three weeks, 15ng/mL until the third month and 10-12ng/mL thereafter and from 2004 
until present target levels 15-18ng/mL during the first three weeks, 12-15ng/mL until the 
third month, and 10-12ng/mL thereafter).
All patients furthermore received P. Jerovici prophylaxis (co-trimoxazole, 960mg on 
alternate days) and Herpes prophylaxis (acyclovir) and from 2001 all patients at risk 
received standard CMV–prophylaxis.
Analysis of performance 
Performance of renal function equations compared to mGFR with respect to systematic 
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and non-systematic error was assessed as proposed by Bostom26 and Stevens27 using 
bias, precision, and accuracy. Bias represents the systematic error and is expressed as 
the median absolute difference (mGFR – eGFR) and the median percentage (relative) 
difference ((mGFR – eGFR)/ mGFR * 100). 
Precision is a measure of non-systematic error and is expressed by the interquartile range 
(IQR) and 95% confidence interval (95%CI) of the absolute and relative difference between 
mGFR and eGFR. Precision is also represented by the overall ‘fit’ of the equations against 
the gold standard expressed by the R2 (the squared correlation coefficient). 
Accuracy incorporates both bias and precision. This is reflected by the proportion of 
subjects with eGFR values within 30% of mGFR (P30), and the root mean squared error 
(RMSE). The mean squared error (MSE) equals the variance of the errors plus the square 
mean of the errors and thus incorporates both bias and precision. The RMSE is measured 
in the same units as the original data and is representative of the size of a typical error. 
Statistical analysis
Data were analyzed with STATA version 11.2 (STATACorp, LP, College Station, Texas, USA). 
Paired sample t-tests were used to analyze differences between mGFR and CG, MDRD, 
CKD-EPI equations and 24-hour creatinine clearance. To assess systematic error we 
performed Bland-Altman analyses. Differences in bias between subgroups of potential 
determinants were tested with analysis of variance (ANOVA). Changes of bias over time 
as well as multivariable analysis of determinants of bias were tested using multivariable 
multilevel analyses allowing for random intercept as well as random slope, with bias as 
dependent variable and potential determinants as independent variables within levels 
of individual patients. Necessity of a random intercept or random slope was tested with 
the likelihood ratio test. Individual slopes of GFR were calculated with individual linear 
regression analysis on the basis of at least 3 measurements >6 months after LTx. Two-
sided P-values less than 0.05 indicated statistical significance. 
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Results
Baseline characteristics
We included 301 adult lung transplantation recipients (LTR) with at least one simultaneous 
assessment of mGFR and serum creatinine. Patient characteristics are presented in table 1. 
Of all LTR, 145 (48.2) were male, mean age was 45.1 ± 12.0 years and the major pulmonary 
diagnosis for lung transplantation (LTx) was emphysema (44.9%). Most patients underwent 
bilateral lung transplantation (74.1) and 49.2% of the patients received cyclosporine-based 
immunosuppression. 
Patient Characteristics
Number of patients 301
Male gender - n (%) 145 (48.2)
Age at time of transplantation - years 45.1 ± 12.0 [18.0-66.7]
Pulmonary diagnosis - n (%)
    Pulmonary Emphysema 135 (44.9)
    Pulmonary Hypertension (PH) 30 (10.0)
    Cystic Fibrosis (CF) 59 (19.6)
    Other 77 (25.6)
Type of transplantation - n (%)
    Unilateral 66 (21.9)
    Bilateral 223 (74.1)
    Combined organ 12 (4.0)
Immunosuppressive regimen
    Cyclosporin-based 148 (49.2)
    Tacrolimus-based 153 (50.8)
Measurement Characteristics
Total number of GFR measurements 2092
   Pre-transplantation 290
   Post-transplantation 1802
Average number of GFR Measurements per patient 6.0 ± 4.5 [1-21]
Age at time of measurement -  years 47.2 ± 11.5 [18.5-72.4]
Follow-up at time of measurement -  years 2.5 ± 3.0 [0-16.0]
Body Mass Index at time of measurement -  kg/m2 23.9 ± 4.5 [13.4-45.5]
Renal function Indices
   Glomerular Filtration Rate -  ml/min 65 ± 28 [6-199]
   Effective Renal Plasma Flow -  ml/min 267 ± 97 [27-695]
   Filtration Fraction - % 0.24 ± 0.05 [0.10-0.50]
Table 1| Patient and measurement characteristics
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Performance
In total,  there were 2092 mGFR measurements with on average 6 (range 1-21) measurements 
per LTR. Measurements were performed prior to transplantation (screening, n=290) or up 
to 16 years after LTx (during follow-up, n=1802). Table 2 presents the performance (bias, 
precision and accuracy) of the 3 creatinine based GFR equations. The median bias, reflecting 
systematic error, was relatively large for all three equations and indicated substantial 
underestimation of mGFR by all three equations. Whereas the absolute bias was larger 
before transplantation than after transplantation, the bias expressed as a percentage of 
mGFR was similar before and after LTx. The bias was least pronounced for the CG (-13.8%) 
equation, most pronounced for the MDRD equation (-28.8 %) and intermediate for the 
CKD-EPI equation (-22.7%, all three comparisons P-value <0.001). In figure 1, Bland-Altman 
analyses are shown to better observe the bias over the whole range of GFR. It can clearly 
be appreciated that systematic error increases (i.e. on average more underestimation of 
mGFR) in the higher range of GFR and that the average systematic error is smaller with 
the CG equation than with the MDRD and CKD-EPI equations. 
The precision, inversely reflecting non-systematic error, is captured by the interquartile 
ranges and 95% confidence intervals of the absolute and relative bias and by R-square 
of the relation between mGFR and the individual equations. The CG, MDRD and CKD-EPI 
equations all had similar association with mGFR (R-squared 0.639, 0.660 and 0.664, resp.). 
As can be observed in figure 2 the precision was best in the lower ranges of mGFR and 
gradually decreased in the higher ranges of mGFR for all three equations (larger deviation 
from the line of identity, dotted line). The curved fitted line in the graphs represents the 
accuracy of the equation, a measure incorporating both systematic and unsystematic 
error (i.e. bias and precision). The curved lines show a similar pattern in all three equations 
with increasing bias and decreasing precision towards the higher ranges of mGFR and 
very large imprecision in the highest range of mGFR. The imprecision in the highest 
ranges of mGFR was less for the CKD-EPI equation. 
The accuracy is also expressed by the P30 (the percentage of estimations within 30% 
of mGFR) and the root mean squared error (RMSE). The P30 was highest for CG (73.1%), 
lowest for MDRD (49.8%) and intermediate for CKD-EPI (61.5%), whereas the RMSE was 
comparable for CG, MDRD and CKD-EPI (according to the RSME eGFR was on average 
within 15.8 to 16.3 ml/min/1.73m2 of mGFR). The different results with these two measures 
of accuracy is due to the fact that occasional large errors (outliers) weigh heavily in the 
RMSE but not in de P30. 
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knots 5; R-sq. 0.1089; RMSE  15.91
CG
Figure 1| Bland-Altman plots of the creatinine-based GFR equations 
The differences between measured GFR and estimated GFR  plotted against the averages of the two. 
The dotted lines indicate the mean difference, and the limits of agreement 
(the mean difference +1.96SD of the difference).
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Figure 2| Scatter plots and lowess function with 95% confidence interval fitting the 
data of the creatinine-based GFR equations 
Measured GF  plotted against estimated GFR. Dotted line is the line of identity. Grey curved area is 
the Lowess function with 95% confidence interval through all data points.
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Determinants of bias
We assessed differences in bias across several of the patient characteristics: tertiles of 
mGFR, tertiles of age, tertiles of BMI, gender and pulmonary diagnosis (figure 3). Mean 
mGFR for the 3 tertiles was 34.6 (range: 5.9-47.4), 58.4 (range: 47.4-70.4) and 93.2 (range: 
70.4-194.8) ml/min/1.73m2 respectively. For all three equations bias increased significantly 
per tertile of higher mGFR. Mean age for the 3 tertiles was 41.8 (range: 18.5-44.2), 49.3 
(range: 44.3-53.7) and 58.9 (range: 53.7-72.4) years respectively. Only MDRD was slightly 
affected by age, with least underestimation of mGFR in the oldest patients. Mean BMI for 
the 3 tertiles was 19.4 (range: 13.4-21.6), 23.3 (range: 21.6-25.1) and 28.9 (range: 28.1-45.5) 
kg/m2 respectively. BMI only affected bias of CG with larger underestimation of mGFR in 
patients with low BMI. Bias of MDRD and CKD-EPI was significantly larger in women and 
bias of CG and MDRD was larger in patients with cystic fibrosis. Pre-transplantation bias 
was much larger than post-transplantation; however, this is likely due to difference in 
mGFR and BMI before and after transplantation. 
Longitudinal course of GFR and bias
In figure 4, the longitudinal changes in mGFR, eGFR and relative bias can be appreciated. 
mGFR initially decreases rapidly after LTx and gradually stabilizes thereafter. At all time 
points the mGFR was underestimated by all three equations. Relative bias of MDRD and 
CKD-EPI remained stable throughout the entire follow-up, whereas the relative bias of CG 
slightly decreased during the first year after LTx and stabilized thereafter. 
We performed multivariable mixed effects analyses to, firstly, assess stability of bias 
over time, taking changes in determinants of bias over time into account and, secondly, 
test whether mGFR age, BMI, gender, and pulmonary diagnosis were independent 
determinants of bias (table 3). In these multivariable analyses bias was stable over time 
for all three equations. In all three equations, underestimation of mGFR increased with 
higher values of mGFR and was larger in female patients. Higher BMI increased bias 
of the MDRD and CKD-EPI equations, but decreased bias of CG. Higher age increased 
underestimation of CG, but not MDRD and CKD-EPI equations. Last, pulmonary diagnoses 
cystic fibrosis and emphysema were associated with significantly larger underestimation 
of CG, MDRD and CKD-EPI equations (latter borderline significant). 
Predictive performance for longitudinal monitoring of renal function
From 6 months after LTx onwards, 220 patients had at least 3 measurements of GFR for 
the calculation of individual GFR slopes. The median annual mGFR decline was -3.04 
[IQR: -4.53, 0.06] (table 4). All creatinine based equations underestimated the annual GFR 
decline with approximately 35-37% (R2 of correlation slopes mGFR with slopes eGFR ranged 
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from 0.63 to 0.65). The 25% patients with fastest mGFR decline had a median annual 
mGFR decline of -8.61 [-11.37, 6.27]. Also the GFR decline in these patients was substantially 
underestimated by all three creatinine-based GFR equations; with median eGFR decline 
of -5.63, -4.74 and -5.43 for the CG, MDRD and CKD-EPI equations respectively (P<0.001 
for all three equations compared to mGFR). Sensitivity of the renal function equations in 
detecting the 25% fastest progressors was comparable, with 65.5, 70.9 and 69.1 % for the 




































































Figure 3| Determinants of bias for the creatinine-based GFR equations
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Discussion
This study evaluated the performance of the CG, MDRD and CKD-EPI equations for accurate 
determination of renal function as well as long term monitoring of renal function in LTR. 
Overall, the cross-sectional performance of creatinine-based renal function equations 
in LTR was modest. All three creatinine-based renal function equations on population 
level substantially underestimated mGFR both before and after LTx, and precision and 
accuracy were limited, especially in the high-normal range of GFR. Longitudinally, the 
long-term course of GFR was substantially underestimated by the creatinine-based renal 
function equations and the equations lacked sensitivity in detecting the recipients with 
fast declining renal function. In conclusion, the renal function equations have important 
shortcomings in accurate determination of renal function and monitoring the course of 
renal function in LTR. 
Cross-sectional Performance
Our study provides the largest analysis on performance of renal function equations in LTR 
so far. Very limited data on this specific population are available. One study assessed the 
correlation of the 6-variable MDRD equation with 24-hour creatinine clearance in nearly 
600 patients screened before LTx.28 They found no systematic bias but did find limited 
precision and accuracy, in particular in the higher range of GFR. It is hard to compare their 
results to our results because their data were based on 24-hour creatinine clearance, 
whereas we used gold-standard renal function measurements as reference. 
Studies in other transplant populations such as kidney and liver transplant recipients 
found that renal function equations had a reasonable performance on group level. In 
renal transplant recipients with average GFR of 55 ml/min, MDRD underestimated GFR 
slightly with ~5%, and CG overestimated GFR with ~10%.9 In liver transplant recipients 
with average GFR of 91 ml/min, both MDRD and CG underestimated GFR with ~10%.29 
No data on CKD-EPI were available. Cautious comparison thus indicates that the bias 
between the GFR equations and mGFR in LTR is larger than in other transplantation 
populations. A possible explanation for this difference may be the relative high frequency 
of abnormal body composition. Other factors that may play a role are the suppression of 
tubular creatinine secretion due to the general use of trimethoprim,30-32 which all LTR use in 
combination with sulfomethoxazol for prevention of P. Jerovici pneumonia, abnormalities 
in creatinine secretion associated with the DF508 mutation underlying cystic fibrosis,33 or 
the use of standardized serum creatinine values in this study. 
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Longitudinal Performance
Besides the modest cross-sectional performance of the renal function equation in LTR, we 
found that the longitudinal performance was hampered by substantial underestimation 
of long-term course of GFR and limited sensitivity/specificity in detecting fast declining 
renal function. The only study that previously looked at longitudinal performance of renal 
function equations in LTR is an early study on a subgroup (N=40) of this cohort addressing 
the first two years after LTx.13 Similar to the current study it was found that creatinine-
based renal function equations underestimate the rate of renal function loss by ~35%. 
Underestimation of the rate of renal function loss by renal function equations is not 
limited to LTR, but has been demonstrated previously in other transplant populations, 
patients with type II diabetes and non-diabetic patients with chronic kidney disease,6,8,a9,29 
and may be explained by the fact that renal function equations have been validated 
almost exclusively for their cross-sectional performance. Due to the underestimation of 
renal function loss, individual patients with fast progressive renal function decline may 
be missed, despite multiple measurements, long-term follow-up and relative rapidly 
declining renal function. This warrants caution in the application of the equations to 
monitor renal function in LTR in clinical practice.
Sources of bias
We found the several important determinants of systematic error. It is well established 
that there is a larger systematic error in the higher range of GFR. Indeed, the bias was much 
larger in the high range of GFR, but it was proportionally similar over the whole range. 
Precision and accuracy, the other two measures of performance, also decreased in the 
high range. The CKD-EPI equation was specifically developed to have better performance 
in this range. Our data indicate that the CKD-EPI indeed performs slightly better than the 
MDRD and CG in the high range.
BMI was a significant determinant of bias of the CG equation, with larger underestimation 
in patients with low BMI. Several studies in renal transplant recipients and renal patients 
found that the MDRD and CG equations had opposite effects on the BMI-related error 
in renal function estimate, with progressive underestimation of renal function at higher 
BMI by the MDRD and progressive overestimation at higher BMI with CG.9,34 Our results 
on multivariate analyses are consistent with these previous findings showing more 
underestimation at higher BMI by MDRD, less underestimation at higher BMI with CG. 
Because bias with CG decreased with increasing BMI, bias in LTR decreased in the year 
after transplantation in LTR that gained weight. 
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Limitations and strengths
Our study has several limitations. First of all, our data are derived from a single center. 
Comparability to other center is nevertheless feasible because of the use of calibrated 
creatinine values to calculate eGFR and the comparison to a robust gold standard 
measurement that is also used for the development of novel renal function equations 
and has a low variability (day-to-day coefficient of variation <2.5%). All patients in this 
study were whites, thus conclusions do not apply to black patients.
The major strengths of this study are the large number (>2000) of measurements by a 
single standardized method in a population LTR with a large range of GFR, age, BMI and 
various diagnoses. In addition, there was long-term follow-up after LTx available with 
multiple measurements per patient, allowing for accurate determination of long-term 
GFR slopes and long-term performance of the equations.
Conclusions 
We found that the performance of creatinine-based renal function equations is modest 
in LTR, with average underestimation of GFR and limited precision/accuracy. Monitoring 
renal function over time with the renal function equations is furthermore hampered by 
the underestimation of long-term course of GFR and limited sensitivity in detecting fast 
decline of renal function. Creatinine-based renal function equations thus have important 
shortcomings in accurate determination and long-term monitoring of renal function in 
individual LTR. Caution is warranted in the application of the equations to monitor renal 
function in clinical practice.
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Summary and discussion
Part I: Type 2 Diabetes and Hypertension
Chronic renal impairment poses a severe burden on the individual patient as well as on 
national healthcare systems. In order to institute adequate preventive measures, early 
identification of patients with fast-progressive renal impairment is of utmost importance. 
This thesis focused on prediction and prevention of renal impairment in high-risk 
populations.
In the first part of this thesis we focused on prediction and prevention of renal impairment 
in type 2 diabetes and hypertension. The first chapters of this part consist of research 
performed within the sysKID consortium, a European collaboration aiming to identify 
persons at risk of developing chronic renal impairment. Earlier detection of patients 
within high-risk groups with an increased risk of renal impairment or fast-progressive 
course of renal function decline could help reduce the number of patients at renal risk 
by implementing early preventive efforts, while alleviating the burden of treatment for 
those with a low risk.1, 2 
Despite the identification of many important risk factors for progression of chronic renal 
impairment such as hypertension, hyperglycaemia, dyslipidemia, smoking and obesity,3-7 
risk stratification of individual patients remains a huge challenge. Once renal disease is 
established, regression of disease is very difficult to achieve. It is therefore imperative to 
find markers that predict, in early stage of disease, which patients are at risk for chronic 
renal impairment, in order to timely institute preventive measures. In recent years multiple 
urinary and serum/plasma biomarkers for the prediction of chronic renal impairment 
have been proposed, and new biomarkers are continuously being put forward. 
In chapter 2, we systematically reviewed the validity of biomarkers for renal impairment in 
type 2 diabetes. We performed a systematic literature search and identified 15 publications 
on longitudinal studies reporting on 27 candidate biomarkers for the prediction of renal 
impairment in type 2 diabetes. Based on the methodological quality of the studies, we 
concluded that the overall study quality of these studies in general is modest. This not 
only limits proper assessment of the potential clinical value of the identified biomarkers, 
but it also limits the generalizability and comparability of the results. 
We addressed several important methodological issues that were relevant for the quality 
of the biomarker research. First, we found that studies of predictive markers frequently 
calculated odds ratios or relative risks to demonstrate the strength of association between 
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the biomarker and the outcome. Odds ratio’s and relative risks are merely a measure of 
association and this does not necessarily translate into improvement in risk stratification 
and prediction. We therefore recommended to not only test associations, but also perform 
separate prediction analyses, such as false-positive/true-positive fractions, c-statistics, 
net reclassification improvement (NRI), integrated discrimination improvement (IDI)8 and 
discriminative likelihood ratio (dLR).9, 10 
A second important issue that we addressed was the lack of validation of results in 
independent studies, as biomarkers only have clinical value if results are independently 
reproducible. Based on the status of current biomarker research in this field, we therefore 
recommended that future research be directed not only at further biomarker discovery, 
but also at validation of promising biomarkers in large well-designed longitudinal 
studies. Specific prediction analyses should be applied to assess the additive predictive 
value of novel and published biomarker candidates beyond conventional risk factors. 
Future research will have to elucidate the true value of current biomarker candidates for 
prediction of onset and progression of renal impairment in diabetes. If these biomarkers 
prove clinically useful in the future, they may get a more prominent role in early non-
invasive screening and assessment of overall renal risk in patient groups, guiding early 
and more aggressive therapy in high risk patients in order to prevent long-term cardio-
renal complications.
Transition between the stages of albuminuria (i.e. normo- to microalbuminuria and 
micro- to macroalbuminuria) is considered a hallmark of progression of renal disease in 
diabetes, and is associated with fast-progressive renal function decline, end-stage renal 
disease and also with cardiovascular disease.11,12 We were therefore interested in novel 
biomarkers that may precede and predict the transition in albuminuria. 
According to current insights leakage of excess albumin is a sign of vascular dysfunction 
resulting from endothelial damage. Markers of early vascular damage could thus be 
eligible as markers for transition in albuminuria in diabetes.13 In chapters 3 and 4, we 
assessed whether the micro-vascular damage marker Growth-Differentiation Factor-15 
(GDF-15) and the micronecrosis marker high-sensitivity Troponin T (hs-TnT) respectively, 
preceded and had additive predictive value in prediction of onset or worsening of 
albuminuria in patients with type 2 diabetes. 
We had the opportunity to investigate these markers using a nested case-control 
design in the Prevention of REnal and Vascular End-stage Disease (PREVEND) study.14 A 
unique feature of our study was that we used patient samples prior to the transition 
in albuminuria in a longitudinal fashion. This study design allows to test whether the 
markers under study preceded and predicted the transition in albuminuria. This contrast 
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most other research in literature in which the biomarker of interest is investigated in a 
cross-sectional fashion. 
The main results of the studies were that both GDF-15 and hs-TnT were independently 
associated with transition in albuminuria in both an intial cohort and a replication cohort. 
Furthermore, both markers improved risk stratification between controls and cases with 
progressive albuminuria in both the initial and replication cohort. The value of GDF-15 
and hs-TnT had not previously been demonstrated for renal disease. Regarding GDF-15, 
previous studies mainly implicated GDF-15 as predictor for cardiovascular events and all-
cause mortality. One observation study linked GDF-15 to end-stage renal disease in type 1 
diabetes.15 Likewise, hs-TnT is mostly regarded as marker for acute myocardial infaction.16 
It has also been implicated as marker for later occurrence of cardiovascular and all cause 
mortality in various populations.17,18 We now for the first time demonstrated that GDF-
15 and hs-TnT may also serve as markers for prediction of progression in albuminuria in 
hypertensive and type 2 diabetic subjects. The exact underlying mechanisms remain 
unclear. Potentially, GDF-15 and hs-TnT indicate vascular stress, causing renal as well as 
cardiovascular damage. 
Our results, if confirmed by other studies, raise the possibility of improving the 
identification of subjects at risk even when traditional risk factors do not indicate risk. 
In patients with (established) renal impairment, treatment with antihypertensive agents 
blocking the Renin-Angiotensin-Aldosteron-System (RAAS) is first-choice treatment to 
halt further progression of the disease.1 In large scale randomized clinical trials it has 
been shown that these agents such as Angiotensin-Converting-Enzyme inhibitors (ACEi), 
Angiotensin-Receptor-Blockers (ARB) and Direct Renin inhibitors (DRi) do not only lower 
blood pressure, but also lower urinary albumin excretion and reduce risk of ESRD and 
mortality in patients with type 2 diabetes and hypertension, compared to treatment with 
other antihypertensives. RAAS-blockade has similar beneficial effects in diabetic patients 
without hypertension and in non-diabetic patients.19-22 
Currently, dose-titration of RAAS blockade is recommended on blood pressure response, 
without taking responses in albuminuria into account. This is comprehensible, given 
that these agents are developed and registered as antihypertensive agents. However, 
recent studies have illustrated that within an individual the response in blood pressure 
is not always paralleled by a response in proteinuria and vice-versa. It is, however, unclear 
whether it is the response in blood pressure, in albuminuria, or their combination which 
is the driving parameter for renoprotection and should be considered a target for reno-
protective therapy. In chapter 5 we assessed the initial treatment responses in albuminuria 
and blood pressure and the association of the initial treatment responses with long-term 
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renal outcome in patients with type 2 diabetes and microalbuminuria. 
We showed that the response to ARB therapy varies for both albuminuria and blood 
pressure and that a substantial amount of patients has a discordant treatment response 
(i.e. a response in either albuminuria or blood pressure). The rate of long-term renal 
function decline and the risk for transition to overt nephropathy was dependent on the 
initial response in albuminuria irrespective the blood pressure response. 
Whereas it was already clear that the reduction in albuminuria achieved during the 
initial months of RAAS blockade is a critical step to achieve renoprotection and is the 
most important determinant of long-term renoprotection, these findings are all based on 
studies in patients with advanced chronic renal impairment (macroalbuminuria and lower 
renal function).23-26 Our results, combined with evidence from studies in patients with 
more advanced renal disease, suggest that a treatment approach solely focusing on blood 
pressure reduction may not be the most efficacious way to achieve renoprotection.27-30 
Monitoring therapy-induced changes in albuminuria in individual diabetic patients is 
important in addition to monitoring blood pressure, since therapy induced changes 
in both parameters do not run in parallel and both parameters were independently 
associated with effectiveness of achieving renal protection.
However, before this finding can be used in risk management strategies, prospective 
randomized controlled trials will be necessary to obtain definitive evidence that an 
approach of targeting UAE confers additional renoprotection. From trials in other 
populations we know that optimal anti-proteinuric dosing of RAAS blockade is feasible 
and results in a substantially larger reduction in proteinuria and slower rate of renal 
function decline.31 
Current guidelines recommend screening for, and treatment of increased albuminuria in all 
patients with type 2 diabetes for the prevention of long-term cardio-renal complications. 
Since 2006, the Dutch primary care guideline recommends yearly albuminuria-screening in 
all diabetes patients with a life-expectancy of at least 10 years.2 For the yearly albuminuria-
screening, measurement of ACR is favored over urinary albumin concentration.32 If the 
measurement indicates the presence of micro- or macroalbuminuria, the increased 
albuminuria has to be confirmed by a repeat measurement within the next few months. 
In addition, all patients with confirmed micro- or macroalbuminuria should be prescribed 
RAAS-treatment (Angiotensin-Converting-Enzyme Inhibitors (ACEi)/ Angiotensin II 
Receptor Blockers (ARB)) even if their blood pressure readings are in the normal range. 
Yet, clinical practice does not always immediately follow and comply with recommendations 
and guidelines. In chapter 6, we assessed the adherence to guidelines for albuminuria 
screening and treatment in patients with type 2 diabetes in a large primary care cohort. 
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In a cohort of over 14,000 patients with type 2 diabetes, primarily treated by their general 
practitioner, we found that an ACR-measurement was observed in less than 60% of 
T2DM patients in Dutch primary care, and that up to one third of patients had never 
been screened in a three year period from 2007 to 2010. The proportion of patients that 
was screened for increased urinary albumin excretion was lower than anticipated from 
looking at screening rates of other risk factors.33-35 Although the proportion increased 
when the interval was extended beyond 12 months, as proposed in a recent study,36 this 
was a marginal increase leaving more than one third of patients not being screened 
in 2009. Also, limiting the patients to those who have a longer life expectation did not 
substantially increase the ACR screening rate.
In our study, we found that cross-sectionally, the proportion of patients receiving RAAS-
treatment among patients with prevalent increased albuminuria was highest, followed by 
patients with incident increased albuminuria. In addition to this, increased albuminuria 
was a trigger for RAAS-treatment initiation following ACR measurement. Nevertheless, 
the proportion of patients that was prescribed RAAS following a finding of increased 
albuminuria was disappointingly low (~13%). It is unclear to what extent RAAS-treatment 
was prescribed to these patients because of uncontrolled blood pressure rather than 
increased albuminuria. Given the fact that initiation of RAAS-treatment was also frequently 
used by patients without any ACR measurement or those with normoalbuminuria, it is 
tempting to speculate that in many patients the main indication for RAAS-treatment 
was uncontrolled blood pressure rather than increased albuminuria. This suggestion is 
further supported by our finding that blood pressure and number of antihypertensives 
used (other than RAAS) were determinants of RAAS-treatment initiation in patients with 
unknown albuminuria or normoalbuminuria. This may indicate that establishment of 
increased albuminuria in itself seems to be insufficiently recognized as an indication for 
starting RAAS-treatment. 
We looked at several external factors, including patient characteristics and organizational 
factors that may explain the low proportion of ACR measurement and RAAS-treatment 
initiation. It is widely recognized that there can be many barriers and incentives contributing 
to the implementation of guidelines in practice.37 We indeed found barriers at the level of 
the health care professional. Its explanation may be twofold; on the one hand, according 
to a study using questionnaires, awareness of the guidelines amongst European GPs was 
limited and could indeed be improved substantially.38 On the other hand logistical issues 
regarding albuminuria screening may play a role. This argument is substantiated by our 
observation that that additional care provided by a diabetes support facility and previous 
ACR measurement were important determinants of ACR measurement. The finding 
that logistical issues play a role in risk factor management is not entirely new. Similar 
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observations were done previously in the management of hypertension.39
Whatever the underlying causes may be, there is room for improvement with regards to 
screening and treatment of increased urinary albumin excretion in the Dutch primary 
care setting. It is well recognized that albuminuria is one of the strongest cardio-renal 
risk markers, and early screening and appropriate treatment have the potential to 
substantially reduce the risk of cardio-renal complications. Nevertheless, this aspect of 
risk-reduction in diabetes now receives insufficient attention and this should be brought 
to the clinicians’ attention. 
Part II: Lung transplantation
In the second part of this thesis we focused on prediction and prevention of renal 
impairment in lung transplantation recipients. This patient population has a much higher 
a priori risk of renal function decline, but due to the relatively small overall number of 
lung transplantation recipients this group does not comprise a large proportion of all 
patients with chronic renal impairment. Nonetheless, in this patient group the burden 
of chronic renal impairment is substantial, with between 5 and 10% of surviving lung 
transplantation recipients ending up in dialysis.40-42 Moreover, the renal impairment poses 
difficulties for effective immuno-suppression to maintain a viable pulmonary graft.43
At variance with the populations described in part I, that are managed mainly in general 
practice, LTx recipients are subject to intensive individual monitoring in specialized 
centers, that usually also include specialist care. Accordingly, the clinical setting for risk 
prediction and prevention is highly different from that in diabetes and hypertension. 
Several patient and transplantation related factors are established or hypothesized as renal 
risk factors in lung transplantation recipients, including age, sex, pulmonary diagnosis, 
type of transplantation, use of cardiopulmonary bypass, hypertension, diabetes, serum 
creatinine and BMI.41,44 Since the first lung transplantations more than 20 years ago, the 
field of lung transplantation has evolved considerably. Due to evolution of acceptance 
policies, lung transplantation recipients are increasingly old and have an increasing load 
of ‘co-morbidities’, adding up to increasing anticipated renal risk. Meanwhile, treatment 
and management of lung transplantation recipients also evolved, with physicians 
increasingly becoming aware of the nephrotoxicity of immunosuppression. This “learning 
curve” may have counterbalanced the increase in renal risk factors in patients accepted 
for lung transplantation. 
In chapter 7 we described these developments and assessed the changes in renal risk 
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factors in the lung transplantation population as well as the incidence of renal function 
impairment after lung transplantation over time. Despite a gradually worsening renal risk 
profile of the lung transplantation recipient population, we found that renal outcome 
improved over time. Several factors may have played a role in this improvement. One of 
the factors that we believe may have played a role in counterbalancing the renal risk is the 
switch from cyclosporin to tacrolimus as standard calcineurin inhibitor since 2001. This is 
line with observations that tacrolimus is less nephrotoxic than cyclosporin in other solid 
organ transplantation populations and experimental studies.
Other factors that may have played a role in the reduction of renal impairment after 
lung transplantation include improvement of surgical techniques and post-operative 
management, increased awareness about renal function impairment and increased 
experience in the management of lung transplantation recipients. The increased 
awareness and experience in the management of renal impairment have led to institution 
of preventive measures, such as preventive tapering of immunosuppression or prescription 
of reno-protective medication in patients with rapidly declining renal function. 
We were also interested in other risk factors for renal impairment. We hypothesized that, 
even after smoking-cessation, smoking history may be relevant for morbidity after LTx, 
in particular chronic renal impairment, because of the high prevalences of both chronic 
renal impairment and former smoking. We therefore assessed whether there was an 
association between smoking history before lung transplantation and renal impairment 
after lung transplantation. 
In chapter 8, we showed that former smoking indeed was dose-dependently associated 
with an increased risk of renal impairment. In addition, former smokers had a lower 
measured renal function after transplantation compared to never smokers, which was 
already apparent from early after transplantation and on. Although never smokers were 
on average younger and had different underlying pulmonary disease, all associations 
remained after adjustment for these differences in patient characteristics. 
Our findings were somewhat in contrast to the general notion that, whereas smoking is 
an established renal risk factor, this risk diminishes after smoking cessation. This notion 
has also proven false for other smoking-related conditions, such as lung cancer. It has 
been shown that the risk of lung cancer remains increased 15-fold in men and 9-fold in 
women for at least ten years after smoking cessation.45 Likewise, other sub-clinical effects 
of smoking remain present for years after cessation.46, 47
We believe that former smoking may have primed the kidneys for accelerated decline in 
GFR after LTx. This would imply there was pre-existent renal damage in former smokers that 
makes them more susceptible for further CNI-induced renal function loss. Nevertheless, 
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adjustment for pre-transplantation renal function did not account for the effects found. 
This seemingly contradictory finding may be explained by the fact that kidneys have a 
certain amount of reserve capacity: pre-existent damage can be compensated for, and 
substantial renal damage can be present without any measurable effect on GFR.48 That 
this may be the case in former smokers is supported by a renal biopsy study, in which it 
was shown that renal effects of smoking could be present in former smokers, without 
an apparent effect on renal function.49 Pre-existent renal lesions - in combination with 
diminished renal reserve capacity - may in turn amplify the nephrotoxic effects of 
CNIs.50 Accordingly, renal lesions induced by prior smoking might well be involved in our 
observations that former smokers are more susceptible to post-transplantation renal 
impairment, despite that they no longer actively smoke. 
Interestingly, especially amongst the most recently transplanted lung transplantation 
recipients there were many former smokers with a history of heavy smoking. This reflects 
the widening acceptance criteria for lung transplantation that also were mentioned in 
chapter 7. In chapter 8, we demonstrated that heavy former smoking was associated with 
increased renal risk. Nevertheless, we observed a reduction in renal impairment in more 
recently transplanted recipients. Of course, this is a good development. However, the 
reduction in renal impairment might even been more pronounced if the amount of heavy 
former smokers transplanted would have been lower. 
Besides the increased renal risk, we could not demonstrate any effect of former smoking 
on survival after lung transplantation. Importantly, patients are all thoroughly screened 
prior to transplantation and therefore have a low risk of mortality after transplantation. 
Therefore, chances were very small to find an association between former smoking 
and mortality. Despite that we did not observe an association of former smoking with 
mortality in general, we did find higher mortality due to malignancy in the former 
smokers (most commonly lung cancer of the native lung), that also gives an indication of 
the long-term risks associated with smoking. Also from clinical experience, the physicians 
have the impression that heavy former smokers experience more complications after 
lung transplantation overall, and thus benefit less in terms of quality of life. All of these 
suspicions remain to be objectified by further research. 
Unfortunately, former smoking is a non-modifiable risk factor and, apart from preventive 
measures for renal impairment after transplantation, not much can be done to reduce 
the renal risk in former smokers. The only way to modify the risk associated with 
former smoking would be to limit the acceptance of heavy former smokers for lung 
transplantation. Given the absence of an effect on survival, the lack of prediction analyses 
that show that former smoking is not only associated, but also predicts renal and other 
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complications and the decreasing burden of renal impairment in this patient group, such 
measures are currently unjustified. 
Last, but not least, monitoring renal function over time is an excellent way to predict 
future renal risk, and the predictive performance of a slope of repeated renal function 
measurements over time has shown to be superior to proteinuria.51 This raises the issue 
how renal function can best be monitored. Usually, creatinine or creatinine based renal 
function equations are used to serve that purpose. However, these options suffer from 
major drawbacks as they frequently underestimate gold-standard measured GFR (mGFR), 
especially in the high and high-normal range, and lack sensitivity in detecting progressive 
renal function loss.52-54 
This is largely a result of the methods and the population in which they were derived. 
The estimate is affected even more substantially in patients with abnormalities in body 
composition, because the equations depend strongly on creatinine generation (and thus 
on body composition).55,56 Apart from one study comparing creatinine-based renal function 
equations with 24-hour creatinine excretion,57 these equations have never been validated 
in lung transplantation recipients. Because of the distinct characteristics of the lung 
transplantation recipients, they may not be very accurate in this particular population. As 
we routinely performed 125-Iothalamate measurements (mGFR) in our outpatient clinical 
practice, we could test the performance of creatinine based renal function equations that 
are most commonly used to monitor renal function in lung transplantation recipients. 
In chapter 9, we assessed how well the more easily available renal function equations 
correlate with gold standard GFR in lung transplantation recipients and assessed the 
factors of systematic bias.
We found that all three creatinine-based renal function equations that we tested 
substantially underestimated mGFR on population level (ranging from 12 to 32%, 
depending on the equation), both before and after lung transplantation. Precision and 
accuracy were also limited, especially in the high-normal range of GFR. As noted before 
it is well established that there is a larger deviation between eGFR and mGFR in the high 
range of GFR. In agreement, we found that the bias was much larger in this range, and 
that bias expressed as a proportion of mGFR was similar over the whole range of GFR. 
Other determinants of bias were BMI, age, sex and pulmonary diagnosis (cystic fibrosis 
and emphysema). The extent to which they bias the equations depended on the equation. 
In theory, the equations account for age, sex, race and weight, but our findings indicate 
that in this particular population, age, sex and BMI were insufficiently accounted for. 
All creatinine based renal function equations are derived from empirical studies in 
defined cohorts with certain weights and body compositions.58-60 In different patients, 
the same weight is consistent with a wide range of body compositions (muscle mass 
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to fat ratio) and creatinine generation rates. We expected abnormal body composition, 
especially reduced muscle mass, of lung transplantation recipients to cause estimates of 
the creatinine based renal function equations to be biased. However, a low muscle mass 
would lead to an overestimation of GFR in stead of the underestimation that we found.
A possible explanation for our results is that lung transplant recipients were especially 
devoid of fat and not so much of muscle mass (abnormal muscle mass to fat ratio). In 
line with this, patients with cystic fibrosis and pulmonary emphysema had the largest 
underestimation of mGFR, and these patient groups are particularly devoid of fat. Another 
issue that may contribute to underestimation of mGFR is that all lung transplantation 
recipients continuously receive trimethoprim (in combination with sulfomethoxazol) 
for prevention of P. Jerovici pneumonia after lung transplantation. This drug suppresses 
tubular creatinine secretion and raises the serum creatinine.61-63 This leads to lower eGFR, 
but does not affect mGFR. Likewise, the DF508 mutation underlying cystic fibrosis also 
suppresses creatinine secretion.64
Importantly, also the slope of renal function over time was underestimated by the 
renal function equations, perhaps inherently to the continuous underestimation of 
renal function over time. Similar to other patient populations, individual patients with 
fast-progressive renal function decline may therefore be missed, despite multiple 
measurements, long-term follow-up and relatively rapidly declining renal function. This 
lack of sensitivity limits applicability of the renal function equations to monitor renal 
function in lung transplantation recipients. 
As creatinine based estimation of renal function has limitations as shown in chapter 9, this 
also affects the use of creatinine based renal endpoints in research. Commonly, creatinine 
based eGFR or doubling of serum creatinine are used as endpoints. Whereas these 
endpoints are flawed to some extent; creatinine based endpoints are easily obtainable, 
and due to their widespread use facilitate comparison across studies. In chapter 7, we also 
used doubling of serum creatinine as the primary outcome measure and mGFR was used 
as a secondary outcome. The results using doubling of serum creatinine were paralleled 
by the results using mGFR. This indicates that despite their limitations, serum creatinine 
based endpoints have value, and can be used in clinical research, albeit cautiously.
Overall conclusions
In this thesis several aspects regarding prediction and prevention of chronic renal 
impairment in high-risk populations were investigated. We have looked at prediction of 
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chronic renal impairment using biomarkers and risk factors, how to improve preventive 
treatment strategies, and clinical reality. 
Whereas the high-risk populations that we’ve studied face the same threat of chronic 
renal impairment and prediction and prevention are important in all high-risk populations, 
several differences have also become apparent. The number of patients with diabetes 
or hypertension is very large and rapidly increasing. A small proportion these patients 
will eventually develop end-stage renal disease. These patients are mostly monitored in 
primary care, until complications become apparent. The number of lung transplantation 
recipients is much smaller, but the risk of chronic renal impairment they face is higher, the 
care for lung transplantation recipients is highly specialized and patients are monitored 
intensively. 
Due to these intrinsic differences, the methods for monitoring and treatment differ in 
certain aspects. In a large high-risk population it is important to limit not only the burden 
of disease in those with the highest risk, but also to limit the burden of treatment in those 
with the lowest-risk. In a small very high-risk population, more intensive monitoring and 
more aggressive treatment are warranted. As chronic renal impairment poses a severe 
burden on the individual patient, every step towards improving prevention of chronic 
renal impairment benefits the patients. 
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Nederlandse Samenvatting en Discussie
Deel I: Type 2 diabetes en hypertensie
Chronische nierziekten vormen een toenemend wereldwijd gezondheidsprobleem. De 
belangrijkste oorzaken die hieraan ten grondslag liggen zijn met name de toenemende 
incidentie van diabetes (ouderdomssuikerziekte) en hypertensie (hoge bloeddruk) door 
de moderne levensstijl. Patiënten met diabetes en/of hypertensie hebben namelijk een 
verhoogd risico op onder andere het ontwikkelen van chronische nierziekten. Geschat 
wordt dat momenteel 10-20% van de bevolking ouder dan 18 momenteel aan enige vorm 
van nierproblemen lijdt. Hoewel veel mensen in eerste instantie niet doorhebben dat 
ze lijden aan nierziekten, o.a. eiwit in de urine en versnelde nierfunctieachteruitgang, 
is het hebben van chronische nierziekten een van de belangrijkste risicofactoren voor 
het ontstaan van terminaal nierfalen. Nierfalen is ernstig invaliderend omdat de enige 
behandelingsmogelijkheid niervervangende therapie is, in de vorm van nierdialyse of 
niertransplantatie. Deze beide behandelingen zijn zeer belastend voor patiënten. 
Het hebben van chronische nierziekten, met name in een vergevorderd stadium, brengt 
daarnaast belangrijke risico’s met zich mee op onder andere hart- en vaatziekten 
en vroegtijdig overlijden. Bovendien wordt de gezondheidszorg fors belast door de 
stijgende prevalentie van chronische nierziekten en zijn de kosten voor behandeling van 
chronische nierziekten en aanverwante complicaties erg hoog, met name wat betreft 
niervervangende therapie bij eindstadium nierfalen.
Als nierziekten vroegtijdig kunnen worden voorspeld of ontdekt, lukt het vaak om 
het verloop en het ontstaan van complicaties met de juiste behandeling gunstig te 
beïnvloeden. Vroegtijdige ontdekking is dus erg belangrijk. Dit proefschrift gaat over het 
voorspellen en voorkómen van chronische nierziekten in patiëntengroepen met een hoog 
risico op het ontwikkelen van chronische nierziekten. 
Het t eerste deel van dit proefschrift gaat over voorspellen en voorkómen van chronische 
nierziekten bij patiënten met type 2 diabetes en hypertensie. De eerste hoofdstukken 
maken deel uit van onderzoek wat verricht werd binnen het SysKID consortium, een 
grootschalig Europees onderzoeksproject wat zich richt op het identificeren van patiënten 
met een verhoogd risico op het ontwikkelen van chronische nierziekten. Vroegtijdige 
identificatie van patiënten met een verhoogd risico op chronische nierziekten of een snel 
progressief verloop van chronische nierziekten kan preventieve maatregelen mogelijk 
maken, waardoor het risico kan worden gereduceerd. Tegelijkertijd kan bij  patiënten die bij 





voorbaat een laag risico hebben de last van preventieve maatregelen (zoals behandeling) 
bespaard blijven.
Hoewel er een grote hoeveelheid risicofactoren bekend is voor het ontstaan of snel 
progressief verloop van nierziekten - onder andere hoge hypertensie, hyperglycemie 
(hoge bloedsuikerwaarden), dyslipidemie (verstoorde cholesterolwaarden), roken en 
overgewicht - , is het nog steeds niet goed mogelijk om patiënten die (ernstige) chronische 
nierziekten zullen ontwikkelen en patiënten die dat niet zullen ontwikkelen van elkaar te 
onderscheiden. 
Als zich eenmaal een chronische nierziekte heeft ontwikkeld, is het lastig dit met 
behandeling terug te draaien. Het is daarom belangrijk om parameters te vinden die 
helpen bij vroegtijdige opsporing van patiënten met een hoog risico om vroegtijdig 
preventieve maatregelen zoals behandeling in te stellen. Biomarkers zijn “in bloed en urine 
voorkomende biologische stoffen” waarvan de concentratie bij bepaalde aandoeningen 
verandert en daardoor een vroegtijdige vaststelling van bepaalde aandoeningen mogelijk 
kunnen maken. De afgelopen jaren zijn er vele biomarkers beschreven die mogelijk het 
ontstaan en/of het voortschrijden van chronische nierziekten voorspellen. 
In hoofdstuk 2 hebben we deze biomarkers systematisch op een rijtje gezet met een 
behulp van literatuuronderzoek en gekeken hoe valide deze markers waren. Hierbij vonden 
we 15 longitudinale studies waarin één of meerdere biomarkers werden beschreven voor 
het ontstaan en/of het voortschrijden van chronische nierziekten in patiënten met type 2 
diabetes. Helaas bleek dat er tot nu toe weinig biomarkers bekend zijn die een substantiële 
bijdrage leveren aan de voorspelling van chronische nierziekten. Voor het beoordelen van 
de validiteit keken we onder andere naar de methodologische kwaliteit van de individuele 
studies. Over het geheel genomen was de kwaliteit niet meer dan redelijk te noemen. 
Hierdoor is het moeilijk de waarde van de markers te beoordelen. Door verschillen in 
studieopzet en uitkomstmaten was het bovendien moeilijk de resultaten te vergelijken 
en te generaliseren. 
Een aantal van de methodologische knelpunten werden uitvoerig bediscussieerd. Een van 
de zwakke punten is dat veel studies met name kijken naar associaties tussen biomarkers 
en eindpunten, maar niet in hoeverre een biomarker bijdraagt aan het verbeteren van 
onderscheidend vermogen tussen patiënten met een hoog en een laag risico, naast de al 
bekende risicofactoren. We raadden daarom aan om in studies die onderzoek doen naar 
voorspelling ten minste één vorm van analyse met betrekking tot voorspellend vermogen 
te verrichten. 
Daarnaast viel het op dat resultaten vaak slechts in één studie met goed effect beschreven 
worden, maar dat er geen andere studies zijn die de resultaten hebben gereproduceerd, 
danwel dat in andere studies zelfs tegenstrijdige resultaten worden gevonden. 
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Ons advies is daarom dat er bij onderzoek op het gebied van biomarkers verder 
onderzoek wordt gedaan naar het ontdekken van nieuwe biomarkers, maar dat validatie 
van biomarkers ook nagestreefd moet worden. Daarnaast is het nodig om biomarkers 
te analyseren met betrekking tot voorspellend vermogen. Verder onderzoek zal meer 
duidelijkheid moeten geven in hoe valide de huidige biomarkers en nieuwe biomarkers 
zijn. Hopelijk zullen biomarkers in de toekomst een waardevolle bijdrage kunnen leveren.
Albuminurie (eiwituitscheiding in de urine) is een belangrijk kenmerk van chronische 
nierziekten. Er worden meerdere stadia van albuminurie onderscheiden op basis van 
de hoeveelheid eiwit die wordt uitgescheiden (respectievelijk normoalbuminurie, 
microalbuminurie en macroalbuminurie). Transitie van een vroeg stadium naar een later 
stadium van albuminurie is een belangrijk kenmerk van voortschrijding van chronische 
nierziekte. Daarnaast is transitie tussen de stadia van albuminurie geassocieerd met snel 
progressieve nierfunctieachteruitgang en met hart- en vaatziekten. 
Volgens de STENO-hypothese is albuminurie een teken van vaatschade, waarbij de 
binnenbekleding van het bloedvat (het endotheel) beschadigd is en de bloedvaten 
albumine gaan lekken. Markers die bij dit proces van vaatschade betrokken zijn zouden 
dus kunnen fungeren als voorspellers van transitie tussen de stadia van albuminurie.
In hoofdstuk 3 en hoofdstuk 4 keken we naar respectievelijk Growth-Differentation 
Factor-15 (GDF-15), als marker van endotheelschade, en naar high-sensitivity Troponin T 
(hs-TnT), als marker van celdood. We onderzochten of deze markers voorafgingen aan een 
transitie tussen de stadia van albuminurie en of ze bijdroegen aan de voorspelling hiervan. 
We onderzochten dit in een subgroep van patiënten die meededen aan de 
‘Prevention of REnal and Vascular End-Stage Disease’ (PREVEND) Study, een Gronings 
bevolkingsonderzoek naar eiwitverlies in de urine voor het voorspellen van nier-, hart- en 
vaatziekten. We selecteerden patiënten die over de tijd een transitie tussen de stadia van 
albuminurie doormaakten, en koppelden deze patiënten aan vergelijkbare patiënten met 
een stabiele albumine uitscheiding in de urine gedurende dezelfde onderzoeksperiode. 
We namen vervolgens bevroren bloedsamples van deze patiënten aan het begin van 
de onderzoeksperiode (toen de gekoppelde patiënten hetzelfde albuminurie-stadium 
hadden) en bepaalden hierin de concentraties van de biomarkers GDF-15 en hs-TnT. Een 
bijzonder kenmerk van deze studie was dat het longitudinaal van opzet was, terwijl veel 
studies een eenvoudigere cross-sectionele studieopzet gebruiken. Alleen bij longitudinaal 
onderzoek kunnen er uitspraken gedaan worden over voorspelling. 
In hoofdstuk 3 lieten we zien dat GDF-15 onafhankelijk geassocieerd was met een transitie 
tussen de stadia van albuminurie, zowel in een primair cohort van patiënten met type 2 
diabetes als in een replicatie cohort van patiënten met hypertensie. Bovendien verbeterde 





GDF-15 de discriminatie tussen patiënten met en zonder een transitie tussen de stadia 
van albuminurie. 
In hoofdstuk 4 lieten we zien dat hs-TnT onafhankelijk geassocieerd was met een 
transitie tussen de stadia van albuminurie, zowel in een primair cohort van patiënten 
met hypertensie als in een replicatie cohort van patiënten met type 2 diabetes, hoewel 
de associatie in het replicatiecohort niet statistisch significant was. Wel verbeterde hs-
TnT de discriminatie tussen patiënten met en zonder een transitie tussen de stadia van 
albuminurie in zowel patiënten met hypertensie als in patiënten met type 2 diabetes.
De waarde van GDF-15 en hs-TnT was nog niet eerder aangetoond voor nierziekten bij 
patiënten met type 2 diabetes en hypertensie. Eerder waren er al aanwijzingen dat 
GDF-15 was geassocieerd met het optreden van eindstadium nierfalen in patiënten met 
type 1 diabetes. Hs-TnT wordt in de dagelijkse praktijk gebruikt als marker voor acute 
hartinfarcten. Daarnaast zijn deze markers in verschillende studies in verband gebracht 
met hart- en vaatziekten en sterfte. Als onze bevinding dat GDF-15 en hs-TnT een rol 
kunnen spelen in voorspellen van progressie van nierziekten kan worden bevestigd 
in andere studies, zou dit het in toekomst tevens mogelijk kunnen maken vroegtijdig 
patiënten met een hoog risico op (progressie van) chronische nierziekten op te sporen. 
Wat betreft de behandeling van patiënten met chronische nierziekten met albuminurie, 
heeft behandeling met bloeddrukverlagende middelen die het Renine-Angiotensine-
Aldosteron Systeem (RAAS) blokkeren de voorkeur. Dit omdat verschillende internationale 
klinische studies hebben aangetoond dat zulke middelen niet alleen de bloeddruk verlagen, 
maar ook de albuminurie verminderen en hiermee het risico op eindstadium nierfalen 
en sterfte in patiënten met type 2 diabetes en hypertensie verminderen, vergelijken met 
andere bloeddrukverlagende middelen. RAAS-blokkade heeft vergelijkbare effecten bij 
patiënten met type 2 diabetes maar zonder hypertensie en patiënten zonder diabetes. 
Momenteel wordt de dosis van RAAS-blokkade getitreerd op basis van de 
bloeddrukverlaging die bereikt wordt, zonder dat daarbij wordt gekeken naar het effect op 
de albuminurie. Dit is begrijpelijk omdat deze middelen in principe bloeddrukverlagende 
middelen zijn en ook als zodanig geregistreerd zijn, en het gunstige effect op de 
albuminurie een later vastgesteld bijkomend voordeel is. Echter, recente studies hebben 
laten zien dat op individueel niveau een daling van de bloeddruk niet altijd gepaard gaat 
met een daling van de albuminurie en omgekeerd. Het is echter onduidelijk welke van de 
twee parameters (de daling in bloeddruk of de daling in albuminurie) of de combinatie 
van beide het belangrijkst is voor de bescherming van de nier. Daarom bestudeerden we 
in hoofdstuk 5 de initiële respons op behandeling met betrekking tot de bloeddruk en de 
albuminurie, en onderzochten we of de initiële respons op behandeling geassocieerd was 
samenvatting.indd   217 5-4-12   21:15
218
Samenvatting en Discussie
met lange termijn uitkomsten van de nier. We onderzochten dit in een cohort van meer 
dan 500 patiënten met type 2 diabetes en microalbuminurie (vroegste stadium van eiwit 
uitscheiding) die meededen met een grote internationale studie naar RAAS-blokkade.
In dit hoofdstuk lieten we zien dat de respons op RAAS-blokkade in de eerste 6 maanden 
verschillend kan zijn voor bloeddruk en albuminurie en dat een groot gedeelte van de 
patienten een goede respons had in één van beide parameters, maar niet in de andere 
parameter (discordante respons). Het risico op transitie van micro- naar macroalbuminurie 
en de mate van nierfunctieachteruitgang gedurende de 2 jaar na starten van de 
behandeling waren met name afhankelijk van de respons in albuminurie en dit was 
onafhankelijk van de respons in bloeddruk. 
Het vernieuwende van deze bevindingen is dat dit nog niet eerder aangetoond is in 
patiënten met een vroeg stadium nierziekte. Onze resultaten vormen samen met 
resultaten van vergelijkbare studies in patiënten met een vergevorderd stadium nierziekte 
een belangrijke aanwijzing dat het slechts in overweging nemen van de bloeddrukdaling 
bij de behandeling met RAAS-blokkade misschien niet de meest effectieve manier is om 
voortschrijding van nierziekten te voorkómen. Voordat de behandelingsstrategie echter in 
de praktijk aangepast kan worden zal er eerst bevestigend prospectief en gerandomiseerd 
onderzoek moeten worden gedaan in deze categorie patiënten. 
De richtlijnen voor huisartsen en specialisten raden screening en behandeling van 
albuminurie aan, met als doel nier-, hart- en vaatziekten te voorkómen bij patiënten 
met type 2 diabetes. De Nederlandse richtlijn voor huisartsen uit 2006 beveelt bij alle 
patiënten met type 2 diabetes en voldoende levensverwachting jaarlijkse albuminurie 
screening aan. Als daarbij albuminurie wordt vastgesteld (bij voorkeur op basis van 
meerdere metingen) dient er te worden gestart met RAAS-blokkade, onafhankelijk of er 
ook hypertensie is. 
Echter, de praktijk is altijd weerbarstiger dan de ideale situatie volgens de richtlijnen. In 
hoofdstuk 6 bekeken we de implementatie van de richtlijn met betrekking tot screening 
en behandeling van albuminurie bij patiënten met type 2 diabetes in de Nederlandse 
huisartsenpraktijk. In een groot cohort van meer dan 14,000 patiënten met type 2 
diabetes die primair behandeld werden door de huisarts zagen we dat in minder dan 60% 
een albuminurie meting was gedaan in het jaar 2009, en dat zelfs in één derde van alle 
patiënten in een periode van 2007 tot 2010 nooit een albuminurie meting was gedaan. 
De getallen verbeterden weinig als we alleen keken naar patiënten met een ruimere 
levensverwachting, of als we het interval oprekten van 12 naar 15 maanden. 
Wat betreft behandeling met RAAS-blokkade vonden we wel dat patiënten met 
verhoogde albuminurie vaker werden behandeld met RAAS-blokkade dan patiënten 





zonder verhoogde albuminurie en patiënten zonder meting. Ook bleek dat het vinden 
van een verhoogde albuminurie inderdaad een trigger was voor het starten van RAAS-
blokkade, echter het absolute percentage voorschriften van RAAS-blokkade na verhoogde 
meting was teleurstellend laag (~13%). Bovendien is het niet geheel duidelijk in hoeverre 
RAAS-blokkade wordt voorgeschreven in verband met verhoogde albuminurie, of dat 
dit met name samenhangt met verhoogde bloeddruk. Omdat RAAS-blokkade ook 
vaak werd voorgeschreven bij patiënten zonder verhoogde albuminurie en patiënten 
zonder albuminurie meting ligt het voor de hand om te speculeren dat met name 
bloeddrukverhoging de doorslaggevende factor voor het voorschrijven van RAAS-
blokkade is. Naast verhoging van albuminurie vonden we bloeddruk inderdaad terug als 
determinant van voorschrijven van RAAS-blokkade. 
Ook wat betreft albuminurie screening verrichtten we een analyse van de determinanten. 
We vonden andere aanwijzingen dat de logistieke organisatie rondom albuminurie 
screening mogelijk een rol speelt; zo kregen patiënten die aanvullende begeleiding kregen 
bij een eerstelijns diabetes-centrum en patiënten die eerder een albuminurie screening 
hadden gehad vaker een albuminurie screening. Andere studies toonden eerder al aan dat 
logistiek een rol kan spelen bij de mate van implementatie van richtlijnen.
Al met al konden we op basis van onze observaties concluderen dat er in de 
huisartsenpraktijk ruimte voor verbetering bestaat met betrekking tot screening en 
behandeling van patiënten met type 2 diabetes met het oog op risicoreductie van 
nier-, hart- en vaatziekten. Dit aspect van de diabeteszorg krijgt momenteel onvoldoende 
aandacht en verdient het om meer onder de aandacht van de huisartsen gebracht te 
worden.




In het tweede deel van dit proefschrift gaat het over voorspellen en voorkómen van 
chronische nierziekten bij patiënten die een longtransplantatie hebben ondergaan. Deze 
groep patiënten hebben een nog veel hoger risico op progressieve nierfunctieachteruitgang 
dan de hoogrisico groepen beschreven in het eerste deel van dit proefschrift, echter, door 
de veel kleinere groep patiënten waar het om gaat maakt deze groep maar een heel klein 
deel uit van het alle patiënten met chronische nierziekten. 
Desalniettemin, in deze groep patiënten die al veel te maken hebben met ernstige ziekte, 
zorgen chronische nierziekten ook voor grote ziektelast. Uiteindelijk zal 5-10% van alle 
patiënten met een longtransplantatie uiteindelijk eindstadium nierfalen ontwikkelen en 
niervervangende therapie nodig hebben. Daarnaast maken de nierfunctiestoornissen het 
effectief behandelen met immuunsuppressieve (afweeronderdrukkende) medicamenten 
ten behoeve van het longtransplantaat lastiger. 
Een andere belangrijke tegenstelling tussen patiënten die een longtransplantatie hebben 
ondergaan en de hoogrisico groepen besproken in deel I van dit proefschrift is dat 
longtransplantatiepatiënten intensief worden begeleid in gespecialiseerde centra, waar 
patiënten met type 2 diabetes en hypertensie met name in de eerstelijns gezondheidszorg 
worden behandeld. Deze andere klinische setting samen met het nog hogere risico maakt 
dat vele aspecten van voorspellen en voorkómen van nierziekten in deze patiëntengroep 
anders zijn. 
In de literatuur worden meerdere patiëntgebonden en transplantatie gerelateerde factoren 
beschreven als risicofactoren voor chronische nierziekten in longtransplantatiepatiënten. 
Dit zijn onder andere leeftijd, geslacht, het chronisch gebruik van immuunsuppressiva die 
schadelijk zijn voor de nier, onderliggend longlijden, type transplantatie (enkele of dubbele 
longtransplantatie), het gebruik van de hart-longmachine tijdens de transplantatie, 
hypertensie, diabetes, roken, de nierfunctie voor de transplantatie en de body-mass index 
(BMI). 
Sinds de eerste longtransplantatie meer dan 20 jaar geleden is er veel gebeurd op 
het gebied van longtransplantatie. Om te beginnen zijn de criteria voor acceptatie 
van een ontvanger geleidelijk soepeler geworden, waardoor de patiënten die een 
longtransplantatie ondergaan steeds ouder zijn geworden en meer bijkomende 
ziekten hebben naast hun onderliggende longziekte. Deze factoren die veranderd zijn 
kunnen, zoals hiervoor vermeld, beschouwd worden als risicofactoren voor nierziekten 
en maken dat de a priori kans op nierfunctiestoornissen groter is geworden. Aan de 
andere kant heeft de medicamenteuze en niet-medicamenteuze behandeling van 





longtransplantatiepatiënten een grote ontwikkeling doorgemaakt, onder andere doordat 
artsen zich steeds meer bewust werden van de gevolgen van de behandeling voor de 
nier. Deze ‘leercurve’ zou het toegenomen aantal risicofactoren voor nierziekten in deze 
patiëntengroep gecompenseerd kunnen hebben. 
In hoofdstuk 7 beschreven we deze ontwikkelingen uitvoerig en gaven we inzicht in 
de veranderingen in de populatie van longtransplantatiepatiënten sinds het begin 
van het longtransplantatieprogramma in Groningen. Hoewel het profiel van de 
longtransplantatiepatiënten geleidelijk ongunstiger is geworden met het oog op 
nierfunctiestoornissen, zijn de uitkomsten met betrekking tot de nier in de loop der 
jaren verbeterd. Een aantal factoren zou hierin een rol kunnen hebben gehad. Een 
van deze factoren in de overgang van ciclosporine naar tacrolimus als belangrijkste 
immuunsuppressieve middel in 2001. In (dier)experimenteel onderzoek en onderzoek bij 
andere patiëntengroepen is namelijk de indruk gewekt dat tacrolimus minder schadelijk 
is voor de nier dan ciclosporine. 
Andere factoren die mogelijk hebben bijgedragen aan de verbeterde uitkomsten met 
betrekking tot nierfunctiestoornissen zijn de verfijning en verbetering van de chirurgische 
technieken, de zorg rondom de operatie, het toegenomen bewustzijn van het bestaan 
van nierschade na longtransplantatie en de groeiende ervaring met de behandeling van 
deze patiënten. De laatste twee factoren hebben ervoor gezorgd dat er tijdig maatregelen 
worden getroffen om verdere schade te beperken, zoals het preventief verlagen van de 
dosis immuunsuppressieve medicijnen of het voorschrijven van beschermende medicatie 
bij patiënten met een snelle nierfunctieachteruitgang. 
We waren daarnaast geïnteresseerd welke andere risicofactoren er bestaan voor het 
ontstaan van nierfunctiestoornissen na longtransplantatie. We vermoedden dat, zelfs 
na het staken van roken, de voorgeschiedenis met betrekking tot roken mogelijk een 
belangrijke risicofactor was voor complicaties na longtransplantie, met name chronische 
nierziekten. Dit omdat roken een belangrijke risicofactor is voor chronische nierziekten 
en er onder de longtransplantatiepatiënten zowel veel ex-rokers zijn, als er een zeer hoge 
incidentie van chronische nierziekten is. 
In hoofdstuk 8 onderzochten we daarom of er een associatie was tussen voorheen gerookt 
hebben en (de tijd tot) het ontstaan van chronische nierziekten bij patiënten die een 
longtransplantatie ondergaan hebben. We toonden aan dat er inderdaad een dergelijk 
verband was, waarbij er bovendien een dosiseffect relatie werd gevonden. Al ten tijde 
van transplantatie hadden de ex-rokers een wat slechtere nierfunctie dan patiënten die 
nooit gerookt hadden. Aan de andere kant waren de patiënten die nooit gerookt hadden 
ook gemiddeld jonger en hadden vaak ander onderliggend longlijden. Gecorrigeerd voor 
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deze verschillen in patiëntkarakteristieken bleef er echter een dosisafhankelijk verband 
bestaan tussen ex-roken en chronische nierziekten. Hoewel over het algemeen wordt 
aangenomen dat het schadelijke effect van roken op de nier verdwijnt op het moment 
van stoppen met roken, blijkt dat in dit geval niet op te gaan. Eerder al bleek dat dit ook 
niet het geval was voor andere aan roken gerelateerde aandoeningen, zoals het risico 
op longkanker. Het risico op longkanker blijft namelijk gemiddeld 15 keer verhoogd voor 
mannen en 9 keer verhoogd voor vrouwen tot in ieder geval 10 jaar na het stoppen met 
roken. 
Het is bekend dat nieren een grote, maar moeilijk meetbare, reserve capaciteit hebben. 
Hierdoor is het mogelijk dat er pre-existente schade was door het roken, die reeds 
gecompenseerd was door de reservecapaciteit van de nier, en waardoor de gemeten 
nierfunctie goed is. Een verklaring voor het verhoogde risico op nierfunctiestoornissen 
zelfs na het stoppen met roken is daarom dat de nieren al wel beschadigd zijn, maar 
zonder dat het tot expressie komt in de nierfunctiemeting, en dat ze daardoor gevoeliger 
zijn voor de schade die wordt toegebracht door de longtransplantatie en de medicatie. 
Opvallend genoeg was het percentage ex-rokers die fors gerookt hadden (>25 pack 
years) het grootst onder de het meest recent getransplanteerde patiënten. Dit is 
een uitting van de geleidelijk soepeler geworden acceptatie criteria die ook werden 
genoemd in hoofdstuk 7. In hoofdstuk 8 lieten we vervolgens zien dat ex-roken en 
in het bijzonder fors ex-roken gepaard ging met een verhoogd risico op chronische 
nierfunctiestoornissen. Desalniettemin zagen we over het geheel genomen een daling in 
de incidentie van chronische nierfunctiestoornissen. Aan de ene kant is dit een hele goede 
ontwikkeling. Echter, als kritische noot kan hierbij worden opgemerkt dat het aantal 
nierfunctiestoornissen wellicht nog verder was teruggelopen als het aantal ex-rokers die 
fors hadden gerookt dat was geaccepteerd voor longtransplantatie kleiner was geweest. 
Naast het risico op nierfunctiestoornissen hebben we ook gekeken naar het effect van ex-
roken op overleving na longtransplantatie. We konden geen effect aantonen. Hierbij is het 
belangrijk te bedenken dat alle patiënten voorafgaand aan longtransplantatie uitvoerig 
worden gescreend en daardoor bij voorbaat een laag risico hebben om te overlijden. Om 
deze reden was de kans erg klein dat we wel een effect van ex-roken op de overleving 
zouden vinden. Desalniettemin vonden we wél een effect van ex-roken op de kans dat 
een longtransplantatiepatiënt zou overlijden als gevolg van kwaadaardige kanker (in 
de meeste gevallen longkanker van de niet-getransplanteerde long), waar toch kwalijke 
effecten van ex-roken uit naar voren komen. Ook in de kliniek bestaat het idee dat de 
ex-rokers, met name de ex-rokers die veel hebben gerookt, na longtransplantatie meer 
complicaties hebben en minder profiteren van de transplantatie met betrekking tot 





kwaliteit van leven. Dit blijkt echter vooralsnog niet uit het onderzoek en zal eerst verder 
geobjectiveerd moeten worden. Helaas is ex-roken een niet-modificeerbare risicofactor 
en kan er, naast de huidige maatregelen die nu getroffen worden na transplantatie, 
weinig gedaan worden om het risico op chronische nierfunctiestoornissen in ex-rokers 
te verlagen. Slechts het niet accepteren van deze patiënten zou de kans op chronische 
nierfunctiestoornissen verkleinen. Daar er echter geen effect van ex-roken op de overleving 
na transplantatie wordt gezien in combinatie met het gebrek aan prospectieve gegevens 
en de dalende incidentie van nierfunctiestoornissen, zijn dergelijke maatregelen op basis 
van deze argumenten niet verdedigbaar.
Tot slot is het belangrijk om de nierfunctie over de tijd te monitoren. Het verloop 
van de nierfunctie over de tijd is een goede manier om het toekomstig risico op 
nierfunctiestoornissen in te schatten, en is dit voorspellend vermogen is zelfs superieur 
aan het voorspellend vermogen van albuminurie. 
Het is echter wel de vraag hoe de nierfunctie het best gemeten kan worden. In de dagelijkse 
praktijk wordt er veel gebruik gemaakt van serum creatinine concentratie of op serum 
creatinine gebaseerde formules om nierfunctie te schatten. Er zitten echter belangrijke 
nadelen aan het schatten van de nierfunctie op basis van het serum creatinine omdat dit 
vaak de met de gouden-standaard methode gemeten nierfunctie onderschat, met name 
in de hoog-normale range, en omdat de geschatte nierfunctie vaak relatief insensitief is 
voor het tijdig herkennen van progressieve nierfunctieachteruitgang. 
Dit komt met name door de manier waarop en de patiëntengroep waarin de formules zijn 
ontwikkeld. Daarnaast schieten de formules nog meer tekort bij patiënten met abnormale 
lichaamssamenstelling aangezien de serum creatinine concentratie grotendeels wordt 
bepaald door de hoeveelheid spiermassa. De nierfunctieformules zijn nooit eerder 
gevalideerd ten opzichte van met de gouden-standaard methode gemeten nierfunctie 
in longtransplantatiepatiënten. Omdat de longtransplantatiepatiënten in veel gevallen 
een afwijkende lichaamssamenstelling hebben is het mogelijk dat de formules een 
afwijking hebben van de geschatte nierfunctie ten opzicht van de gemeten nierfunctie. In 
Groningen werd bij alle longtransplantatie de nierfunctie na transplantatie vervolgd met 
125-iothalamate nierfunctie metingen (gouden-standaard meting, mGFR). In hoofdstuk 
9 hebben de formules vergelijken met de gouden standaard, en keken we welke factoren 
verantwoordelijk zijn voor de deviatie van de formules.
Er werd een opvallend grote afwijking tussen de geschatte nierfunctie en de gemeten 
nierfunctie gezien, waarbij de formules gemiddeld een onderschatting gaven van de 
nierfunctie (van 12-32%, afhankelijk welke formule gebruikt werd) zowel voor als na 
longtransplantatie. Precisie en accuraatheid waren ook beperkt, en er was een zeer grote 
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intra-individuele spreiding in de afwijking. De afwijking tussen geschatte en gemeten 
nierfunctie was groter bij hogere nierfunctie, maar uitgedrukt als percentage was de 
afwijking over de gehele range gelijk. Andere factoren die verantwoordelijk waren voor 
afwijkingen waren body-mass index, leeftijd, geslacht en onderliggend longlijden. Dit 
verschilde per formule. Theoretisch nemen de formules leeftijd, geslacht, ras en gewicht 
mee in de berekening, maar onze resultaten wijzen erop dat dit onvoldoende tot een 
goede schatting van de nierfunctie lijdt in deze specifieke patiëntengroep. 
Daarnaast viel op dat de helling van de nierfunctieachteruitgang over tijd werd onderschat 
als er slechts gebruik werd gemaakt van de nierfunctieformules, waarschijnlijk doordat 
de nierfunctie over de hele range wordt onderschat. Hierdoor worden patiënten met 
een snelle achteruitgang van de nierfunctie met behulp van de formules niet tijdig 
opgespoord, ondanks herhaalde metingen. Dit beperkt de toepasbaarheid van de formules 
bij het vervolgen van de nierfunctie na longtransplantatie. Desalniettemin worden de 
nierfunctieformules in veel klinieken wel voor dit doel gebruikt omdat het simpelweg 
duur en zeer belastend voor de patiënten is om de nierfunctie te vervolgen met gouden-
standaard metingen. 
Omdat de nierfunctieformules op basis van serum creatinine tot een slechte schatting 
van de nierfunctie leidt, wat we in hoofdstuk 9 hebben laten zien, beperkt dit ook de 
toepasbaarheid van serum creatinine als uitkomstmaat voor wetenschappelijk onderzoek. 
Desondanks worden uitkomstmaten vaak gebruikt in wetenschappelijk onderzoek, ook 
op gebied van nierfunctie na longtransplantatie. Er zijn ook goede kante aan op serum-
creatinine gebaseerde uitkomstmaten: metingen zijn gemakkelijk te verkrijgen, en worden 
overal gebruikt. Hierdoor kunnen resultaten van studies gemakkelijk vergeleken worden. 
In hoofdstuk 7 maakten we ook gebruik van een uitkomstmaat gebaseerd op serum-
creatinine (namelijk (tijd tot) verdubbeling van het serum-creatinine). Om de gevonden 
resultaten te ondersteunen, deden we daarnaast de analyse met gemeten nierfunctie 
als uitkomstmaat. Omdat de resultaten met beide uitkomstmaten vergelijkbaar waren, 
blijkt hieruit dat, ondanks de intrinsieke beperkingen van serum creatinine, op creatinine-
gebaseerde eindpunten toch van waarde kunnen zijn en voorzichtig als uitkomstmaat 
gebruikt kunnen worden in wetenschappelijk onderzoek.
Conclusies
In dit proefschrift zijn diverse aspecten van voorspellen en voorkómen van chronische 
nierziekten in hoogrisico patiëntengroepen onderzocht. We keken onder andere naar 





het voorspellen van chronische nierziekten met behulp van risicofactoren en biomarkers, 
optimalisatie van strategieën voor het voorkómen van chronische nierziekten en de 
realiteit van de dagelijkse praktijk.
Hoewel de verschillende patiëntengroepen die we onderzochten als overeenkomst 
allemaal een verhoogd risico hebben op het ontwikkelen van chronische nierziekten 
en voorspellen en voorkómen van deze nierziekten belangrijk is, zijn er ook belangrijke 
verschillen tussen de patiëntengroepen. Het aantal patiënten met type 2 diabetes en 
hypertensie is erg groot en neemt in snel tempo verder toe. Van al deze patiënten zal 
uiteindelijk een klein percentage eindstadium nierfalen ontwikkelen. Deze patiënten 
worden over het algemeen in de eerstelijns zorg begeleid en behandeld, totdat complicaties 
de kop opsteken. Het aantal longtransplantatiepatiënten is vele malen kleiner, maar het 
absolute risico op chronische nierziekten daarentegen groter. Daarnaast is de zorg voor 
deze patiënten zeer gespecialiseerde zorg en worden de patiënten intensief begeleid en 
behandeld.
Door deze intrinsieke verschillen tussen de patiëntengroepen die aan bod kwamen 
in dit proefschrift zijn er ook bepaalde verschillen in het monitoren en behandelen. In 
een grote patiëntengroep met licht verhoogd risico op chronische nierziekten is het niet 
alleen van belang om de ziektelast van degenen met het hoogste risico zo veel mogelijk te 
beperken, het is eveneens van belang de last van onnodige behandeling van de degenen 
met het laagste risico zo veel mogelijk te beperken. In een kleine patiëntengroep met 
een zeer sterk verhoogd risico op chronische nierziekten zijn meer intensieve monitoring 
en behandeling op z’n plaats. Omdat chronische nierziekten een zware belasting voor 
patiënten kunnen vormen is elke stap op weg naar het verbeteren van voorkómen van 
chronische nierziekten uiteindelijk in het belang van de patiënt. 
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De motivatie vinden om met het dankwoord te beginnen blijkt erg lastig. Het betekent 
dat het laatste stukje is aangebroken van een project waar het allemaal om draaide 
de afgelopen jaren, waar ik veel van geleerd heb en waarin ik heb samengewerkt met 
ontzettend veel leuke, inspirerende, bijzondere en fantastische mensen. Het is jammer 
te beseffen dat er écht een einde is gekomen aan die tijd. Dit promotietraject was een 
fantastische leerschool. Het voorliggende resultaat was er niet geweest zonder alle 
bijdragen en daar wil ik al die genen voor bedanken. In het bijzonder wil ik hier aan aantal 
mensen noemen die over de tijd waardevolle bijdragen hebben geleverd aan het tot stand 
komen van dit proefschrift. 
De eerste kennismaking met onderzoek was al vroeg tijdens mijn studie. Via via 
kwamen er wat verschillende projecten op m’n pad, data invoeren vanuit statussen op 
de niertransplantatie, het nierperfusie-team, experimenten met nierperfusie op het 
chirurgisch onderzoekslab en vervolgens het eerste onderzoek bij de longtransplantatie. 
Ik wil iedereen die betrokken was bij mijn eerste kennismaking met wetenschappelijk 
onderzoek bedanken dat jullie me enthousiast hebben gemaakt.
Mijn eerste onderzoek op gebied van longtransplantatie deed ik met Dr. E.A.M. 
Verschuuren. Erik, als we afspraken wijdde je altijd eerst een half uur uit over interessante 
casuïstiek en thoraxfoto´s, voordat we het echt over onderzoek gingen hebben, en tja, dan 
was de tijd meestal alweer snel voorbij. Het onderzoek doen was vaak met name gezellig 
en ging niet zo snel, maar uiteindelijk is daardoor misschien wel m´n enthousiasme voor 
longziekten ontstaan. Desalniettemin was er resultaat: m’n eerste oral presentation 
op een longtransplantatiecongres in Boston. Daar leerde ik de rest van de vakgroep/ 
onderzoeksgroep kennen (Wim van der Bij, Michiel Erasmus en Barbara Wagemakers) 
en ontstond het idee om i.s.m. de afdeling nefrologie te kijken naar nefrologische 
complicaties na longtransplantatie, een project wat al een tijd op de plank lag.
Dr. W. Van der Bij, Wim, jouw deur stond altijd open (“Wicht, kom der in”) voor vragen 
of gewoon voor een praatje. Met jou ging ik me richten op nierfunctiestoornissen bij 
longtransplantatiepatiënten. Ik heb je leren kennen als een heel betrokken dokter die 
ook zeer gewaardeerd wordt door zijn patiënten, droog, gevat, kritisch en met een sterke 
mening. Je was altijd bereid mee te denken en ik heb je kennis, je mening en je ideeën erg 
gewaardeerd. Soms kun je je verschrikkelijk opwinden over dingen en een verschrikkelijk 
humeur hebben (waar ik meestal tijdig voor werd gewaarschuwd door jullie zeer 




waardevolle secretaresse Willy), altijd van korte duur en zonder enig kwaad bloed in je. 
Dank voor al je adviezen en je hulp bij verdere carrièremoves. 
Dr. M.E. Erasmus, Michiel, dank voor je betrokkenheid. Je bent denk ik de sympathiekste 
chirurg die ik ken. Dr. G. Nossent, dank voor het verder aanwakkeren van mijn 
enthousiasme over longtransplantatie.
Prof. Dr. G.J. Navis, Gerjan, bij het voorstel om eindelijk eens naar de nieren van 
longtransplantatiepatiënten te kijken was je meteen enthousiast, zoals jij eigenlijk bij 
alles enorm enthousiast bent. Resultaten vallen nooit tegen, onverwachte resultaten zijn 
op z’n minst interessant. Zelfs als een stuk al vrijwel helemaal uitgekristalliseerd is heb 
jij vaak nog nieuwe inzichten of ideeën, wat nieuw licht schijnt op het stuk en het verder 
verbetert. Je manier van onderzoek doen is erg inspirerend en je bent een goed voorbeeld 
van girl power in het onderzoek. Ik vond het erg leuk om de afgelopen jaren samen met 
je te werken. 
Prof. Dr. D. de Zeeuw, Dick, je hebt me kansen gegeven binnen de vakgroep klinische 
farmacologie. Je hebt me vaak overdonderd met allerlei plannen, voorstellen en meningen. 
Toen je me tijdens onze eerste kennismaking vertelde dat ik zou gaan rekenen aan grote 
datasets had ik vooral weinig idee wat ik kon verwachten. Uiteindelijk ben ik de datasets 
gaan waarderen en statistiek onverwachts leuk gaan vinden. Ik respecteer je visie en je 
toewijding en heb veel van je geleerd. Jij krijgt alles voor elkaar wat je in je hoofd hebt. 
Soms botste dat als ik een andere mening was toegedaan. Soms wist ik niet wat ik met je 
aan moest, maar uit de verhitte discussies kwamen vaak de mooiste dingen. Uiteindelijk 
denk ik dat we allebei erg tevreden mogen zijn over het resultaat wat we hebben bereikt 
en ben ik dankbaar voor de samenwerking.
Dr. S.J.L. Bakker, Stephan, ik heb jou voor zover ik me kan herinneren nog nooit chagrijnig of 
boos gezien; een brede glimlach is ongeveer getatoeëerd op je gezicht. Ondanks periodes 
waarin het werk je bijna boven het hoofd groeit is stress nooit aanwezig. Je had nooit zo 
veel haast, terwijl het voor mij eigenlijk nooit snel genoeg kon. Samen kwamen we op 
een prettige manier altijd ergens in het midden uit. Je hebt veel ervaring met schrijven en 
hebt me daar veel van meegegeven bij alle stukken die we samen hebben geschreven; je 
was nooit te beroerd om mee te kijken en altijd even consciëntieus. Dank voor alles wat ik 
van je geleerd heb en de prettige samenwerking!
Dr. H.J. Lambers Heerspink, Hiddo, je bent enorm gedreven in wat je doet en krijgt 
ontzettend veel voor elkaar in weinig tijd. Vanaf het begin van het SysKID project hebben 
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we nauw samengewerkt. Samen hebben we meerdere stukken geschreven op bijzonder 
efficiënte wijze door je snelle feedback en up to date literatuurkennis. Je zag vaak de 
potentie van data eerder dan ik en had daar meestal gelijk in. Je hebt niet voor niets die 
Veni in de wacht gesleept! Dank voor de samenwerking en veel succes met je verdere 
carrière. 
The reading committee assessing this thesis consisted of Prof. Dr. G. Mayer,  Prof. Dr. H.A.M. 
Kerstjens and Prof. Dr. H.J.G. Bilo. Your effort is highly appreciated. 
I would furthermore like to express my thanks to all the collaborators within SysKID with 
whom I’ve had the pleasure of working with and who all strive to make the project a 
success, in particular Bernd and Gert Mayer, Klaus Weinberger, Ulrika Lundin, Harald 
Mishak, Joachim Jankowski, Martin de Borst, Paul Perco, Maria Lajer and Peter Rossing. I 
would also like to thank the co-authors of the post-hoc analysis of IRMA-2 for their fruitful 
collaboration (Dr. Frederik Persson, Dr. Peter Rossing and Prof. Dr. Hans-Henrik Parving). 
Ook Prof. Dr. Paul de Jong en Dr. Ron Gansevoort wil ik bedanken voor de toegang tot 
PREVEND data en samples voor de SysKID discovery study. 
Vanuit GIANTT wil ik Dr. Petra Denig en Dr. Jaco Voorham voor de prettige samenwerking. 
Alle vrijwilligers die meegewerkt hebben aan één van de studies die ik gebruikt heb voor 
dit proefschrift; zonder jullie was dit onderzoek nooit mogelijk geweest. Evenmin was het 
mogelijk geweest zonder de verdere ondersteuning (Marja), de behulpzame secretaresses 
(Willy, Winie, Ellen, Ardy en Alexandra) en de dames op de nierfunctiekamer die jarenlang 
alle nierpompen van de longtransplantatiepatiënten apart bijhielden (Roelie, Marian en 
Dirkina). 
De AIO ’S op de afdelingen Nefrologie & Klinische farmacologie (Onder andere Dorien, 
Steef, Ferdau, Else, Hilde, Esther, Jan, Solmaz, Wendy, Lieneke, Maartje, Arjan, Tsjitske, Edwin, 
Michel, Hanneke, Janneke, Laura, Heleen, Alaa, Sigrid, Sieta, Paul, Yan, Arna, Katharina, 
Grigori, Matthijs, Maggie, Pramod) wil ik bedanken voor de fijne samenwerking, de 
bereidwilligheid om te helpen met statistiek, andere praktische problemen of samples 
uitzoeken en natuurlijk de gezelligheid bij lunches/congressen. Mijn kamergenootjes 
op de klinische farmacologie Frank en Margje; het was gezellig met jullie op de kamer! 
Sara, jij gaat een deel van mijn projecten verder overnemen, succes! Collega’s op andere 
afdelingen (o.a. cardiologie), bedankt voor de gezelligheid en de hulp.
M’n nieuwe opleiders en collega’s in het Spaarne Ziekenhuis wil ik bedanken voor de 
nieuwe uitdaging, het feit dat ik met hen mag werken, maar met name omdat ze me zo 




prettig hebben opgevangen en hebben ondersteund in de afronding van dit proefschrift. 
Binnenkort ben ik er voor de volle 100%!
Lieve paranimfen, ik ben blij dat jullie de taak als paranimf zo dankbaar aanvaard hebben! 
Lycke, we kennen elkaar als sinds het begin van de studie en hebben al heel wat lief en 
leed gedeeld! Kirsten, wat hebben we een fantastische tijd gehad in Curaçao. Leuk dat 
we sindsdien nog zo vaak samen hebben gesport, en nog vele avonden samen hebben 
doorgebracht. Marthe, ook jou ken ik van dushi Korsou. We hebben samen heel wat 
onderzoeksfrustraties gedeeld tijdens alle gezellige lunches en etentjes. Fijn dat jullie 
me willen bijstaan bij de verdediging van dit proefschrift én zorg gaan dragen voor een 
fantastische borrel/ feest. Ik weet zeker dat het goed komt!
Mijn lieve vriendinnen & vrienden hebben gezorgd voor veel afleiding met gezellige 
avonden, leuke diners, feestjes, salsa, sport, vakanties etc. Ook mocht ik van tijd tot tijd 
m’n hart luchten en accepteerden jullie het dat ik af en toe enkele weken verdween 
zonder enig teken van leven. Curacao-dushinan: Fijn dat jullie hebben gezorgd voor de 
nodige ontstress-momenten en dat jullie m’n Groningen tijd zo leuk hebben gemaakt! 
Lieve studievriendinnetjes: ondanks dat we uitgewaaierd zijn over het land en allemaal 
wisselende diensten doen hoop ik dat we elkaar veel blijven zien! Bizarre: ik kijk uit naar 
de eerste vrijdagen en de clubweekenden die nog gaan komen. 
Mijn ouders, Paul en Rita, mijn allergrootste supporters. Jullie hebben me altijd geleerd 
kansen te zien en vooral om ze aan te grijpen als ze zich voordeden. Altijd maakten jullie 
alles mogelijk en hebben jullie me gestimuleerd zonder druk uit te oefenen. Ik wil jullie 
bedanken voor de bagage die ik heb meegekregen en dat ik altijd bij jullie terecht kan, ook 
in moeilijke tijden. Mijn broertjes Hans en Frank en nichtje Corine, fijn dat jullie er zijn. 
Iedereen die geïnteresseerd was en bij wie ik af en toe m’n verhaal kwijt kon, dank voor de 
steun en alle ontspannen momenten!
Tijmen, wij kenden elkaar pas een paar maanden toen ik moest beslissen of ik wilde 
verhuizen naar Groningen voor een promotietraject. Ondanks dat ik er erg tegenop zag 
was jij van begin af aan overtuigd dat ik het moest doen en dat we het ook op afstand 
zouden redden. Niets is minder waar gebleken en ik ben er nog elke dag blij om. Dank voor 
je liefde en je onvoorwaardelijke steun. Het leven met jou is een avontuur!
Merel
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